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Abstract 
The goal of this thesis was to increase understanding of the role of the human microbiome in 
kidney stone disease, from stone nidus formation through to surgical stone treatment, using a 
combination of in vitro, in vivo, and human clinical investigations. 
We first optimized our methods of sample collection for the use of such protocols in clinical 
studies involving urinary and gut microbiota investigations. We developed a novel method of 
fecal sampling that is amenable to study participants, inexpensive, and results in reliable 
downstream sequencing results. 
We then utilized this sampling methodology in clinical investigations into the microbiota of 
surgical kidney stone patients using a systems-level approach. We determined that there is a 
microbiota present in all kidney stone crystalline compositions, which was previously 
unknown. The urinary microbiome was distinct between stone formers and controls in both 
microbiota composition and based on targeted metabolomics. Stone formers had higher 
urinary oxalate concentrations and elevated relative abundance of inflammatory and 
uropathogenic microbes throughout the course of stone treatment. In the gut, stone formers 
had altered microbial community composition at both a taxonomic and functional level, with 
implications for uropathogen abundance and host oxalate homeostasis. We determined that 
the gut has a significant and multipronged contribution to kidney stone formation.  
In a cohort of primarily nephrolithiasis-related urological patients, we further characterized 
the microbiota associated with ureteral stents, an almost ubiquitous component of surgical 
stone treatment. We determined that the stent microbiota is reproducible and patient specific, 
and not represented by the urinary microbiota. Patient factors and comorbidities drive the 
stent microbiota composition, and neither the microbial community nor degree of stent 
encrustation were altered by antibiotic use, indicating that perhaps antibiotic use in stent 
patients needs recalibration. 
Finally, we investigated host-microbe interactions in stone formation using in vitro and in 
vivo models, specifically how uropathogens may contribute to stone formation and how 
probiotics may provide therapeutic benefit. We determined that both pathogenic and 
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beneficial bacteria have the capability of shaping stone disease progression and should be 
considered in stone treatment. 
Collectively, these studies have shed light on the contribution of microbes in this prevalent 
and morbid condition, and elucidated novel ways to harness the microbiome in 
nephrolithiasis management. 
 
Keywords 
Kidney stone disease, microbiome, next generation sequencing, endourology, Drosophila 
melanogaster, ureteral stents 
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Summary for Lay Audience 
Kidney stone disease affects approximately 10% of the population; it has been described as a 
pain worse than childbirth and its treatment is a financial drain to the health care system. 
Many people develop stones time and time again, but why this happens is not well known. 
This project aimed to determine if the microbiota, the bacteria that live within us, is a factor 
in this disease. We determined that the bacteria, and the products they make, in the gut and 
urinary tract of people with stone disease are different from healthy individuals in ways that 
may exacerbate stone formation. The majority of kidney stones are composed of calcium 
oxalate, and the gut bacteria in stone formers may be causing the increased levels of oxalate 
that we measured in the patient’s urine. Stone formers that are exposed to antibiotics more 
often also carried antibiotic-resistant bacteria within them, indicating previous antibiotic 
exposure damages the beneficial microbial ecosystem. When we investigated medical 
devices (ureteral stents) that are used in stone patients which can become infected with 
bacteria, antibiotic use did not prevent the presence of harmful bacteria on the devices, or in 
the bladder. We also found that the stent microbiota was different if the patient had diabetes, 
IBS/IBD, and other comorbidities. These factors should be considered in future stone patients 
that require ureteral stents and we believe the standard of care of antibiotics needs to be 
modified. Using a model of stone disease in fruit flies, we determined that beneficial bacteria 
could protect against stone formation, and that harmful bacteria in the urinary tract may be 
making stone disease worse. Future research could lead to the development of effective 
probiotics against kidney stones. Overall, we have found that bacteria are intimately involved 
in stone formation — some harmful bacteria present in stone formers encourage stone 
formation, while beneficial bacteria in healthy people can be protective. This condition is 
increasing in prevalence, and we need better solutions to prevent it — this work illustrates 
that bacteria may be the key to future kidney stone treatment. 
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Chapter 1  
1 General Discussion 
Kidney stone disease, or nephrolithiasis, is one of the most prevalent urologic pathologies. 
The disease has existed in parallel with civilization: it is referred to in the Hippocratic Oath, 
and stones have even been discovered in ancient Egyptian mummies. Various different 
compositions of kidney stones exist, each with unique etiology and associated risk factors. 
Despite a wealth of research existing on the mechanisms of stone formation, much still 
remains elusively idiopathic.  
In the field of urology, bacteria have traditionally been thought of only in the context of 
infection, but we now know there to be a microbial community present in the healthy urinary 
tract. The microbial ecosystems living on and in us, as well as their genes and products are 
collectively referred to as the microbiome. The extensive human microbiome research field 
has uncovered previously unknown relationships with various states of systemic health and 
disease; however, consideration of the microbiome in urological conditions is only just 
emerging. The gut microbiome may indirectly affect stone disease by dictating what solutes 
ultimately end up in the urine, whereas the urinary microbiome may have a direct effect at 
the site of stone formation. Herein we explore how the human microbiome as a whole may 
impact stone disease, from the relative risk factors, to the inception of stone formation, and 
the role of bacteria in future disease treatment. 
1.1 Kidney stone disease 
Nephrolithiasis affects approximately 10% of the North American population; prevalence 
rates appear to be rising and have more than doubled over the last four decades in adult 
Americans (Pearle et al., 2005). Nephrolithiasis also has an extremely high rate of 
recurrence, estimated at 50% within 5 years (Pearle et al., 2005, Stamatelou et al., 2003). 
These features compound the burden of the disorder when the patient morbidity and 
economic onus are also considered. While some stones may be asymptomatic and detected 
incidentally, others can cause extreme renal colic and complications leading to emergency 
room visits, hospitalization, and surgical intervention (Khan et al., 2016). The loss of work 
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and treatment costs due to urolithiasis were associated with an estimated annual expenditure 
of greater than $ 5 billion in the United States (Pearle et al., 2005).  
Kidney stones are composed of organic and inorganic crystals combined with various urinary 
macromolecules (Rodgers, 2017) and can form in the renal pelvis and calyces either freely or 
bound to renal papillae (Figure 1). These calculi result from supersaturation of urinary 
solutes that can precipitate and crystallize, leading to crystal aggregation and stone growth. 
Many stones begin as Randall’s plaques, which are calcium phosphate deposits found on the 
tips of renal papillae and are often associated with recurrent stone formation (Daudon et al., 
2015; Kim et al., 2005; Kuo et al., 2003; Matlaga et al., 2007). Of the various compositions 
of kidney stones, calcium-based stones are by far the most common, comprising more than 
80% of all stones, the majority of which are calcium oxalate (CaOx) (Moe, 2006). Less 
common stone compositions include uric acid (5-10%), struvite (5-15%), cystine (1-2.5%), 
and drug-induced stones (<1%) (Moe, 2006).  
The propensity for stone formation differs by sex, age, geography, race, and body mass index 
(BMI) (Scales Jr. et al., 2012). Historically stone disease was between 2-3 times more 
common in men than women (Soucie et al., 1994), however in recent years this disparity has 
narrowed significantly (Ordon et al., 2015; Scales Jr. et al., 2007; Strope et al., 2010). In 
Ontario, it was found that the rate of kidney stone procedures performed per year between 
1991 and 2010 increased by approximately 48%, which was accounted for mainly by an 
increase in procedures performed on women (Ordon et al., 2015). This rise in disease burden 
in women may be due to inflating rates of obesity, decreased fluid intake, and other lifestyle 
changes that are associated with risk of stone formation, as discussed later (Strope et al., 
2010).  
Kidney stone data are collected in different fashions, but among countries with age-stratified 
stone prevalence data there is a rise and fall pattern where incidence normally peaks around 
age 50, and subsequently decreases (Romero et al., 2010). Geographical variation in stone 
disease in the United States reflects environmental risk factors; stone prevalence is increased 
in hotter climates leading to decreased hydration status and more concentrated urine, as well 
as areas with high sunlight and increased Vitamin D production. This manifests in the 
southeastern states, where stone prevalence is highest, compared to the lowest rates in the 
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northwest (Romero et al., 2010; Soucie et al.,1994). In the US, race impacts stone prevalence 
whereby rates are highest for non-Hispanic white individuals, followed by Hispanics, African 
Americans, and Asian-Americans (Scales Jr. et al., 2012). The reason for race differences has 
not been determined but may pertain to diet and lifestyle. 
Interestingly, conditions known to be associated with kidney stones include obesity, diabetes, 
metabolic syndrome, and cardiovascular disease. In a prospective study of over 240 000 
individuals, Taylor et al. (2005) determined weight, weight gain since early adulthood, waist 
circumference, and body mass index to all be positively associated with the risk of incident 
kidney stones. The mechanisms of these associations are unclear but may be related to 
increased urinary excretion of calcium, oxalate, and uric acid in larger body sizes, which may 
lead to stone formation (Lemann Jr. et al., 1996). Hyperinsulinemia and diabetes are also 
known to be associated with stone disease: Lieske et al. (2006) determined that the 
probability of being diabetic was increased by 22% when comparing kidney stone formers to 
a group of non-stone formers after adjusting for age and BMI. This increased risk may be due 
to altered urine composition and lower urine pH which can result in uric acid crystalluria, a 
risk factor for both calcium and uric acid stone formation (Daudon and Jungers, 2007; Khan 
et al., 2016; Lieske et al., 2006). Metabolic syndrome traits (abdominal adiposity, increased 
serum triglyceride level, decreased serum high-density lipoprotein cholesterol level, 
hypertension and impaired glucose tolerance) was determined to significantly increase the 
odds of self-reported kidney stone disease, and the presence of four or more traits was 
associated with an approximately two-fold increased odds (West et al., 2008). Kidney stone 
formers often have risk factors associated with atherosclerosis, and several studies have 
shown cardiovascular disease to be associated with stone formation (Alexander et al., 2014; 
Ferraro et al., 2013; Rule et al., 2010). Alexander et al. (2014) found that after adjusting for 
confounders, individuals that had at least one kidney stone were at higher risk for both 
myocardial infarction and stroke, but the reason for this correlation is not known. 
1.2 Mechanisms of stone formation 
Stone formation initiates by urinary salt supersaturation: when a solute (salt) is added to a 
solution (urine), it will dissolve until a certain concentration is reached, beyond which the 
solution is saturated and the solute crystallizes (Aggarwal et al., 2013). The concentration of 
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saturation can be altered based on the presence of crystallization inhibitors and promoters 
that are normally found in urine, however urine is generally reported as metastable with 
respect to most stone components (Ratkalkar and Kleinman, 2011). Despite this, if the 
supersaturation raises high enough, crystal nucleation will still occur. Crystal nucleation 
occurs when free solute ions dispersed in the solvent (urine) change to a solid phase and 
associate into particles (Ratkalkar and Kleinman, 2011; Rodgers, 2017). This nucleation can 
occur in free solution, on cell surfaces, or in other micro-environments such as areas within 
the nephron (Figure 1) (Evan et al., 2003; Khan et al., 2016). Following nucleation in 
solution, crystals will aggregate into larger particles, the surface of which can further act as a 
nucleation site for new crystals. The aggregation process can be promoted by various 
compounds and cell-derived material such as proteins, lipids, polysaccharides, and 
glycoproteins which can eventually form the organic matrix between crystals in the stone 
(Hess et al., 1993; Khan and Hackett, 1993). 
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A) Stones can form in the renal calyces or pelvis and can be either free-floating or attached to 
renal papillae. Struvite stones can often develop into a staghorn morphology, where the stone 
body occupies the entirety of the renal calyces and pelvis. Most stones less than 5 mm in size 
can pass on their own, but those > 5 mm may become lodged in the ureter or bladder. The 
length of the ureter shown is not to relative scale, the average adult ureter is between 25-30 
cm. B) The induction of a stone nidus is hypothesized to occur in two ways. In the fixed-
particle mechanism of Randall’s plaques, calcium phosphate precipitates in the basement 
membrane of the loop of Henle, aggregating in the interstitium and eventually eroding into 
the renal pelvis. In the free-particle mechanism of Randall’s plugs, crystals form in the renal 
tubules and aggregate, plugging the terminal collecting ducts. When both plaques and plugs 
are exposed to the renal pelvis, they act as a nidus of further crystal deposition from 
supersaturated pelvic urine. Image templates from Servier Medical Art by Servier were used 
and modified under the Creative Commons Attribution 3.0 Unported License. 
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Figure 1. Anatomy of the urinary system and mechanisms of stone nidus formation 
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The two dominant models of stone formation were first described by Randall as plugs and 
plaques (Figure 1B) referring to the free and fixed particle mechanisms respectively 
(Randall, 1937; Randall, 1940). In the free particle model, urinary supersaturation leads to 
crystal formation in the renal tubules, which aggregate and plug the terminal collecting duct’s 
opening to the renal pelvis (Khan and Canales, 2015). These plugs are then exposed to the 
pelvic urine and act as a nidus for further crystal deposition and stone formation. In the fixed 
particle theory of Randall’s plaques, calcium phosphate (CaP) crystals precipitate in the 
basement membrane or vasa recta of the loop of Henle (Evan et al., 2003; Matlaga et al., 
2006; Stoller et al., 2004). These crystals then aggregate in the interstitium, accumulating 
and eventually eroding through the papillary surface. When exposed to the pelvic urine, the 
CaP crystals act as a nidus for CaOx crystal deposition. Indeed, several autopsy studies have 
shown CaOx stones to be formed attached to Randall’s plaques, while other studies have 
validated that CaP is often found at the nidus of CaOx stones (Haggitt and Pitcock, 1971; 
Meyer et al., 1975; Randall, 1940; Stoller et al., 1996; Weller et al., 1972; Xie et al., 2014). 
An examination of both modes of stone formation demonstrates various sites where bacteria 
could form a nidus in the kidney. 
1.3 Kidney stone composition 
As stated above, the most common kidney stones are calcium-based in the form of CaOx 
(75%) and CaP (5-10%) (Moe, 2006). The former can exist as CaOx monohydrate (COM) or 
dihydrate (COD). The COM crystals have a characteristic “dumbbell” appearance and form 
the most thermodynamically stable kind of stone (Alelign and Petros, 2018; Coe et al., 1992; 
Khan and Hackett, 1986). COD is seen less often than COM in clinically relevant stones, and 
forms crystals with tetragonal “envelope” appearance (Daudon et al., 2004; Khan and 
Hackett, 1986). Pure CaP stones are rare, but the crystals are the most abundant in mixed 
stones (Coe et al., 1992). CaP is most commonly found in the form of apatite 
(Ca10[PO4]6[OH]2) and brushite (CaHPO4∙2H2O) (Coe et al., 1992; Siener et al., 2013b). Risk 
factors for all calcium stones include hypercalciuria and hypocitraturia; hyperoxaluria and 
hyperuricosuria are risks for CaOx stones while urinary pH > 7.5 is a risk for CaP stones 
(Siener et al., 2013b).  
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Uric acid (UA) stones typically account for between 5-10% of all stones, with increased 
prevalence among patients with obesity, diabetes, and metabolic syndrome (Cameron and 
Sakhaee, 2007; Pearle et al., 2005). The urate anion is soluble at pH > 5.3, so consistently 
acidic urine is a risk factor for UA stones (Cameron et al., 2012). Hyperuricosuria can be 
caused by elevated endogenous UA production (for example in conditions such as gout), 
increased purine catabolism (as occurs in patients receiving chemotherapy), consumption of a 
purine-rich diet, or chronic diarrhea leading to loss of bicarbonate and acidified urine (Abou-
Elela, 2017; Landgren et al., 2017; Liebman et al., 2007; Tsimberidou and Keating, 2005). 
Struvite or infectious stones represent between 5-15% of all stones (Pearle et al., 2005). The 
magnesium ammonium phosphate crystals that struvite stones are composed of typically 
have a “coffin-lid” appearance (Khan et al., 1986). These form in patients with urinary tract 
infections due to organisms that produce urease, most commonly Proteus mirabilis and less 
frequently Klebsiella spp., Pseudomonas aeruginosa, Staphylococcus saprophyticus, and 
Ureaplasma urealyticum (Thompson and Stamey, 1973). Urease cleaves urea to ammonia 
and CO2, which elevates urinary pH and causes precipitation of the magnesium ammonium 
phosphate hexahydrate crystals (Das et al., 2017). These stones are approximately three 
times more common in women than men, presumably due to the higher prevalence of urinary 
tract infections in women (Han et al., 2015). Struvite stones commonly present as staghorn 
calculi, named for the horn-like shapes formed when the stones occupy the renal pelvis and 
extend into the calyces (Figure 1A) (Preminger, 2005). 
Cystine stones comprise less than 2% of all stones and unlike other compositions are the 
result of an inherited defect in renal cystine transport affecting about one out of every 20 000 
people (Knoll et al., 2005). Due to an autosomal recessive mutation on chromosome 2 in the 
dibasic amino acid transporter gene heavy chain subunit rBAT (SLC3A1) or its light chain 
subunit (SLC7A9) on chromosome 19, cystine is unable to be reabsorbed in the renal tubule 
and cystinuria occurs (Eggermann et al., 2012). At normal urinary pH cystine is insoluble 
and forms hexagonal crystals, though solubility is improved with alkalization. Traditionally 
cystine stones are quite hard and appear amber coloured and slightly opaque due to their 
sulphur content (Khan and Hackett, 1986). They tend to present as multiple, bilateral, large 
stones, (Han et al., 2015). Due to their genetic origin, cystine stones usually present earlier in 
life than other stone compositions (Harnevik et al. (2003) found that around 20% of patients 
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had their first stone before the age of 3) and have very high rates of recurrence (Shim and 
Park, 2014). No previous studies have investigated whether these stones or their high 
recurrence involves a bacterial component.  
A small proportion of stones (>1%) are miscellaneous in composition and are drug induced 
(Han et al., 2015). Various xenobiotics including medications and environmental toxicants 
can directly crystalize in urine forming stones, or cause urinary metabolic abnormalities 
forming stones from conventional components such as calcium oxalate or uric acid (Daudon 
and Jungers, 2004). Perhaps the most notorious example of a lithogenic drug is indinavir-
sulfate, a protease inhibitor used in HIV treatment, where incidence of stones in indinavir-
treated patients has been reported to exceed 40% (Saltel et al., 2000). Other drugs known to 
crystallize in urine and have been found in stones include antibiotics such as ciprofloxacin 
and trimethoprim-sulfamethoxazole that are ironically commonly prescribed in urological 
practice (Albala et al., 1994; Cek et al., 2012; Chopra et al., 2000; Daudon and Jungers, 
2004). Others include the diuretic triamterene (Daudon and Jungers, 2004; Ettinger et al., 
1979; Gault et al., 1981), and cough and stimulant preparations composed of ephedrine and 
guaifenesin (Assimos et al., 1999; Bennett et al., 2004; Daudon and Jungers, 2004; Whelan 
and Schwartz, 2004). Melamine consumption can cause stones in acidic urine (Dalal and 
Goldfarb, 2011; Grases et al., 2009), and cadmium exposure is associated with significant 
risk of calcium and uric acid stone formation (Guo et al., 2018; Ramaswamy et al., 2016; 
Thomas et al., 2013).  
In comparison to stones made of the crystallized drug itself, several xenobiotics can cause 
metabolically induced stones. For example, calcium and vitamin D supplements are known to 
induce hypercalciuria and calcium stones (Sorensen, 2014), vitamin C is an oxalate precursor 
and overdosing can lead to hyperoxaluria and calcium oxalate stone formation (Ferraro et al., 
2016), and laxative abuse can lead to formation of ammonium urate stones (Dick et al., 
1990). More generally, medications known to alter the urinary pH can also cause 
susceptibility to stones; acidic urine is a risk factor for uric acid stone formation, and alkaline 
urine can predispose to stones from urate salts and calcium phosphate (Abou-Elela, 2017; 
Daudon and Jungers, 2004; Moe, 2006). Although drug-induced stones are rare, they deserve 
consideration due to their preventable nature. 
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1.4 Kidney stone management and treatment 
While stones can be removed surgically or in some cases dissolved as described below, their 
prevention is deemed most important because of the extremely high recurrence rate and the 
potential for stones to cause serious complications such as chronic kidney disease and end-
stage renal disease (El-Zoghby et al., 2012; Rule et al., 2009). 
In addition to the specific metabolic changes required to prevent stones detailed in Table 1, 
the simplest risk factor to control for in the management of kidney stone disease is low urine 
volume. A preventative strategy should involve increasing water intake to achieve a urine 
volume of at least 2.5 litres per day (Borghi et al., 1996; Pearle et al., 2014; Xu et al., 2015). 
This increased hydration can be accompanied by several dietary modulations to further lower 
the risk of stone formation. A balanced diet with reduced animal protein intake has been 
shown to protect against recurrence of calcium and uric acid stones (Han et al., 2015; 
Nguyen et al., 2001; Borghi et al., 2002). Reduced sodium intake can also decrease the risk 
of calcium stones since sodium prevents renal calcium reabsorption and therefore increases 
urinary calcium levels (Nouvenne et al., 2010). In general, increased vegetable and fruit 
consumption is beneficial for stone formers as components such as potassium can be 
metabolized into alkali and thereby raise urinary pH (Berg et al., 1992; Moe, 2006; Rose and 
Westbury, 1975). It is important for stone formers to not restrict calcium intake, as this 
decreases the amount of calcium available in the gastrointestinal tract to bind to dietary 
oxalate, which subsequently increases oxalate absorption and oxaluria (Jaeger et al., 1985; 
von Unruh et al., 2004). Similarly, since oxalate is present in many common (and otherwise 
healthy) foods, stone formers should only avoid those that are very high in oxalate and shown 
to increase urinary oxalate levels such as rhubarb, spinach, green tea, chocolate, nuts, 
strawberries, and wheat bran (Grases et al., 2006; Massey et al.,1993). 
Other aspects of medical management of stone disease involve the treatment of renal colic, 
medical expulsive therapy, and stone dissolution therapy. Renal colic can occur when stones 
shift within the urinary tract, causing obstruction and/or hydronephrosis, and may be 
associated with hematuria, dysuria, urinary urgency and frequency, nausea, and vomiting 
(Teichman, 2004). Nonsteroidal anti-inflammatory (NSAID) drugs and opiates are the first 
line therapy for analgesia of renal colic, with an added benefit of NSAIDs being that they 
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reduce glomerular filtration rate (Clark et al., 2011; Portis and Sundaram, 2001). Medical 
expulsive therapy can involve the use of !- blockers such as tamsulosin which can inhibit 
ureteral spasm and uncontrolled contraction, dilating the ureter and increasing the probability 
of spontaneous stone passage (Assimos et al., 2016). Stone dissolution therapy is generally 
only effective for uric acid stones, where alkalizing urine with potassium citrate (or other 
compounds) to pH ≥6.0 with increased urine volume has been shown to partially dissolve the 
stones (Moran et al., 2002; Pearle et al., 2014; Teichman, 2004). 
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Table 1: Pathophysiology and associated treatment of nephrolithiasis 
Metabolic Anomaly Associated Stone Composition Treatment 
Hypercalciuria • Calcium oxalate 
• Calcium phosphate 
• Decreased sodium and 
protein consumption 
Hypocitraturia 
• Calcium oxalate 
• Calcium phosphate 
• Uric acid 
• Consumption of citrate (citrus 
fruits, potassium citrate) 
Hyperoxaluria • Calcium oxalate 
• Reduced oxalate 
consumption 
• Avoidance of calcium 
restriction 
Hyperuricosuria • Uric acid 
• Decreased consumption of 
purine-rich foods 
• Allopurinol 
Cystinuria • Cystine 
• Increase urine pH 
• Increased urine volume 
• Thiol-based chelating agents 
(Andreassen et al., 2016) 
Low urinary pH • Uric acid 
• Cystine 
• Potassium citrate 
• Sodium bicarbonate (Pinheiro 
et al., 2013) 
Urinary tract 
infection • Struvite • Antibiotics 
 
  
12 
 
 
 
Most stones less than 5 mm will pass on their own, but surgical management is required 
when stones are greater than 10 mm in diameter, cause severe colic, have not passed in four 
weeks, or cause other complications (Khan et al., 2016). The three most common methods of 
stone treatment are extracorporeal shockwave lithotripsy (ESWL), rigid or flexible 
ureteroscopy (URS), and percutaneous nephrolithotomy (PCNL). These procedures account 
for about 40-50%, 30-40%, and 5-10% of worldwide surgical stone treatments, respectively 
(Khan et al., 2016). The choice between treatment modalities depends on patient 
characteristics such as medical co-morbidities and anatomy, stone features such as location, 
radiodensity, size, and the experience of the treating physician. 
ESWL is a non-invasive method of fragmenting calculi; acoustic shock waves are created 
from electrohydraulic, electromagnetic, or other generators and focused on the stone with a 
lens (Rassweiler et al., 2014; Elmansy and Lingeman, 2016). The stone is visualized with 
ultrasonography or fluoroscopy, and fragmented when the focused shockwaves pass through 
it and energy is released (Elmansy and Lingeman, 2016). The stone fragments then pass out 
of the body during urination, and success of the ESWL is usually assessed by 
ultrasonography or radiography in the following weeks (Chiang et al., 2017; Elmansy and 
Lingeman, 2016). ESWL is usually the first line treatment for stones < 1 cm in size, and 
treatment success rates are lower for larger stones, those located in the lower pole, and in 
shockwave resistant stones such as calcium oxalate monohydrate and cystine (Turk et al., 
2016). ESWL success is also associated with lower BMI and skin-to-stone distance (McClain 
et al., 2013; Nakada et al., 2000; Pareek et al., 2005). General or regional anesthesia is 
utilized in ESWL procedures for analgesia and to minimize movement and the respiratory 
motion of the kidney (Eichel et al., 2004; Turk et al., 2016). ESWL has a low risk of 
complications and morbidities but can sometimes induce hematuria, infection, steinstrasse, 
and very rarely sepsis (Kelley, 1990). Interestingly, experiments performed almost thirty 
years ago demonstrated that bacteria suspended in urine lost viability when exposed to 
ESWL, and even more so when incorporated into agar beads mineralized with calcium 
carbonate crystals simulating stones (Reid, et al., 1990). 
Stone-free rates are comparable for treatment with ESWL and URS; URS may achieve better 
stone-free rates with a single procedure whereas ESWL may require multiple, however 
ESWL has fewer complications (Turk et al., 2016). URS is minimally invasive and involves 
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retrograde passage of a rigid or flexible endoscope from the urethra proximally to the ureter 
and kidney, aided by fluoroscopy. Ureteral stones have higher surgical success rates from 
treatment with rigid ureteroscopes, whereas flexible ureteroscopes are better utilized for 
proximal stones and less anatomically accessible calyces (Turk et al., 2016; Wright et al., 
2014). Lithotripsy during URS is most commonly achieved with the use of a holmium laser 
and has highest stone free rates in stones between 10-20 mm in size (Turk et al., 2016; 
Wright 2014). Spinal or general anesthesia is utilized in URS for analgesia and to minimize 
the visceral response to urinary tract dilation (Khan et al., 2016). Although URS 
complication rates are slightly higher than ESWL at 9-25%, most complications are minor 
and do not require intervention; the majority of complications following URS are secondary 
to the placement of a ureteral stent following the procedure which can cause morbidity and 
irritative voiding (Turk et al., 2016). 
Percutaneous nephrolithotomy was first introduced in 1976 and is now the standard of care 
for large (>20 mm) or complex renal stones (Fernström and Johansson, 1976; Turk et al., 
2016). The procedure is usually performed with the patient in prone position, where 
fluoroscopic imaging is utilized to aid endoscopic renal access via a posterior calyx through 
an initial needle puncture of the skin, muscle, and perineal fat (Khan et al., 2016; Vicentini et 
al., 2009; Turk et al., 2016). Once the access tract has been dilated, various instruments may 
be inserted and utilized for stone removal including lithoclast and ultrasound probes, 
graspers, and baskets. Overall, the stone free rate of PCNL is between 80-90% but it is more 
invasive and thus associated with more complications than both ESWL and URS. The most 
common complications postoperatively are fever, bleeding requiring transfusion, and stent-
associated morbidity, but more rarely PCNL can lead to sepsis, pneumothorax, embolization, 
or injury to other organs (Turk et al., 2016). 
In summary, management of renal calculi can be expensive, complicated, and in many 
patients, it does not prevent recurrence; these painful events adversely and multifactorially 
affect quality of life. Thus, investigation into the potential role that bacteria may play in stone 
formation, prevention, and treatment is required in order to decrease the burden of this 
disease. 
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1.5 Evidence for microbial involvement in nephrolithiasis 
The microbiota is the term used to describe the microorganisms present in a given 
environment (Whiteside et al., 2015). The term microbiome encompasses the biotic and 
abiotic factors in an environment, including the genes and genomes of the microbiota, as well 
as the products of the microbiota and the host (Whiteside et al., 2015). In the human body, 
the largest collection of bacteria resides in the colon (Sender et al., 2016). Although 
previously considered sterile, it is now known that the healthy urinary tract also harbours a 
unique microbiome that is distinct from the communities of the gut and vagina (Hilt et al., 
2014; Lewis et al., 2013; Wolfe et al., 2012). With the advent of next generation sequencing 
technologies, extensive research has been done on the role of the microbiome in human 
health.  
We now know that gut microbial dysbiosis can impact host metabolism (Larsen et al., 2010; 
Ley et al., 2006; Turnbaugh et al., 2006), immunity (Scher et al., 2013), the brain (Rhee et 
al., 2009), and even the heart (Gan et al., 2014). On the other hand, consuming beneficial 
microbes such as those present in probiotics and fermented foods may lower the risk of 
urinary conditions such as bladder cancer for reasons not yet uncovered (Larsson et al., 
2008). In addition, there are some studies suggesting that fermentation can reduce dietary 
derived phytates and oxalates, potentially lowering the risk of stones (Al-Wahsh et al., 2005). 
Overall, the intestinal microbiome and barrier is important for not only preventing pathogens 
from entering the bloodstream, but also for adsorption of nutrients, drugs, and coordinating 
immune responses. A range of proteins are key to its protective barrier, and if those are 
damaged a range of metabolic and inflammatory diseases can occur (Lee et al., 2018). 
To date, relatively little is known about the role of the gut and urinary microbiome in kidney 
stone disease. Several studies have identified differences in the gut microbiota of a small 
population of kidney stone formers compared to non-formers, and it has long been thought 
that gut colonization with Oxalobacter formigenes reduces oxalate kidney stone risk 
(Kaufman et al., 2008; Sidhu et al., 1998; Stern et al., 2016; Zampini et al., 2019). However, 
a closer investigation of the total human microbiome in nephrolithiasis as a whole is needed. 
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1.5.1 Oxalate and Oxalobacter 
As discussed above, urinary oxalate levels are a major risk factor for calcium oxalate kidney 
stone formation (Curhan et al., 2001). Blood oxalate levels are dictated by a combination of 
exogenous dietary consumption (Hatch and Freel 2005; Holmes et al., 2001), as well as 
endogenous production by the liver (Baker et al., 2004; Holmes and Assimos, 1998), 
erythrocytes (Jennings and Adame, 1996; Marengo and Romani, 2008), and the metabolism 
of ascorbate (Figure 2) (Knight et al., 2006; Linster and van Schaftingen, 2007; Marengo and 
Romani, 2008). One approach to lowering urinary oxalate levels is to decrease dietary 
oxalate intake by eliminating high oxalate foods, however the effectiveness of this method is 
not well established (Liebman and Al-Wahsh, 2011). Oxalate absorption occurs in the 
gastrointestinal tract (GIT) through both paracellular and transcellular transport (Hatch and 
Freel, 2005; Hatch and Freel, 2008), and can also be excreted from the circulation into the 
GIT (Figure 2) (Freel et al., 2006; Hatch et al., 2011).  
It has long been hypothesized that intestinal colonization by bacteria with oxalate-degrading 
capacity is inversely correlated with kidney stone risk. One such bacterium is the Gram-
negative obligate anaerobe O. formigenes, which utilizes oxalate in the intestine as its 
primary carbon source (Allison et al., 1985; Stewart et al., 2004). There have been numerous 
studies and reviews relating to O. formigenes, and it is now considered a keystone 
microorganism of the healthy microbiome (Barnett et al., 2016; Duncan et al., 2002; 
Goldfarb, 2004; Hatch et al., 2008; Knight et al., 2013; Liebman and Al-Wahsh, 2011; 
Prokopovich et al., 2007; Siener et al., 2013a; Stewart et al., 2004). However, until now, 
there has not been extensive research done on other bacterial types that may also be involved 
in human oxalate homeostasis. Some may degrade oxalate similarly to O. formigenes, while 
others may occupy important roles maintaining the intestinal barrier or altering oxalate 
transport in the GIT (Figure 2). We therefore need to consider the entire ecosystem including 
human intestinal barrier health for the handling of oxalate, and consequently, nephrolithiasis. 
1.5.2 The microbiota and kidney stone disease 
Several contemporary studies have looked to characterize the microbiota of kidney stones 
and of the stool of kidney stone formers (Barr-Beare et al., 2015; Stern et al., 2016; 
Tavichakorntrakool et al., 2012; Wang et al., 2014; Zampini et al., 2019). Although struvite, 
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not calcium oxalate stones, are typically associated with infection, Barr-Beare et al. (2015) 
revealed that oxalate stones retrieved from pediatric patients contained small numbers of 
bacteria. It may be that if bacteria ascend to the kidney from the bladder, an inflammatory 
event occurs which when combined with elevated urinary oxalate could form a nidus for 
crystal deposition (Figure 2) (Tavichakorntrakool et al., 2012). Thus, unlike urinary tract 
infections which tend to harbour 105 bacteria per mL urine, much smaller numbers may be 
sufficient to induce stone formation. In the first small study of the gut microbiota of kidney 
stone patients (23 patients, 6 healthy controls), Stern et al. (2016) detected higher levels of 
Bacteroides spp. and lower Prevotella spp. and beta diversity relative to healthy controls. 
Later in 13 stone patients and 13 healthy controls, Tang et al. (2018) showed similar findings 
with a decreased relative proportion of Eubacterium and bacterial beta diversity in the stone 
disease cohort. While interesting, these studies require a cautionary note: the tremendous 
heterogeneity of the gut microbiota can make drawing conclusions from so few participants 
extremely dubious, so it is evident that more studies are necessary. For now, the evidence 
suggests that members of the intestinal microbiota, not just O. formigenes, may affect stone 
disease. 
1.5.3 Sulfate-reducing bacteria 
An important factor connecting oxalate homeostasis, the microbiota, and intestinal barrier 
function is the sulfate anion transporter (Sat-1) protein, which is primarily expressed in the 
large intestine, but also in the liver and kidneys (Figure 2) (Schnedler et al., 2011). Albeit in 
a small cohort, a positive correlation has been shown for human variants of the SLC26A1 
gene (encoding Sat-1), and risk of recurrent calcium oxalate stones, suggesting a biologically 
and clinically relevant role for this protein in nephrolithiasis (Dawson et al., 2013). This 
transmembrane antiporter can be positioned on the apical and basolateral membrane surface 
of epithelial cells, acting to transport oxalate into the intestinal lumen for excretion via the 
bidirectional exchange of sulfate anions (Figure 2) (Hatch and Freel, 2005). One would 
expect populations of sulfate-reducing bacteria in the gut microbiota to play a key role in the 
activity of this transporter through modulating the bioavailability of its influx substrate, 
sulfate. This effect may be most notably observed in autistic cohorts that demonstrate three-
fold greater plasma oxalate levels, exhibit severe sulfate deficiencies, and harbour 
significantly higher levels of sulfate-reducing bacteria (e.g. Desulfovibrio spp.) in 
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comparison to controls (Konstantynowicz et al., 2012; Finegold, 2011). These traits when 
taken together are suspected to be involved in a greater risk of nephrolithiasis in these 
patients. 
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Oxalate is consumed in the diet and produced endogenously in the liver; it can be excreted 
through the intestine or kidneys. In the gut lumen, beneficial microbes can break down 
dietary oxalate, and O. formigenes is also able to stimulate the excretion of oxalate anions 
into the gut from the circulation via the SLC26A family of transporters. In the bladder, the 
beneficial endogenous microbiota can become displaced by uropathogens during urinary tract 
infections. If uropathogens ascend to the kidney, an inflammatory event can occur leading to 
the development of a crystal nidus. Consumption of fermented foods and beneficial bacteria 
may promote microbiota robustness, aiding in oxalate-handling and decreasing risk of stone 
formation. Substances that deplete the microbiota such as antibiotics, environmental 
pollutants, poor Western diet and lifestyle factors could alternatively increase the risk of 
stone formation. Dietary oxalate could be both beneficial (by stimulating oxalate-degrading 
bacteria within the gut), or detrimental (if the oxalate-handling capacity of the gut microbiota 
is insufficient and serum oxalate levels become elevated). Image templates from Servier 
Medical Art by Servier were used and modified under the Creative Commons Attribution 3.0 
Unported License. 
  
Figure 2. Oxalate flow in the body and proposed mechanism for microbial 
involvement in stone disease 
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1.6  Microbiome disruption and links to stone formation 
1.6.1 Antibiotics 
If the microbiome is involved in kidney stone disease, one would expect there to be a 
relationship between the disease and substances which disrupt or alter microbial populations, 
such as antibiotics. Disruptions to the microbiome have been well studied in metabolic 
syndromes such as obesity and diabetes, and there appears to be some correlation in the 
United States between where antibiotics are more frequently prescribed and these diseases, 
implicating the microbiome (Larsen et al., 2010; Turnbaugh et al., 2006; Turnbaugh et al., 
2009). There also appears to be some overlap of high antibiotic prescription and 
nephrolithiasis in the south-eastern United States (Mandel and Mandel, 1989; Fisang et al., 
2015; Hicks et al., 2013). It has been suggested that these “belts” of stone disease are related 
to dehydration; urinary solute precipitation is accelerated with decreased urine volume. 
Similarly, it has been suggested that the rise in kidney stone disease may be associated with 
global warming (Mandel and Mandel, 1989; Romero et al., 2010). Due to these multifactorial 
risks, it is difficult to ascertain whether these are just generally ailing populations, or whether 
their microbiomes have in fact been disrupted by antibiotic use, leading to stone formation 
and metabolic dysfunction. 
In a more direct fashion, a recent study by Tasian et al. (2018) showed significantly 
increased odds of urinary stone disease with the use of five classes of antibiotics. In an 
impressive study looking at over 285,000 healthy controls and nephrolithiasis patients, they 
determined the association between 12 oral antibiotic classes and stone disease. Specifically, 
significantly increased odds of stone disease were associated with sulfas, cephalosporins, 
fluoroquinolones, nitrofurantoin/methenamine, and broad-spectrum penicillins. These effects 
were most significant with recent exposure and use at younger ages.  
The incidence of nephrolithiasis in children also appears to be increasing rapidly, specifically 
in calcium-based calculi (Cameron et al., 2005). The reasons why this is occurring in 
children are unclear; it has been suggested that this is related to increasing BMI, salt 
consumption, decreased calcium and water intake, though perhaps it is due to the use of 
antibiotics in this young population (Sas, 2011). A mouse study modelling paediatric 
antibiotic treatment with either beta-lactam or macrolide antibiotics demonstrated altered 
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host and microbiota development, with a decrease in the relative abundance of oxalate 
metabolism genes, and fecal oxalate levels (Dethlefsen and Relman, 2011). Recent studies 
also suggest nephrolithiasis is up to four times more common in children with asthma, a 
condition that in turn has links with early childhood antibiotic use and microbiome dysbiosis 
(Nobel et al., 2015). Asthma is often treated with steroids, and glucocorticoid-mediated 
alterations on gut microbiota are known to occur (Kartha et al., 2017).  
In adults, patients treated with antibiotics for Helicobacter pylori had decreased detection of 
O. formigenes (Kelly et al., 2011; Kharlamb et al., 2011). Of four O. formigenes strains 
tested against commonly used antibiotics, all were resistant to amoxicillin, 
amoxicillin/clavulanic acid, ceftriaxone, and vancomycin and at least one strain to 
nitrofurantoin (Lange et al., 2012). This would imply that the organism would survive 
administration of these antibiotics, but it does not rule out the depletion of supportive or 
symbiotic bacterial types. 
Many mechanisms could be leading to these observed relationships with antibiotics and stone 
disease. If antibiotics increase stone formation, it could be that they are depleting other 
members of the gut microbiome that degrade and maintain oxalate homeostasis. 
Alternatively, direct crystallisation of various antibiotics can occur, and this precipitation in 
the kidney may act as a stone nidus (Chopra et al., 2000). Finally, the over- and misuse of 
antibiotics could be leading to antibiotic resistant uropathogens in the bladder which may 
ascend to the kidney, inciting inflammation and stone disease. The microbiome studies of the 
future will have to better control for antimicrobial substances (most recent usage, antibiotic 
class, use of sanitizers and detergents), as some of these compounds can have extremely 
long-term effects on the microbiome (Huang et al., 2015; Korpela et al., 2016). 
1.6.2 Environmental damage to the microbiota 
In addition to antibiotics, Western society is, in general, heavily medicated and bombarded 
with pharmaceuticals on a daily basis; in the United States, an average of over 11 
prescriptions were filled per person per year in 2011 (Nash, 2012). This reflects consumption 
of prescription or over-the-counter medication, but also inadvertently through drinking water 
(Khan and Nicell, 2015). It is now known that drugs originally developed to target human 
cells rather than microbes can alter the microbiome, and while many such drugs often induce 
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gastrointestinal side effects, the direct effect on the microbiome is rarely investigated. An 
exception to this, Maier et al. (2018) completed an extensive screening of more than 1000 
non-antibiotic marketed drugs against 40 representative gut bacterial strains. They found that 
almost a quarter of the tested drugs inhibited growth of at least one of the tested strains 
(Maier et al., 2018).  
Similar trends exist with other environmental pollutants such as pesticides and industrial 
chemicals. These compounds can persist in the environment thereby exposing humans 
through dietary consumption, allowing direct interaction with the microbiota in the 
gastrointestinal tract (Jin et al., 2017). Work by Defois et al. (2018) examined a panel of 
persistent organic pollutants in chemostat fermenters and determined that all chemicals tested 
shifted fecal microbial composition and metabolic activity, with the potential to induce a pro-
inflammatory state in the gut. 
Many lifestyle factors of Western society are also significantly damaging to the human 
microbiome. In the current age, stress is recognized to be a significant burden; in the United 
States, the Center for Disease Control and Prevention estimates stress to account for around 
75% of all doctor’s visits (Simmons and Simmons, 1997). Chronic psychosocial stress is 
known to have negative effects on the immune system and microbiome, which can ultimately 
result in diseases such as inflammatory bowel disease and colitis (Duffy et al., 1991; Gao et 
al., 2018; Langgartner et al., 2018). Kidney stone disease is also known to be impacted by 
stress and may be accounted for by the chain reaction of negative and microbiome-altering 
lifestyle factors that can be associated with stress such as poor diet, dehydration, and weight 
gain (Miyaoka et al., 2012).  
A sedentary lifestyle not only contributes to obesity but can also directly impact the 
microbiome. Exercise has been found to directly alter the microbiome composition and 
metabolic function independently of diet and can increase the bacterial production of 
beneficial short-chain-fatty acids important in maintaining intestinal barrier function (Allen 
et al., 2017; Allen et al., 2018). Importantly, light exercise can significantly decrease the risk 
of stone formation (Sorensen et al., 2014), and short-chain fatty acids as well as the bacteria 
responsible for their production have been shown to be depleted in the gut of kidney-stone 
patients compared to matched healthy controls (Liu et al., 2019; Ticinesi et al., 2018). A 
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potential mechanism for this relationship which warrants further investigation may be that 
the bacterially produced short-chain fatty acids, through maintaining intestinal barrier 
integrity, decrease the paracellular absorption of intestinal oxalate into circulation (Hatch and 
Free, 2005; Vaziri et al., 2016). 
The classical Western diet high in refined foods, animal protein, fat, and sugar, is known to 
cause negative alterations to the gut microbiome, including changes to bacterial abundance 
and community structure as well as decreased overall diversity (Turnbaugh et al., 2006; 
Turnbaugh et al., 2008). As discussed above, direct relationships between diet and stone 
formation have been established (for example, animal protein consumption and uric acid 
stone formation), and studies on the Western diet have shown it to promote risk factors for 
nephrolithiasis such as calcium oxalate crystalluria (Siener and Hesse, 2002). 
Alterations to the colonic microbiome can affect the intestinal environment at various levels, 
and lead to gut permeability (Marchesi et al., 2016). This can directly increase the absorption 
of oxalate and allow inflammatory bacterial components to enter the body (Hatch and Freel, 
2008). Alternatively, the repetitive insults against the microbiome through the average 21st 
century Western lifestyle can lead to indirect susceptibility to stone formation via collateral 
damage, depleting us of the protective microbial diversity we once had (Smits et al., 2017). 
1.7 Microbiome restoration therapies 
While the evidence of bacterial involvement in kidney stones is still emerging, it looks as if 
future preventative therapies will need to account for bacteria playing a role in the pathology 
of the disease. If childhood antibiotic use is truly determined to be a contributor to the 
condition, an objective of future treatments might be to cultivate or reacquire a beneficial 
microbiome. We obtain most of our bacteria externally, starting from our mothers, followed 
by other family members and then through our food and environment. In fact, while many 
factors determine the composition of the gut microbiome, diet has been shown to change its 
composition in as little as two days (David et al., 2014). Thus, it may be possible to resurrect 
or restore the microbiota of children exposed to antibiotics using beneficial microbes, before 
it moves to an intransigent profile. While high dietary oxalate has been associated with the 
risk of kidney stones in adults, it may be that it also facilitates propagation of oxalate-
degrading organisms. Studies suggest that the microbiota is an important factor allowing 
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humans to quickly adapt to altered diets, facilitating dietary diversity (David et al., 2014; 
Zimmermann et al., 2005). Thus, perhaps a compromise can be achieved whereby a diet can 
facilitate oxalate-degrading bacteria but not induce urolithiasis. In addition to dietary 
alterations, other approaches may be utilized to restore a beneficial and protective 
microbiome against stone disease. 
1.7.1 Oxalobacter replacement 
As detailed above, there are many studies which support the potential role that O. formigenes 
plays in degrading oxalate and enhancing its intestinal secretion; epidemiological evidence 
also supports its existence in ‘healthy’ people (Duncan et al., 2002). Studies have 
investigated the use of Oxalobacter as a probiotic, but surprisingly there have not been many 
studies in large cohorts that include O. formigenes supplementation while simultaneously 
controlling dietary oxalate intake (Duncan et al., 2002; Jairath et al., 2015). Although some 
stability and delivery studies have been performed on O. formigenes, its relatively limited use 
in human trials may be attributable to regulatory concerns when delivering a live 
microorganism without a history of safe use in foods for humans (Ellis et al., 2015). While 
the species is considered a strict anaerobe, it does appear to exhibit tolerability to bile salts 
and low pH, indicating O. formigenes could survive through the harsher regions of the GIT 
(Duncan et al., 2002). The Oxalobacter-containing probiotic Oxabact® is currently utilized 
for oxaluria and may be one such product urologists lean on in the future of kidney stone 
treatment and prevention. 
1.7.2 Probiotics 
Some species of lactic acid bacteria are also able to degrade oxalate, though to a much lesser 
degree than O. formigenes (Miller and Dearing, 2013). Studies have shown both positive and 
negative outcomes when testing non-Oxalobacter probiotic strains as therapy for patients 
with kidney stones (Abratt and Reid, 2010; Campieri et al., 2001; Lieske et al., 2010; 
Okombo and Liebman, 2010). It is important that probiotic studies be evaluated on a strain, 
dose, and format basis. It is not yet possible to determine whether this potential treatment has 
value due to the small numbers of patients, lack of follow-up, and broad preparations that 
have been used in these studies thus far (Abratt and Reid, 2010; Campieri et al., 2001; Lieske 
et al., 2010; Okombo and Liebman, 2010). Although yet inconclusive, the concept has merit 
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and deserves further investigation. Not only might some probiotic strains degrade dietary 
oxalate before absorption, but they could also stabilize intestinal barrier integrity- a factor 
known to be critical in oxalate absorption into circulation and the luminal secretion of oxalate 
during host-mediated detoxification (Del Piano et al., 2012). 
1.7.3 Engineered microbial solutions 
Oxazyme® is a non-systemic orally delivered drug composed of recombinant oxalate 
decarboxylase for the treatment of primary hyperoxaluria. In vitro studies have shown that 
Oxazyme® can degrade oxalate in both simulated gastric and small intestinal environments, 
acting as an intercept therapy for the management of dietary oxalate prior to absorption 
(Mufarrij et al., 2013). However, it remains to be seen how often the enzyme has to be taken, 
when and at what concentration, and what impact it has on the microbiome and long-term 
risk of urolithiasis. Bacillus subtilis contains the oxalate decarboxylase gene Yvrk and has 
also been investigated for its functionality in oxalate nephrolithiasis treatment (Tanner and 
Bornemann, 2000). An Escherichia coli strain expressing the Yvrk from B. subtilis was 
developed and successfully degraded oxalate in vitro; purified enzyme from the recombinant 
E. coli showed oxalate degradation ability in a rat model of hyperoxaluria (Jeong et al., 2009; 
Lee et al., 2014). Similarly, a recombinant Lactobacillus plantarum was created to express 
and secrete oxalate decarboxylase which showed some efficacy in a rat model (Sasikumar et 
al., 2014a; Sasikumar et al., 2014b). While these studies demonstrate it is possible to design 
and engineer strains to produce oxalate-degrading enzymes, it is undetermined if they will 
promote oxalate’s intestinal secretion. There are likely other factors that impact how O. 
formigenes has adapted to handle oxalate in the colonized human gut, and it is unclear if 
recombinant probiotics or purified enzymes would provide long-term therapeutic value to 
oxalate nephrolithiasis patients. 
1.7.4 Fecal microbiome transplantation 
Animal studies have demonstrated that improved oxalate degradation may be achieved after 
whole community microbial transplants. Miller et al. (2016) showed that a fecal microbiota 
transplant (FMT) from the wild mammalian herbivore Neotoma albigula into laboratory rats, 
resulted in significant increases in oxalate degradation, an effect that persisted up to 9 months 
after the initial transplant. The selection of Neotoma albigula was important as it is uniquely 
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attuned to consume a diet high in oxalate (up to 9% dietary oxalate by weight), a phenotype 
which, as in all mammals, in conferred exclusively by the gut microbiota as opposed to 
mammalian enzymes. It will be interesting to see if this approach is developed and shown to 
be efficacious in humans for the treatment for oxalate kidney stone disease. 
 
Currently, the primary use of FMT in humans is for recurrent Clostridium difficile infection, 
with reported success rates of up to 90% (Cammarota et al., 2015; Jiang et al., 2017; Kelly et 
al., 2016; van Nood et al., 2013). In Canada, FMT is performed on a routine basis for C. 
difficile infections and is proving to be one of the best treatment options (Chanyi et al., 
2017). The therapy is now being tested for treatment in extra-intestinal diseases, including 
metabolic syndrome, non-alcoholic fatty liver disease, and even multiple sclerosis (Borody et 
al., 2013; Craven et al., 2020; Henao-Mejia et al., 2012; Vrieze et al., 2012). Of interest, in a 
small metabolic syndrome study, patients who received an FMT from a lean donor often 
restored keystone microbes, including O. formigenes (Vrieze et al., 2012). This treatment 
method may be promising for nephrolithiasis because of the known role of intestinal bacteria 
in oxalate degradation, barrier function, and oxalate secretion. While introduction of O. 
formigenes or other single-strain probiotics to a dysbiotic microbiome may only have short-
term effects, an FMT could show promise as a more potent form of microbiome modification 
and treatment. Such an approach will require a new inclusion criterion for the donor, namely 
that they carry the Oxalobacter organism or other similarly beneficial traits. 
A potentially more regulated approach to the FMT would be strategic microbiome 
reconditioning (Allen-Vercoe, 2013; Petrof et al., 2013). A dysbiotic microbiome from a 
diseased individual could be collected, restored for specific functions ex vivo, then 
reintroduced to the patient (Chanyi et al., 2017). This could be achieved by culturing the 
original sample in fermenters, or chemostat systems that have been pulsed with specific 
substances in order to increase the relative abundance of bacterial groups of interest. As 
discussed above, patients with oxalate stones are often advised to limit dietary oxalate. This 
is controversial because some people with diets high in oxalates, such as vegetarians, are 
often not at an increased risk of developing stones, perhaps because their microbiome is well-
adapted to oxalate processing. Culturing of a stone patient’s fecal sample in the presence of 
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oxalate may offer a way to restore oxalate-degrading species to higher abundance, without 
the risks of the dietary oxalate consumption. The benefit of such a fermenter system would 
be that stone patients are receiving modified autologous transplants, thereby minimizing the 
risk of receiving any unwanted phenotypes that sometimes occur in allogeneic transplants 
(Alang and Kelly, 2015). 
1.8 In vivo models of stone disease 
It is important to utilize models to explore the many mechanistic questions that remain in 
nephrolithiasis and stone formation research. Both vertebrate and invertebrate models exist, 
each with their own strengths and limitations: models in both rats and mice have been 
developed, as well as in porcine, canine, and fruit flies. All models will be briefly reviewed 
with emphasis on similarities and differences compared to human stone pathophysiology and 
anatomy. 
1.8.1 Rodent models of stone disease 
In rats, hypercalciuria, several models of hyperoxaluria, as well as struvite stones have been 
developed. Bushinsky and Favus (1988) first published their model of hypercalciuria from an 
inbred strain of Sprague-Dawley rats. The model was developed after four successive 
generations of rats were selected with hypercalciuria caused by an increased number of 
vitamin D receptors in the gut, kidneys, and bones leading to increased calcium absorption 
(Bushinsky and Favus, 1988; Krieger et al., 1996; Li et al., 1993; Yao et al., 1998). 
Hyperoxaluria has also been induced in rats via intraperitoneal injection of sodium oxalate, 
dietary consumption of glycolic acid, ethylene glycol in drinking water, intraperitoneal 
injection of hydroxy-L-proline, dietary consumption of potassium oxalate, dietary vitamin B6 
deficiency, ileum resection, and Roux-en-Y gastric bypass (Canales et al., 2013; Gershoff 
and Andrus, 1961; Khan et al., 1992; O’Connor et al., 2005; Ogawa et al., 1990; Robinson et 
al., 1990; Tawashi et al., 1980; Wiessner et al., 2011). A struvite stone model was also 
developed in outbred Sprague-Dawley rats, whereupon zinc discs were implanted in the 
bladder followed by instillation of Proteus mirabilis, leading to subsequent bladder calculi 
formation (Olson et al., 1989). 
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In mice, hyperoxaluria is associated with the ob/ob model, and has been induced by similar 
methods to the rat models (ethylene glycol, hydroxy-L-proline and glyoxalate), but genetic 
knockout models are more commonly available and utilized in mice (Amin et al., 2018; Khan 
and Glenton, 2010). For example, knockouts for oxalate transporter SLC26A1 have been 
shown to induce CaOx stones, others for the sodium-hydrogen exchanger regulator factor-1 
(NHERF-1) have been shown to induce renal calcium phosphate crystals, and knockouts for 
the cystine transporter light chain subunit SLC7A9 induce cystinuria and cystine stones 
(Feliubadalo et al., 2003; Jiang et al., 2006; Weinman et al., 2006). Both mice and rats have 
quite disparate kidneys compared to humans as they are obviously significantly smaller and 
have unipapillate- compared to human multi-papillate structure, although microscopically 
they have similar components and the species are genetically around 90% similar to humans 
(Mullins and Mullins, 2004; Tzou et al., 2016). 
1.8.2 Porcine models of stone disease 
The porcine models of stone disease have utilized dietary supplementation of hydroxyproline 
and gelatin to induce hyperoxaluria (Mandel et al., 2004; Patel et al., 2012). Anatomically 
porcine and human kidneys are both multi-papillary, with comparable urine concentrations 
and glomerular filtration rates (Sachs, 1994). Although a benefit in terms of their relevance to 
humans, the major limitation of the porcine model is the animal’s size and subsequent high 
cost of husbandry. Another significant limitation for the purposes of urological study in pigs 
is that urine collection can also be quite challenging, as several studies have reported missed 
data due to urinary tract infections and catheter problems (Kaplon et al., 2010; Patel et al., 
2012). 
1.8.3 Canine models of stone disease 
Much like humans and unlike other experimental models, canines commonly suffer from 
highly recurrent, spontaneous kidney stones (Furrow et al., 2017). The breeds Bichon Frise, 
Miniature Schnauzer, and Shih Tzu are considered clinically at substantially higher risks than 
others for struvite, calcium oxalate, and apatite stone formation (Low et al., 2010). Based on 
the spontaneous nature of their stone formation, canines present an animal model that is easy 
to work with in the laboratory and appropriate for cross-sectional studies in pet breeds. 
Having said that, the high cost, stringent ethical standards, and smaller sample size studies 
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are a hindrance. In addition, canine kidneys are significantly smaller than that of humans 
(except in dogs with a height >70 cm (137 g vs 39 g)), and the glomerular filtration rate for 
canines is approximately 2-fold that of humans (Maurya et al., 2018; von Hendy-Willson and 
Pressler, 2011). The collecting system is also structurally disparate between humans and 
dogs, whereby dogs are unipapillary but multipyramidal (Pereira-Sampaio et al., 2009). 
1.8.4 Drosophila melanogaster models of stone disease 
The conception of urinary stones in Drosophila melanogaster (DM) was first described by 
Chi et al. (2010) and solidified as a model of nephrolithiasis by Chen et al. (2011). Since its 
advent, it is now one of the most utilized models of the disease, due to its numerous 
advantages (Miller et al., 2013). DM have a short life cycle of fewer than 60 days in a 
laboratory setting and reproduce prolifically, while husbandry costs are very economical. As 
invertebrates, experimentation on DM also rarely requires approval by organizational ethical 
review boards. These features all facilitate easy experimentation and rapid data generation. 
There is a wealth of genetic tools available in DM, and mutant fly lines are readily available 
and inexpensive from commercial and academic stock centres. While the anatomy of humans 
and DM are inherently different, there are many functional, structural, and genetic 
similarities between the DM Malpighian tubule and the human renal tubule, grounding DM 
as a valid model for the study of nephrolithiasis (Miller et al., 2013).  
The renal system in DM is composed of nephrocytes and Malpighian tubules (MTs)- two 
functionally distinct organs (Figure 3A). The DM hemolymph is filtered by the nephrocytes 
which are located in a cluster near the heart and esophagus, in a process which mirrors the 
filtration of blood by podocytes within the glomerulus in vertebrates (Weavers et al., 2009). 
Nephrocytes were at one point referred to as “storage kidneys”, where waste products filtered 
from haemolymph are actively endocytosed and are thought to be stored for the insect’s 
lifetime or coordinatively released in times of excessive diuresis (Weavers et al., 2009). The 
MTs resemble the remainder of the human nephron and collecting duct, actively transporting 
ions and solutes from the hemolymph and producing urine in the tubule lumen (Miller et al., 
2013). DM have a posterior and anterior pair of MTs which join at two common ureters 
between the mid- and hindgut. Despite their relatively small genome size on just four 
chromosomes, nearly 80% of renal transporters in humans have genetic orthologs in DM 
(Reiter et al., 2001).  
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Several models of stone formation exist in DM, including both dietary and genetic varieties. 
Hyperoxaluria and calcium oxalate stone formation can occur in flies’ MTs upon 
supplementation of ethylene glycol, sodium oxalate, and hydroxy-L-proline, as well as 
through genetic knockdown of dPrestin, the DM homolog of the anion exchanger SLC26A6 
(Chen et al., 2011; Hirata et al., 2012). A model of xanthine stone formation was generated 
through the silencing of xanthine dehydrogenase, while disruption of the Uro gene for urate 
oxidase is being investigated with regards to uric acid stone formation (Ali, 2017; Chi et al., 
2015; Lang et al., 2018). 
Some of the limitations of the DM stone models include the differences in anatomy between 
flies and humans. Where humans have the glomerulus and nephron, flies have the distinct 
organs nephrocytes and Malpighian tubules. The separate alimentary canals for liquid and 
solid waste in humans differ from flies which have a common cloaca where the ureters join 
the gut. Finally, as an invertebrate lacking bone, DM have a fundamentally different 
mechanism of calcium homeostasis from humans (Miller et al., 2013).  
Compared to the human microbiota, that of DM is extremely simplistic and of very low 
diversity. Specifically, the genera Lactobacillus and Acetobacter comprise upwards of 95% 
of the microbiota in DM (Figure 3B) (Wong et al., 2011; Blum et al., 2013). Although in 
some regards this is a disadvantage for direct comparability of DM to humans, it is useful in 
experimentation in order to deconstruct potentially complex polymicrobial effects. Taken 
together, this simple in vivo model is useful for understanding the effects of specific 
members of the microbiome and how they may impact stone disease.  
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Figure 3. Drosophila melanogaster excretory anatomy and microbiota 
A) The nephrocytes filter DM hemolymph, and urine is produced in the lumen of the 
Malpighian tubules. DM have one anterior pair and one posterior pair of Malpighian tubules; 
each pair connects at a common ureter at the junction of mid- and hindgut. B) The DM 
microbiota (i) is dominated by the genera Lactobacillus (phylum Firmicutes) and 
Acetobacter (phylum Proteobacteria), in comparison to the more complex human gut 
microbiota (ii). Average bacterial phyla present in i) DM based on Wong et al. (2011) and ii) 
humans based on Li et al. (2014). 
B 
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i ii 
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1.9 Methodologies to assess microbial communities 
For around 350 years, microscopes have been used to evaluate microbial communities. When 
van Leeuwenhoek first visualized bacteria in water samples in the late 1670’s, he was able to 
characterize them by relative size and morphology (Bardell, 1982). Van Leeuwenhoek was 
later the first to describe human-associated microbiota in his microscopic surveys of human 
saliva (Bardell, 1982). Fast forward to today, and immense technical advancement has 
drastically improved the visualization of microbes. Optical microscopy is still a very useful 
tool when visualizing the diversity and spatial organization of bacteria in different 
environments, especially when combined with bacterial staining or labelling strategies 
(Tropini et al., 2018).  
Historically, when studying the human microbiota, culture techniques were utilized to grow 
bacterial isolates in predetermined medium. However, upwards of 80% of bacteria that reside 
within us are fastidious with very specific and complex growth requirements, making them 
“unculturable” under standard lab conditions. Thus, the diverse microbial composition of the 
human gut was drastically underestimated (Wilson et al., 1996).  For this reason, the 
development of molecular, culture-independent techniques has been paramount in 
understanding the human microbiome. Early studies of the microbiota involved the 
generation of clone libraries of the small subunit ribosomal RNA genes (16S rRNA) 
followed by Sanger sequencing of short inserts (Wilson et al., 1996). Denaturing gradient gel 
electrophoresis (DGGE) was also used but necessitates significant user skill and lacks 
sensitivity (Burton and Reid, 2002). Fluorescence in situ hybridization (FISH) can now be 
used to enumerate bacteria with flow cytometry based on the binding and subsequent 
fluorescence of complementary 16S rRNA sequence probes, but this is probe-dependent and 
cannot identify unknown species (Fraher et al., 2012; Namsolleck et al., 2004). PCR-
electrospray ionization mass spectrometry (PCR-ESI-MS) is yet another molecular technique 
capable of characterizing microbial communities, involving mass spectrometry of PCR 
amplicons such that the composition of nucleotides is deduced and compared against a 
database (Ecker et al., 2008; Nickel et al., 2015). This technique appears to perform 
comparatively to 16S rRNA gene sequencing with shorter workflow times but has not been 
widely implemented in the microbiome field, and instead has found favour for clinical 
diagnostics (Peeters et al., 2016; Zhang et al., 2019). Now, the most commonly used method 
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in the microbiota research field is 16S rRNA gene sequencing; it has become a powerful tool, 
requiring PCR with carefully designed barcoded primers and sequencing adapters that 
facilitate massive parallel sequencing output (Figure 4) (Gloor et al., 2010).  
Classical techniques such as Sanger sequencing are capable of sequencing the entire 16S 
rRNA gene length, but lack multiplexing capability; when utilizing next generation 
sequencing (NGS, for example with the Illumina platform as was used in Chapters 2, 3, 4, 
and 5 of this thesis), sequencing read length is limited. The bacterial 16S rRNA gene has 
regions of high conservation flanking 9 regions of hypervariability (V1-V9, Figure 4). Due to 
NGS’s shorter read lengths, the variable region of interest to be sequenced should be 
carefully chosen to optimize the resolution of the microbiota profiling (Soergel et al., 2012). 
Based on the GC content of variable regions within different bacterial genera, PCR 
amplification may not work optimally biasing the data (Alcon-Giner et al., 2017). 
Alternatively, the variable regions of different bacterial groups may not in fact be that 
“variable”, limiting differentiation at lower taxonomic levels (Alcon-Giner et al., 2017). 
Thus, the V-region primer selection should be mindful of the suspected bacterial populations 
found within the sampled environment. Primers 515F-806R targeting the V4 region are 
utilized in the Earth Microbiome project and throughout this thesis, and are capable of 
differentiating common genera within the gut upon paired end sequencing (Thompson et al., 
2017). Comparatively, primers targeting the V6 region can provide resolution between 
species of Lactobacillus, and thus would be utilized in sequencing of vaginal samples or 
yogurt, for example (Thompson et al., 2017). 
Through the early years of microbiota analysis, the Roche 454 method of pyrosequencing 
was favoured due to the ability to generate reads upwards of 500 bases in length, spanning 
multiple variable regions on the 16S rRNA gene (Caporaso et al., 2010). When the Illumina 
platform was first utilized in the human microbiota field in 2010, the sequence length was 75 
bases, but modern incarnations of the Miseq and HiSeq systems can generate lengths > 600 
bp and have superseded 454 as the favoured contemporary platform (DiBella et al., 2013; 
Hummelen et al., 2010; Salipante et al., 2014). Nascent long-read sequencing technologies 
(capable of generating read lengths of 10s to 100s of kilobases) including those developed by 
PacBio and Oxford Nanopore may soon replace 16S variable region amplicon sequencing 
altogether (Callahan et al., 2019; Dohm et al., 2020). 
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Where 16S rRNA gene amplicon sequencing is the classic microbiota sequencing, shotgun 
metagenomic sequencing surveys the entire genome and genetic material of all organisms 
present in a sample, as opposed to only the 16S rRNA gene in bacteria. Shotgun 
metagenomic sequencing was utilized in Chapter 3 of this thesis. Metagenomic sequencing is 
less susceptible to biases inherent in amplicon sequencing, can provide higher taxonomic 
resolution, and can capture information from host, bacterial, viral, and fungal DNA, as well 
as functional pathways present in a sample (Hillmann et al., 2018; Jovel et al., 2016). 
However, it is significantly more expensive than 16S rRNA gene sequencing for both 
sequencing platform and computational costs and has fewer computational tools and 
databases available for analysis (Gevers et al., 2012). 
The bioinformatic analysis of NGS data is complex, time-consuming, and there is no 
standard methodology across the field. Datasets generated by high-throughput sequencing are 
compositional in nature, as there is an arbitrary “total” imposed by the sequencing 
instrument; although the reads are discrete counts, they represent just a sampling of the 
original genetic material present in the sample (Gloor et al., 2017). When microbiome data 
are not treated in the appropriate compositional manner, incorrect assumptions and 
conclusions can be drawn (for example, the difference between claims of changes in absolute 
vs. relative abundance). Quantitative Insights Into Microbial Ecology (QIIME) is a 
commonly used analysis toolkit originally developed for pyrosequencing datasets, which 
facilitates data visualization, diversity analysis, and simple statistics (Caporaso et al., 2010). 
Several other analysis tools have been developed to overcome challenges in microbiome data 
analysis, including ALDEx2, and compositional data analysis packages within R software 
(van den Boogaart and Tolosana-Delgado, 2008; Fernandes et al., 2013; McMurdie and 
Holmes, 2013; R Core Team, 2013). These sequencing and bioinformatic tools have been 
utilized throughout the chapters of this thesis in various patient and sample populations, with 
the aim of determining how the microbiota influences stone disease. 
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A) The 16S rRNA gene has highly conserved (light blue) regions surrounding nine variable 
(dark blue) regions. B) The primers utilized in this thesis amplified base pairs 515-806 
encompassing the fourth variable region, and contained an Illumina adapter (sequences 
shown), followed by four random nucleotides, one of sixteen unique 12-mer barcodes (not 
shown), and the forward and reverse primers (sequences shown).   
Figure 4. Schematic of 16S rRNA gene and Illumina primer design 
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1.10 Project scope and purpose 
At the commencement of my doctoral studies, little was known about the gut or urinary 
microbiome’s role in nephrolithiasis beyond O. formigenes colonization and the weakly 
described association between stones and a history of urinary tract infections. Thus, this 
project sought to increase the understanding of how the microbiome as a whole impacts stone 
disease, with specific emphasis on non-infectious stones. The following chapters will address 
four objectives of this project.  
Objective 1. Before first evaluating the microbiome of kidney stone patients, the second 
chapter of this thesis aimed to establish a standard method of collecting and storing fecal 
samples for the purpose of next generation sequencing (NGS). While previous studies in our 
lab have evaluated best practices for processing urinary samples, the most patient-amenable 
and highest fidelity method of collecting fecal samples had not previously been assessed. In 
Chapter 2 it was determined whether toilet paper collected at home would be appropriate for 
NGS analyses after experiencing temporal and temperature variability, as would be 
experienced through the Canadian Postal Service. Additionally, it was investigated whether 
or not preservation with a nucleic acid stabilization agent was necessary. The methodology 
determined here was then utilized for the clinical study in Chapter 3 of this thesis. 
Objective 2. Chapter 3 involved a clinical study into the differences in the human 
microbiome at different anatomical sites in kidney stone forming patients and healthy control 
participants. This study is the first of its kind utilizing shotgun metagenomic sequencing to 
evaluate the entire genetic capability of the gut community, as well as 16S rRNA gene 
sequencing to characterize the bacterial communities present in the bladder from multiple 
time points throughout stone treatment, and the microbiota within the stone itself. We 
detected significant and novel alterations in both the urinary and gut bacterial communities 
between the cohorts at both a taxonomic and functional level, which may be directly 
implicated in stone disease. 
Objective 3. Chapter 4 describes a second clinical study that was undertaken to characterize 
the microbial communities associated with ureteral stents in a cohort of kidney stone forming 
patients, as stent placement is an almost ubiquitous component of surgical kidney stone 
management. This study is the largest and most comprehensive of its kind to date. The results 
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show that bacteria are commonly associated with stents and can lead to encrustation. It was 
established that the urinary microbiota is often not representative of the microbiota on the 
stent surface and is not an appropriate biomarker of stent encrustation. Several patient 
attributes were associated with altered stent microbiota, and antibiotic use was determined 
not to impact the microbiota, nor the degree of stent encrustation. 
Objective 4. The fifth chapter investigates how specific beneficial and pathogenic microbes 
impact stone formation utilizing in vivo and in vitro models of stone disease. This chapter 
includes further method development and establishment of novel imaging techniques, 
evaluation of the implications of uropathogen exposure, as well as determination of the 
therapeutic potential of a novel probiotic for the treatment of nephrolithiasis. Results 
demonstrate that different uropathogens have diverging implications for stone disease, and 
the bacterium Bacillus subtilis strain 168 has promising probiotic capacity, improving stone 
disease burden in our Drosophila melanogaster model. 
Overall, through both discovery and hypothesis-driven research, the unifying theme of this 
thesis is the desire to understand how the microbiome impacts stone disease, from the 
relative risk factors, to the inception of stone formation, and how it may further impact 
treatment and be exploited in preventative therapy. I hope that this body of work and the 
resulting publications from my PhD will have translational impact on urological practice and 
improve our understanding of microbes in human health. 
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Chapter 2  
2 Evaluation of sampling and storage procedures on 
preserving the community structure of stool microbiota: A 
simple at-home toilet-paper collection method 
This chapter is adapted with permission (Appendix A) from: 
Al, K.F., Bisanz, J.E., Gloor, G.B., Reid, G., and Burton, J.P. (2018). Evaluation of sampling 
and storage procedures on preserving the community structure of stool microbiota: A simple 
at-home toilet-paper collection method. J. Microbiol. Meth. 144, 117-121. 
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2.1 Abstract 
The increasing interest on the impact of the gut microbiota on health and disease has resulted 
in numerous human microbiome-related studies emerging. However, multiple sampling 
methods are being used, making cross-comparison of results difficult. To avoid additional 
clinic visits and increase patient recruitment to these studies, there is the potential to utilize 
at-home stool sampling. The aim of this pilot study was to compare simple self-sampling 
collection and storage methods. To simulate storage conditions, stool samples from three 
volunteers were freshly collected, placed on toilet tissue, and stored at four temperatures 
(−80, 7, 22 and 32 °C), either dry or in the presence of a stabilization agent (RNAlater®) for 
3 or 7 days. Using 16S rRNA gene sequencing with the Illumina MiSeq platform, the effect 
of storage variations for each sample was compared to a reference community from fresh, 
unstored counterparts. Microbial diversity and composition were not significantly altered by 
any storage method. Samples were always separable based on participant, regardless of 
storage method suggesting there was no need for sample preservation by a stabilization 
agent, which may complicate sample collection for the study participant and lead to increase 
costs. In summary, if immediate sample processing is not feasible, short term storage of 
unpreserved stool samples on toilet paper offers a reliable way to assess the microbiota 
composition by 16S rRNA gene sequencing. 
  
69 
 
 
 
2.2 Introduction 
The human body, specifically the intestinal tract, is the site of a vast array of metabolically 
active microbes, collectively referred to as the microbiome. Over recent years the accuracy 
and scale of microbiome studies have increased dramatically due to the availability of next 
generation sequencing, and it is now recognized that the gut microbiota has a role in human 
health and disease (Manichanh, 2006.; Turnbaugh et al., 2006). The most common method of 
assaying the gut microbiota is through a fecal sample, but unfortunately there is no standard 
protocol for sample collection or processing. A fresh sample with immediate DNA extraction 
is the gold standard for microbiome researchers, however immediate freezing at -80 °C has 
also been shown to maintain the microbial composition (Carrol et al., 2012; Fouhy et al., 
2015). Unfortunately, these are often not viable sampling procedures for clinical or field 
studies, where -80 °C may not be available or at the very least would require an additional 
clinic appointment for study participants. Thus, altered sampling and storage methodologies 
are often utilized for the purpose of maintaining the microbial community composition 
throughout storage (Choo et al., 2015; Song et al., 2016). 
Such factors can all contribute to additional study costs and reduced participant recruitment. 
Additionally, various methodologies can make cross comparison between studies difficult. 
The American Gut sampling methodology is the simplest developed protocol to date 
(McDonald et al., 2015). Participants use a swab to take a small amount of fecal material 
from a stool or soiled toilet paper and mail it to the laboratory for processing. Of note, the 
length of time in transit and temperature exposure for each sample is variable depending on 
the time of year and participant location. Others have suggested that nucleic acids from fecal 
bacteria should be preserved in hyperosmotic solutions containing agents to prevent their 
degradation (Voigt et al., 2015). We sought to determine if a method adapted from the 
American Gut Project would provide reliable 16S rRNA gene profiles, even if stored under 
different conditions modelling seasonal temperature changes experienced during postal 
shipment (Gilbert et al., 2014; McDonald et al., 2015). 
Although the immediate processing or deep freezing of samples is preferred, research groups 
have utilized cold chain storage and various nucleic acid preservation agents designed to 
maintain the bacterial DNA and microbial community structure of fecal samples (Blekhman 
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et al., 2016; Flores et al., 2015; Fouhy et al., 2015). In the present pilot study, we used a 
standard DNA extraction protocol based upon the Human and Earth Microbiome Project 
protocols and compared preservation-free stool to that stored in RNAlater® (Gilbert et al., 
2014). In addition, each stabilization condition was tested at multiple temperatures and 
lengths of time, to simulate those experienced in the mailing of samples through the 
Canadian postal service, which can range in extremes of temperature beyond 35 °C and −35 
°C. The use of RNAlater® was selected as it is nontoxic and quickly stabilizes RNA and 
DNA, thus may be easily utilized by study participants during at-home stool collection. 
Based on previous literature, we hypothesized that the use of RNAlater® would contribute to 
an initial skew in the microbiota profile compared to immediately extracted, unpreserved 
stool samples, but would minimize alterations in the profile over storage at increased 
temperature (Flores et al., 2015; Hale et al., 2015; Liang et al., 2020; Voigt et al., 2015). We 
also speculated that unpreserved samples would alter greatly in their microbiome profile over 
increasing temperatures and days in storage, while frozen samples would most closely 
resemble the immediately extracted, unpreserved stool samples (Hang et al., 2014). 
2.3 Materials and Methods 
2.3.1 Stool sample collection and processing 
Three volunteers were recruited at St. Joseph's Hospital in London, Canada. The Western 
University Health Science Research Ethics Board granted ethical approval for all 
experiments involved in the study. The methods were carried out in accordance with the 
approved guidelines and all participants provided written informed consent (REB #105443). 
The group was unrelated and comprised of one male recently immigrated to Canada from 
China, and one male and female Canadian of European ethnicity. Participants ranged in age 
from 23 to 29 years old and had not used antibiotics recently. Samples were collected in 
sterile containers from which 5 g was immediately removed (within 10 min of collection), 
suspended with 10 ml of sterile phosphate buffered saline (PBS), and vortexed in a sterile 
centrifuge tube until homogenization. A protocol was designed to model direct shipment of 
soiled toilet paper in sterile collection bags, as it would be a simple and more appealing 
method for study participants, compared to the use of sterile swabs. For this reason, 200 μL 
of the homogenized stool was aliquoted onto a sheet of clean toilet paper for every storage 
method condition to be tested (Figure 5). For samples stored in a preservation agent, the 
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paper was fully submerged in 5 mL RNAlater®, before being placed in a sterile 15 mL 
centrifuge tube; unpreserved paper was dry. A total of 18 aliquots were prepared from each 
individual (Figure 5, Table 2). 
DNA extraction was performed in accordance with the Earth Microbiome Project standard 
protocols, with the MoBio PowerSoil® DNA Isolation Kit (Mobio, Carlsbad, CA). Sterile 
PBS (5 mL) was added to unpreserved samples immediately prior to DNA extraction. 
Samples in either RNAlater® or PBS were vortexed for 5 min prior to extraction to 
homogenize the toilet paper with the stool sample. The stool homogenate (250 μL) was 
added to the PowerBead tubes provided in the PowerSoil® kit. All samples were extracted in 
duplicate. The fresh extraction samples (N/A days in storage) were extracted immediately 
following the sample preparation, while the flash frozen samples were placed at − 80 °C for 
30 min, and then immediately extracted. DNA was stored at −20 °C following extraction. 
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Figure 5. Methodological schematic of study design 
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Table 2. Sample identifiers 
  
Condition Sample identifier 
Subject of origin 3 individuals (sub1, sub2, sub3) 
Preservation method RNAlater, or no preservation (Pres, NoPres) 
Days in storage None, 3, or 7 (NA, d3, d7) 
Storage temperature -80, 7, 22, or 32°C (80C, 7C, 22C, 32C) 
DNA extraction Performed in duplicate (ex1, ex2) 
PCR Performed in duplicate (p1, p2) 
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For PCR amplification, 20 μL of the DNA template extract was transferred to 96-well PCR 
plates, in duplicate. These plates were then used with the BioMek® 3000 Laboratory 
Automation Workstation for automated PCR reagent set up. Amplifications of the V4 region 
of the 16S ribosomal RNA gene were carried out with the primers (5′-3′) 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNxxxxxxxxGTGCC 
AGCMGCCGCGGTAA and (5′-3′) CGGTCTCGGCATTCCTGCTGAACCG 
CTCTTCCGATCTNNNNxxxxxxxxGGACTACHVGGGTWTCTAAT wherein xxxxxxxx is 
a sample specific nucleotide barcode and the preceding sequence is a portion of the Illumina 
adapter sequence for library construction. Ten microlitres (3.2 pmol/μL) of a total of 32 
primers (16 left and 16 right) with unique barcodes were arrayed in 96 well plates. The 
BioMek® robot transferred 2 μL of the DNA template into a plate containing 10 μL of each 
unique primer. Then 20 μL of Promega GoTaq® Colourless Master Mix (Promega, 
Maddison, WI) was added to the DNA template and primers. The final plate was firmly 
sealed with a foil PCR plate cover. This plate was placed in the Eppendorf Mastercycler® 
thermal cycler (Eppendorf, Mississauga, ON), where the lid was kept at 105 °C. An initial 
warm-up temperature of 95 °C was used for 2 min to activate the GoTaq®. Afterwards, the 
volumes underwent 25 cycles of 95 °C for 1 min, 52 °C for 1 min, and 72 °C for 1 min. After 
completion, the temperature of the thermal cycler was held at 4 °C, and amplicons were then 
stored at −20 °C. 
2.3.2 DNA sequencing and data analysis 
Processing of DNA samples and DNA sequencing was conducted at the London Regional 
Genomics Centre at Robarts Research Institute (London, ON). Amplicons were quantified 
using pico green (Quant-It; Life Technologies, Burlington, ON) and pooled at equimolar 
concentrations before cleanup (QIAquick PCR clean up; Qiagen, Germantown, MD). The 
final samples were sequenced using the MiSeq by Illumina® platform, with 2 × 300 bp 
paired-end chemistry. The returned reads were then analyzed using Mothur, the SILVA 
database, Core R packages, and ALDEx2 (Fernandes et al, 2013, Quast et al., 2013; R Core 
Team, 2018; Schloss et al., 2009). Fastq files may be accessed in the NCBI Sequence Read 
Archive: BioProject ID PRJNA418287. 
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2.4 Results 
After employing all quality control criteria described above, 234 OTUs were identified from 
the 216 samples (18 conditions × 3 individuals × 2 duplicate DNA extractions × 2 duplicate 
PCR reactions). OTUs were filtered and removed if the mean read count across all samples 
was less than 10. A bar plot and dendrogram illustrating the relative proportion of genera in 
the samples is shown in Figure 6. The dendrogram illustrates that samples strongly clustered 
by each participant when analyzed by Aitchison distance, an appropriate metric for 
compositional data (Gloor and Reid, 2016; Gloor et al., 2017; Van den Boogaart and 
Tolosana-Delgado, 2013). Figure 6 also illustrates that the three participants were dominated 
by the genera Bacteroides, Faecalibaterium, and Prevotella. Using a centre log ratio (CLR) 
transformation, the sample-wise Aitchison distances were generated, and principal 
components analysis performed (Figure 7). Components 1 and 2 explain 79.3% of total 
variance. The samples from each individual participant clustered together regardless of 
preservation method (Figure 7). However, when observing on a per-participant basis the 
samples did not cluster by any storage condition (data not shown). When summarized to 
phylum or genus level, no trends in taxonomy were associated with the samples between or 
within individuals (data not shown). 
The distance between technical and inter-individual samples was compared (Figure 8). Paired 
Aitchison distances between PCR replicates, DNA extraction replicates, and preservative 
method (technical variants) were found to be lower than distances between paired samples 
from different participants. To further characterize the significance of the separation between 
individuals, k-means clustering was utilized to attempt partitioning all samples into n groups. 
When n = 3 which is the number of participants, samples clustered without overlap into 
groups based on the participant of origin (Figure 9). On a within-participant basis, no sample 
clustering was observed for any number n. 
The centres of the clusters (n = 3) on the PCA (Figure 7) were determined and sample 
distance-to-centre calculated. The samples closest to centre may be considered the most 
reliable or “true” within the cluster. Table 3 displays the distances of the closest 10 samples 
within each cluster to the cluster centre. Within and between participants there is no pattern 
for storage methods that cluster most closely to the centre.  
76 
 
 
 
The average of all PCR and DNA extraction replicates of the fresh extracted samples was 
then calculated to determine a “fresh centre” for each subject. Table 4 displays the distance to 
fresh centre of the samples from which the average was generated, as well as the closest 10 
samples within each cluster to the fresh centre; these are the 10 samples that most closely the 
fresh sample in microbial composition. For participants 1 and 3, samples that were stored at 
−80 °C without RNAlater most closely resembled the microbiota of fresh samples. For 
participant 2, there does not appear to be a definitive relationship between the storage method 
of the 10 closest samples to the fresh samples. 
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Figure 6. Microbial composition of stool samples 
Bar plot displays the stool microbiota profiles. Each bar represents a single sample, with each colour representing a different bacterial 
genus. Samples are clustered hierarchically by the dendrogram, where samples originating from Subjects 1, 2, and 3 are coloured on 
red, green, and blue branches, respectively. 
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PCA was performed on CLR-transformed Aitchison distances from samples with pooled 
PCR and DNA extraction duplicates. Samples (points) that cluster together on the two-
axis plot are similar in microbiota composition and abundance. As shown, samples 
cluster by participant of origin without overlap, but no distinct patterns exist between 
storage conditions. This exploratory analysis illustrates that 79.3% of the total variance of 
the samples is explained by the first two components.  
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Figure 7. Principal component analysis of all samples 
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Distance was measured between technical replicates and paired inter-individual samples. 
The violin plot illustrates the upper and lower quartiles with median and an overlapped 
kernel density estimation. The technical replicates were separated by significantly lower 
Aitchison distance than the paired inter-individual samples. 
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Figure 8. Aitchison distance between paired experimental replicates 
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Figure 9. K-means clustering silhouette plot 
When n = 3 groups, k-means clustering analysis successfully partitions all samples based 
on subject of origin. High silhouette coefficients (0.68-0.79) illustrate high confidence 
and large separation between sample clusters. 
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Table 3. Distance of the ten closest samples within each participant cluster to the 
cluster centroid 
 
  
Subject 1 Subject 2 Subject 3 
Sample ID Distance 
to Centre 
Sample ID Distance 
to Centre 
Sample ID Distance 
to Centre 
sub1_Pres_d7_7C_ex
t2_pcr1 
21.3905401
1 
sub2_NoPres_d3_m80
C_ext2_pcr2 
19.7243205
9 
sub3_NoPres_d3_m80
C_ext1_pcr2 
7.00892770
8 
sub1_Pres_d7_7C_ex
t1_pcr1 
21.5611832
4 
sub2_NoPres_d3_m80
C_ext2_pcr1 
20.2465105
8 
sub3_NoPres_d3_m80
C_ext2_pcr2 
7.78201741
6 
sub1_Pres_d7_32C_e
xt2_pcr1 
21.7969815
7 
sub2_Pres_d3_m80C_
ext1_pcr2 
23.4302725
6 
sub3_Pres_d7_7C_ext2
_pcr1 
7.86135943
6 
sub1_NoPres_d7_7C
_ext1_pcr1 
23.2127724
5 
sub2_Pres_d3_m80C_
ext2_pcr2 
24.3277820
7 
sub3_NoPres_d7_7C_e
xt1_pcr2 
7.86727699
4 
sub1_NoPres_d7_22
C_ext1_pcr1 
23.7193545
7 
sub2_Pres_d3_m80C_
ext1_pcr1 24.3665596 
sub3_NoPres_d7_7C_e
xt1_pcr1 
7.88688108
5 
sub1_NoPres_d7_32
C_ext1_pcr1 
24.0860736
3 
sub2_Pres_d3_22C_ex
t1_pcr1 
24.5908928
1 
sub3_Pres_d3_m80C_e
xt2_pcr2 
8.30008891
8 
sub1_Pres_d7_22C_e
xt2_pcr1 
25.0428990
7 
sub2_Pres_d3_7C_ext
1_pcr2 25.3202099 
sub3_NoPres_d3_22C_
ext2_pcr1 
8.83229289
5 
sub1_NoPres_d7_7C
_ext2_pcr1 
25.3876228
9 
sub2_NoPres_d0_NA
_ext1_pcr2 25.397876 
sub3_NoPres_d3_m80
C_ext2_pcr1 
8.89887260
1 
sub1_NoPres_d7_22
C_ext2_pcr1 
25.5216591
4 
sub2_Pres_d3_22C_ex
t2_pcr1 
25.7295934
6 
sub3_NoPres_d3_7C_e
xt1_pcr1 
9.18473290
2 
sub1_Pres_d7_7C_ex
t1_pcr2 
26.7598476
6 
sub2_NoPres_d3_22C
_ext1_pcr1 
25.8184855
9 
sub3_Pres_d3_m80C_e
xt1_pcr2 
9.31718906
3 
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Table 4. Distance of the 10 closest samples to the "fresh centre" within each 
participant cluster 
Subject 1 Subject 2 Subject 3 
Sample ID Distance to 
Fresh 
Centre 
Sample ID Distance to 
Fresh 
Centre 
Sample ID Distance to 
Fresh 
Centre 
sub1_NoPres_d0_N
A_ext2_pcr1 4.099769923 
sub2_NoPres_d0_N
A_ext2_pcr2 7.741715028 
sub3_NoPres_d0_
NA_ext2_pcr2 4.599199044 
sub1_NoPres_d0_N
A_ext2_pcr2 4.5118112 
sub2_NoPres_d0_N
A_ext1_pcr2 7.865818862 
sub3_NoPres_d0_
NA_ext2_pcr1 4.79650351 
sub1_NoPres_d0_N
A_ext1_pcr1 4.594732795 
sub2_NoPres_d0_N
A_ext2_pcr1 7.894678476 
sub3_NoPres_d0_
NA_ext1_pcr2 5.105475976 
sub1_NoPres_d0_N
A_ext1_pcr2 4.733602626 
sub2_NoPres_d0_N
A_ext1_pcr1 8.014097687 
sub3_NoPres_d0_
NA_ext1_pcr1 6.616679361 
sub1_NoPres_d0_m
80C_ext2_pcr2 6.931155897 
sub2_NoPres_d3_m
80C_ext1_pcr2 9.518267963 
sub3_NoPres_d7_
m80C_ext1_pcr1 7.138155018 
sub1_NoPres_d0_m
80C_ext1_pcr2 7.685999985 
sub2_NoPres_d3_m
80C_ext1_pcr1 10.33991077 
sub3_NoPres_d3_
m80C_ext2_pcr2 7.665244301 
sub1_NoPres_d7_m
80C_ext1_pcr2 8.531981606 
sub2_Pres_d3_7C_
ext1_pcr1 11.22479013 
sub3_NoPres_d3_
m80C_ext2_pcr1 8.254854519 
sub1_NoPres_d3_m
80C_ext2_pcr2 8.574646696 
sub2_Pres_d3_7C_
ext1_pcr2 11.56172214 
sub3_NoPres_d3_
m80C_ext1_pcr2 8.437884311 
sub1_NoPres_d0_m
80C_ext1_pcr1 8.904700784 
sub2_NoPres_d0_m
80C_ext2_pcr2 11.94384465 
sub3_NoPres_d7_
m80C_ext2_pcr1 8.509218755 
sub1_NoPres_d0_m
80C_ext2_pcr1 9.062602321 
sub2_NoPres_d3_7
C_ext1_pcr2 12.01324338 
sub3_NoPres_d3_
m80C_ext1_pcr1 9.726049853 
sub1_NoPres_d3_m
80C_ext2_pcr1 9.915761448 
sub2_Pres_d3_7C_
ext2_pcr2 12.09124961 
sub3_NoPres_d3_
7C_ext1_pcr1 10.09143841 
sub1_NoPres_d7_m
80C_ext1_pcr1 10.16077497 
sub2_Pres_d3_m80
C_ext2_pcr2 12.7616741 
sub3_NoPres_d0_
m80C_ext2_pcr1 10.43377554 
sub1_NoPres_d3_7
C_ext1_pcr2 10.36808667 
sub2_Pres_d3_7C_
ext2_pcr1 13.00538835 
sub3_NoPres_d7_
7C_ext1_pcr1 11.07853315 
sub1_NoPres_d3_m
80C_ext1_pcr2 10.88863058 
sub2_NoPres_d3_m
80C_ext2_pcr2 13.03267418 
sub3_NoPres_d3_
22C_ext2_pcr1 11.57081857 
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2.5 Discussion 
This study investigated if and how sampling and storage would impact the microbial 
community structure of fecal samples collected on toilet paper. With the use of various 
techniques including principal components analysis and k-means clustering, the samples 
consistently grouped by participant, not storage method. In the principal component 
analysis, all samples clustered based on their participant of origin without overlap. 
Technical replicates of participant samples had significantly less variation than the 
variation between paired samples from different participants. Similar to other studies in 
healthy people, we showed that Bacteroides, Faecalibaterium, and Prevotella dominated 
the gut microbiotas of the three participants (Arumugam et al., 2011; King et al., 2019). 
Together, these results illustrate that regardless of the storage conditions, a participant's 
stool samples still resemble “self”. 
It was somewhat surprising that no distinguishing patterns were found between storage 
methods and variance within participants (Tables 3 and 4). It was expected that the use of 
RNAlater® would initially alter the microbiome of exposed samples, skewing it to 
appear less like the fresh sample (Choo et al., 2015; Gorzelak et al., 2015; Hale et al., 
2015; Liang et al., 2020). Due to the preservative nature of RNAlater®, it was expected 
that samples would be stabilized over storage in increased temperatures (Hale et al., 
2015); surprisingly neither of these trends were observed. In two of the three participants, 
immediate freezing of the samples at −80 °C resulted in the microbiota most closely 
resembling that found in fresh stool. In the other participant, there were no storage 
methods that consistently resembled the fresh sample. These results imply that there is no 
“perfect” method of sample storage appropriate for every participant. It appears that 
utilizing a preservative agent such as RNAlater® is unnecessary for samples stored up to 
seven days from −80 °C to 32 °C, with an added study cost and inconvenience for 
participants. 
The analysis of next generation sequencing has become the favoured method to 
investigate the composition of the microbiome and how it relates to various clinical 
conditions. The methodology is sensitive and requires much standardization to achieve 
reproducible results. A strength of the current study is the use of paired-end Illumina 
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sequencing and exploration of the variation in DNA extraction and PCR technical 
replicates, which allowed us to explore the extent to which our entire sample-processing 
and sequencing pipeline may inadvertently vary between samples. Our results 
demonstrate that technical variation between sample replicates was extremely minor and 
did not contribute to demonstratable downstream effects when our bioinformatic filtering 
was applied. Because some of the methods utilized herein may be influenced by human 
error, others utilize robotic pipetting, and all were subject to basal variability inherent in 
Illumina MiSeq runs, this study was an important primary validation in establishing the 
microbiome analysis standard operating procedures at our centre (Wen et al., 2017). 
This study also verifies the use of toilet paper sampling, which is an extremely 
convenient and low-cost methodology for acquiring fecal samples for the purpose of 
microbiome analysis in clinical studies. Although the method of aliquoting stool onto 
toilet paper used herein does not account for the transfer of skin microbes during at-home 
sampling, the potential contamination from skin microbes would be negligible in 
abundance (Sender et al., 2016).  
The storage treatments investigated did not significantly impact the microbial 
communities and do not validate the use of storage preservative agents in the short term, 
although no conclusions can be made regarding the efficacy of such preservatives for 
long-term storage. These findings are comparable to similar studies in the literature 
(Dominianni et al., 2014; Nel van Zyl et al., 2020; Voigt et al., 2015). This method can 
be employed where patients are required to conduct at-home sampling, and based on the 
temperatures investigated herein, validate this method for the shipment of samples via 
standard postal service. Depending on the season, samples in post may be exposed to 
temperatures above 30 °C  or below 0 °C for up to a week, however we found that even 
storage for 7 days at 32 °C did not push the microbial communities beyond the 
recognition of “self” when compared to fresh samples from the same participant.  
Despite these conclusions, we suggest careful documentation of sample collection if this 
method is to be utilized in future clinical studies. For example, the study participant 
should record the date of sample collection, when it was mailed, and the lab should 
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record the samples receipt with regional weather trends throughout the sample’s 
shipment. Although no differences were determined based on temperature in this short-
term pilot study, curated sample metadata should always be utilized in downstream 
analysis to identify the true source of microbial community variability (Allaband, et al., 
2018). If this method is utilized in future studies, we also suggest the use of nuclease-free 
transport bags (such as VWR CA93000-724), such that external contamination after 
sample collection is minimized. Indeed, regardless of which sample collection method is 
chosen, consistency of methodology between samples in a study (down to the container) 
is an important feature of collection (Liang et al., 2020). 
In conclusion, although immediate processing of samples is preferable, fecal samples 
collected on toilet paper can be stored and shipped short-term in varied temperatures 
without the preservative agent RNAlater®, without fear of vast microbial changes. 
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Chapter 3  
3 The microbiome at multiple body sites in a kidney stone 
patient population: revisiting the role of Oxalobacter 
formigenes in stone formation 
3.1 Abstract 
Mounting evidence suggests a role for both the urinary and gut microbiome in 
nephrolithiasis. Intestinal colonization of Oxalobacter formigenes has been proposed to 
reduce the risk of oxalate stone disease through its capacity to degrade calcium oxalate. 
However, literature on the impact of this microbe in nephrolithiasis is controversial. The 
aim of the present study was to use a systems-level approach to fully characterize both 
the urinary and gut microbiota of stone formers and healthy controls and assess the 
bacterial contribution to this disease. Urine and fecal samples from 83 stone formers (SF) 
and 30 healthy controls (HC) were evaluated with 16S rRNA gene sequencing, and whole 
shotgun metagenomic sequencing. Stone fragments and intraoperative urine from SFs 
were also analyzed. The SF gut microbiota was significantly enriched in 
Enterobacteriaceae and potential uropathogens, however there was no observable 
difference in relative abundance of O. formigenes compared to HC. The urinary 
microbiota and oxalate concentrations were altered between HC and SF, and significantly 
differed in the SFs over time (pre-operative vs. intraoperative urine samples), exhibiting 
enrichment in pathogenic bacteria following perioperative antibiotic treatment. 
Interestingly, kidney stones harboured a microbiota distinct from urine, and this was not 
dictated by the stone’s crystalline composition. The gut microbiota of SFs was aberrant 
compared to HC in several functional capacities, including increased resistance to toxic 
compounds (antibiotics and heavy metals), altered micronutrient biosynthesis and 
utilization implicated in host oxalate homeostasis, and an elevated osmotic stress 
response. Together these findings suggest that the microbiota of SF is altered in a 
multimodal manner, aggravating stone formation. The microbiome as a system likely 
plays a much more significant role in nephrolithiasis beyond the dogmatic perspective 
that O. formigenes colonization is the key to stone prevention. 
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3.2 Introduction 
Kidney stone disease, or nephrolithiasis, is an extremely prevalent condition that causes 
significant morbidity to sufferers and is a draining financial burden to public health 
(Pearle et al., 2005). Although classically believed to be an affliction of the obese and 
middle-aged white man, prevalence has risen in recent decades, specifically in young 
women in children (Scales Jr. et al., 2007; Scales Jr. et al., 2012; Soucie et al., 1994; 
Tasian et al., 2016). The human microbiota, defined as the microorganisms present in a 
certain environment, is known for its role in systemic human health and disease, 
including metabolic syndrome, cardiovascular disease, and diabetes (Gan et al., 2014; 
Gurung et al., 2020; Turnbaugh et al., 2006; Whiteside et al., 2015). Interestingly, these 
conditions are known comorbidities associated with nephrolithiasis, and their increasing 
prevalence over recent years along with that of stone disease indicate systemic declines in 
our population’s overall health (Logan et al., 2016). Importantly, the human gut 
microbiota is also implicated in nephrolithiasis, but a consensus on the mechanisms 
behind this relationship remain elusive. 
Calcium oxalate (CaOx) is the most common crystalline composition of stones, followed 
by calcium phosphate, uric acid, struvite, and cystine (Moe, 2006). Oxalate is a toxic 
terminal metabolite produced endogenously and consumed in the diet (Hatch and Freel, 
2005). The infamous Oxalobacter formigenes utilizes oxalate as its sole carbon source, 
and some studies have shown that people intestinally colonized by the bacterium have 
lower urinary oxalate levels and are subsequently at lower risk of developing CaOx 
stones (Kaufman et al., 2008; Jiang et al., 2011). However, many studies also find no 
difference in colonization rates between healthy persons and stone formers (Magwira et 
al., 2012; Miller et al., 2019; Tang et al., 2018; Ticinesi et al., 2018). Other members of 
the gut microbiota are capable of degrading oxalate including various lactobacilli and 
bifidobacteria (Miller and Dearing, 2013). In kidney stone patients, supplementation with 
oxalate-degrading bacteria has been suggested as a potential preventive therapy, however 
trials thus far have been limited and inconclusive (Hoppe et al., 2006; Siener et al., 2013; 
Klimesova et al., 2015). It remains unclear if direct oxalate metabolism by gut colonizers 
is the key to preventing kidney stones. 
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Beyond oxalate utilization, previous studies have demonstrated generalized “dysbiosis” 
in the intestinal microbiota of kidney stone formers (Miller et al., 2019; Suryavanshi et 
al., 2018; Stern et al., 2016; Tang et al., 2018; Ticinesi et al., 2018; Zampini et al., 2019). 
However, the significant perturbations determined in these studies are often not 
consistent; this may be an artifact of small sample size, or different sequencing and 
analysis methodologies. Most of the studies to date have also focussed primarily on the 
presence or absence of O. formigenes and direct oxalate utilization pathways, but the 
narrow focus towards these analyses may be overemphasizing their true functional 
significance to the disease pathology.  
Although historically believed to be sterile, the urinary microbiota in healthy people has 
been well described in the last decade (Wolfe et al., 2012); it is compositionally distinct 
and of lower abundance than the microbiomes of the gut and vagina (Whiteside et al., 
2015). The recent characterization of this microbiome has led investigators to question 
the role it may play in nephrolithiasis (Xie et al., 2020). Indeed, while struvite stones are 
known to be associated with urinary tract infections (UTI), recent culture-dependent and -
independent studies have confirmed the presence of bacteria in calcium-based stones 
(Barr-Beare et al., 2015; Dornbier et al., 2019; Zampini et al., 2019). As direct bacterial 
oxalate utilization is likely not at play in the urinary tract, it is unknown how these 
bacteria may be contributing to the disease, and whether these stone-bound microbes 
result from an aberrant urinary microbiota. 
The use of multiple classes of oral antibiotics has been directly associated with increased 
risk of nephrolithiasis, with aggravated effects coinciding with more recent exposure and 
antibiotic use in younger ages (Tasian et al., 2018). The long-term perturbations to the 
microbiome caused by antibiotics and the associated stone risk are yet another indication 
of a role for the microbiome in this disease. Which body site is of most significance to the 
pathology is still unclear, and a role for the microbiome beyond direct oxalate utilization 
has been underexplored. 
The aim of the present study was to fully characterize the urinary and gut microbiota of 
kidney stone formers and healthy controls to assess the bacterial contribution to 
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nephrolithiasis. It was hoped that this would provide insights to the bacterial implications 
for stone formation from multiple body sites and provide foundational knowledge upon 
which personalized medicine and targeted therapies could be developed for the 
prevention and treatment of nephrolithiasis. 
3.3 Materials and Methods 
3.3.1 Study design and sample collection 
Nephrolithiasis patients were recruited from the Urology Department at St. Joseph’s 
Hospital in London, Ontario. Ethical approval for the study was granted by Lawson 
Health Research Institute (CRIC R 15-117) and the Health Sciences Research Ethics 
Board at the University of Western Ontario (REB #105443, Appendix B) in London, 
Ontario. Written consent was obtained from all the study participants at the time of study 
inclusion and the methods were carried out in accordance with the approved guidelines. 
The study aimed to recruit up to 200 participants over a 5-year period, but the final 
numbers of subjects enrolled were 83 stone patients and 30 healthy controls. Inclusion 
and exclusion criteria for the participants are provided in Table 5. All stone patients who 
met the inclusion criteria were recruited during regularly scheduled clinic appointments, 
and healthy control subjects were approached in the community and through poster 
advertisements. Upon recruitment, subjects were asked about relevant demographic and 
medical history including antibiotic usage and their history of urinary tract infections. 
Following enrolment, participants provided a mid-stream urine sample, oral swab, and 
mailed in a fecal sample on toilet paper (Al et al., 2018). During surgical stone removal, 
additional clinical samples were collected: urine, upon first insertion of the catheter and 
prior to instilling saline into the urinary tract, and where possible, stone fragments. These 
were placed by the surgeon into a sterile collection cup. An operating room (OR) 
environmental control sample was also collected where a sterile urine container 
containing 200 uL of nuclease-free water (Ambion, Mississauga, ON, CAN) was left 
open beside the patient for the duration of their surgery. 
From home, participants completed a diet history questionnaire either by paper copy 
which was mailed back to the laboratory, or online through the diet questionnaire 
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website. The food frequency questionnaire investigated past year intake and included 
questions about portion size, providing outputs with nutrient estimates (Subar et al., 
2001). 
3.3.2 Clinical sample processing 
All processing of clinical samples was performed with PCR-grade filter pipette tips in a 
biosafety cabinet (FroggaBio, Toronto, ON, CAN). All urine samples (i.e. from healthy 
subjects as well as pre-operative and intra-operative urine from stone patients) were 
processed in two portions within 2 hours of collection. Where possible, 10 mL of whole 
urine was collected and frozen at -80 °C for high-performance liquid chromatography 
(HPLC) analyses of urinary metabolites. The remainder was stored for future 16S rRNA 
gene sequencing: the entire remaining volume of urine was centrifuged for 10 minutes at 
5,000 x g, after which the supernatant was decanted off and the pellet was stored dry at -
80 °C until DNA extraction. If the total urine volume was under 25 mL, only 2 mL of 
whole urine was reserved for HPLC. The urine volume that resulted in the pellet for 16S 
rRNA gene sequencing was recorded to identify confounding factors in the downstream 
sequencing analysis associated with processing conditions.  
Oral swabs and fecal samples on toilet paper were frozen at -80 °C for future 16S rRNA 
gene sequencing: oral swabs within 2 hours of their initial collection and fecal samples 
within 2 hours of their receipt to the laboratory. Within 2 hours of collection, the water 
inside the OR-environmental control sample was shaken in the cup for 2 minutes and the 
entire volume was transferred to a PCR-grade Eppendorf tube (Thermo Scientific, 
Waltham, MA, USA), and frozen at -80 °C for future 16S rRNA gene sequencing. 
Within 2 hours of their initial collection, one stone fragment per patient was transferred 
to a PCR-grade Eppendorf tube, frozen at -80 °C and stored until DNA extraction. If 
further fragments were available, they were cultured using the streamlined Extended 
Quantitative Urine Culture technique (EQUC) (Hilt et al., 2014; Price et al., 2016). 
Stones for culture were first surface sterilized with 70% ethanol for 10 seconds, followed 
by 2 washes with sterile phosphate buffered saline (PBS). They were then pulverized 
with a mortar and pestle sterilized with 70% ethanol until only sand-like fragments were 
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present. The fragments were suspended in 1000 µL of sterile PBS, and 100 µL of the 
suspension was pipetted and spread onto plates of Columbia blood agar (CBA, BD, 
Mississauga, ON, CAN) with 5% defibrinated sheep’s blood (Cedarlane, Burlington, ON, 
CAN), colistin-nalidixic acid agar (CNA, BD), MacConkey agar (BD), and 
CHROMagar™ orientation plates (CHROMagar, Paris, FR). The CBA and CNA plates 
were incubated at 5% CO2 for 48 hours, and the MacConkey and CHROMagar plates 
were incubated aerobically for 48 hours. If colonies were cultured, DNA was extracted 
with the Monarch Genomic DNA Purification Kit (New England Biolabs, Whitby, ON, 
CAN) as per the manufacturer’s instructions. The DNA was then PCR amplified with 
pA/pH primers (8F and 1522R) of the 16S gene as previously described and Sanger 
sequenced at the London Regional Genomics Centre (http://www.lrgc.ca; London, ON, 
CAN) (Edwards et al., 1989). Sequences were then assessed with the Ribosomal 
Database Project to determine colony identification (https://rdp.cme.msu.edu). 
3.3.3 High performance liquid chromatography 
Urine samples were analyzed with HPLC to determine creatinine and oxalate levels 
(Maalouf et al., 2011; Murray et al., 1982). Reserved whole urine samples were thawed 
and vortexed for 30 seconds. Using PCR-grade filter tips, 50 μL of urine was transferred 
to an Eppendorf tube for creatinine quantification, and 950 μL of urine was transferred to 
a 15 mL conical tube for oxalate quantification.  
For quantifying creatinine, 450 μL HPLC H2O and 500 μL of HPLC acetonitrile were 
added to the urine and vortexed. The urine mixture was incubated at 4 °C for 15 minutes, 
facilitating precipitation of debris. Samples were then centrifuged for 15 minutes at 
16,000 × g at 4 °C and filtered through 0.2 μm syringe filters into labelled amber HPLC 
vials (Agilent, Mississauga, ON, CAN). Standards of creatinine were prepared in HPLC 
H2O at concentrations of 1 ppm, 5 ppm, 10 ppm, 50 ppm, 100 ppm, 150 ppm, 200 ppm, 
250 ppm, and 300 ppm. The Agilent 1100 HPLC was utilized with the conditions stated 
in Table 6. 
For oxalate quantification, the 950 μL of urine (or oxalic acid standards at concentrations 
of 1 ppm, 10 ppm, 25 ppm, 50 ppm, 100 ppm, 150 ppm, 200 ppm, 250 ppm) was 
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combined with 50 μL of 10 M HCl and 1 mL of 0.1 M o-phenylenediamine dissolved in 
4 M HCl and vortexed. The tubes were capped, being careful to tighten the lids as much 
as possible. The tubes were then incubated in a laboratory oven at 100 °C for 6-7 hours, 
then moved to 4 °C overnight. The following day, volume in the tube was carefully 
inspected and tubes that had experienced cracking or evaporation were discarded, 
requiring repeat processing. Five hundred μL of 200 mM KHPO4 (pH 7.0) and 480 μL of 
10 M KOH were added to the tubes with gentle vortexing. One mL of the mix was then 
transferred to labelled Eppendorf tubes and incubated at 4 °C for 15 minutes, then 
centrifuged for 15 minutes at 16,000 × g at 4 °C. Large pellets were present and were 
carefully avoided when transferring the entire volume to a 0.2 μm syringe filters; samples 
were filtered into labelled amber HPLC vials (Agilent). The HPLC was utilized with the 
conditions stated in Table 6. 
3.3.4 DNA extraction 
On the day of DNA extraction, the samples were thawed and processed in a sterile 
biosafety hood. Using tweezers sterilized with RNase AWAY™ (Thermo Fisher 
Scientific, Waltham, MA, USA), the kidney stone was transferred to a sterile cell strainer 
mounted onto an empty 50 mL conical tube (Thermo Fisher Scientific). New sterile cell 
strainers and conical tubes were used for every sample. Two mL of nuclease free water 
was gently rinsed over the external surface of the stone. The stone was then transferred to 
a mortar and pestle that was sterilized with 5% sodium hypochlorite followed by RNase 
AWAY™ and pulverized into sand-like fragments. The fragments were suspended in 100 
µL of nuclease-free water and pipetted directly into wells of the bead plate of the DNeasy 
PowerSoil HTP 96 Kit utilized for DNA extraction (Qiagen, Toronto, ON, CAN). Urine 
pellets were thawed and suspended in 100 uL of nuclease-free water, then pipetted into 
the bead plate. The 100 uL OR environmental control water sample was transferred 
directly to the bead plate. Toilet paper samples were dissected and trimmed with RNase 
AWAY™-treated scissors and forceps such that a piece of visibly soiled paper 
approximately 1 cm2 in size was added directly to the bead plate. 
Urine, stone, and OR environmental control samples were randomized across DNA 
extraction plates together; fecal samples were extracted on separate plates to mitigate 
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potential contamination to the other samples which were of significantly lower biomass 
in comparison. 
Two wells in every DNA extraction plate were left empty and acted as negative controls. 
Two positive controls, or “spikes”, were added to each plate and were 100 μL of pure 
bacterial culture: Spike 1 was Escherichia coli strain DH5α, and Spike 2 was 
Staphylococcus aureus strain Newman. For preparation of the spikes, a single colony of 
the bacteria was inoculated into 10 mL of Luria-Bertani (LB) broth and grown overnight 
at 37 °C. One hundred 100 μL aliquots of the overnight cultures were portioned into 1.5 
mL Eppendorf tubes and frozen at -80 °C. For each DNA extraction plate, a single tube 
of both spikes was thawed and pipetted directly into the PowerSoil HTP bead plate with 
PCR-grade filter tips. 
DNA was isolated from samples using the DNeasy PowerSoil HTP 96 Kit according to 
the manufacturer’s instructions. Briefly, 750 μL of bead solution and 60 μL of Solution 
C1 were added to the bead plate loaded with all samples and controls. Plates were shaken 
for 20 minutes at speed 20 using the MoBio 96-well plate shaker (Qiagen), then 
centrifuged for 10 minutes (all centrifuge steps were conducted at room temperature at 
2250 x g). Five hundred μL of the supernatant was added to a fresh plate with 250 μL 
Solution C2 and mixed by pipetting. The plates were incubated at 4 °C for 10 minutes 
followed by centrifugation for 10-minutes. The resulting supernatant was then transferred 
to a fresh plate and the centrifugation step was repeated. Approximately 600 μL of the 
solution was then transferred to a fresh plate containing 200 μL Solution C3 and mixed 
by pipetting. The plate was incubated at 4 °C for 10 minutes followed by centrifugation 
for 10-minutes. The entire volume, with the exception of the pellet, was again transferred 
to a fresh plate for centrifugation. Carefully avoiding the loose residual pellet, 650 μL 
was transferred from each well to a fresh plate containing 1300 μL Solution C4. The 
plates were then sealed with sealing tape and stored at 4°C overnight. The following day 
the plates were briefly centrifuged and sealing tape was removed. Solution in the wells 
was then mixed by pipetting and 500 μL was transferred to a Spin Plate, which was 
centrifuged for 5 minutes. The flow-through was discarded, and this step was repeated 
until the entire sample-Solution C4 mix was processed through the Spin Plate. A volume 
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of 500 μL Solution C5-D was then added to the Spin Plate and centrifuged twice for ten 
minutes, where the flow-through was discarded between spins. 100 μL Solution C6 was 
then added to the Spin Plate, incubated at room temperature in the biosafety hood for 10 
minutes and the resulting DNA was eluted to a Microplate via centrifugation for 15 
minutes. DNA was stored at -20 °C until downstream processing. 
3.3.5 16S rRNA gene sequencing 
Urine, stone, and OR-environmental control samples underwent 16S rRNA gene 
sequencing. PCR amplification was completed using the Earth Microbiome universal 
primers (515F and 806R) which are specific for the V4 variable region of the 16S rRNA 
gene (Figure 4). Primers contained an Illumina adapter, followed by four random 
nucleotides, one of 24 unique 12-mer barcodes, and the annealing left or right primer 
(Figure 4) (Parada et al., 2016). Primers and barcode sequences are listed in Table 7. 
PCR reagent set-up was performed using a Biomek® 3000 Laboratory Automation 
Workstation (Beckman-Coulter, Mississauga, ON, CAN). Ten μL of each left- and right- 
barcoded primers (3.2 pMole/μL) were arrayed in 96-well plates (Axygen-Corning, 
Oneota, NY, USA) such that each well contained a unique combination of left- and right- 
barcodes (up to a maximum of 576 unique combinations). Two μL of DNA template was 
added to the primer plate, followed by 20 μL of Promega GoTaq hot-start colourless 
master mix (Promega, Madison WI, USA). The reaction was briefly mixed by pipetting, 
then plates were sealed with foil plate covers (Axygen-Corning) and centrifuged for 2 
minutes at room temperature at 2250 x g. 
Amplification was carried out using an Eppendorf thermal cycler (Eppendorf, 
Mississauga, ON, CAN), where the lid temperature was maintained at 104 °C. An initial 
warm-up of 95 °C for 4 minutes was utilized to activate the GoTaq, followed by 25 
cycles of 1 minute each of 95 °C, 52 °C, and 72 °C. 
DNA extraction was completed across a total of 3 x 96-well plates. Sequencing was 
carried out at the London Regional Genomics Centre. Amplicons were quantified using 
pico green (Quant-It; Life Technologies, Burlington, ON) and pooled at equimolar 
concentrations before cleanup (QIAquick PCR clean up; Qiagen, Germantown, MD). 
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Using the 600-cycle MiSeq Reagent Kit (Illumina Inc., San Diego, CA, USA), paired-end 
sequencing was carried out as 2 × 260 cycles with the addition of 5% ɸX-174 at a cluster 
density of ~1100. Data was exported as raw fastq files and analyzed using R, DADA2, 
the SILVA database (version 132), and ALDEx2 (Callahan et al., 2016; Fernandez et al., 
2013; Quast et al., 2013; R Core Team, 2019). 
3.3.6 Shotgun metagenomic sequencing 
Fecal samples from 25 healthy control participants and 36 confirmed calcium-oxalate 
stone forming patients underwent shotgun metagenomic sequencing at The Centre for 
Applied Genomics (TCAG) at The Hospital for Sick Children in Toronto, ON, CAN. 
DNA concentration was quantified using the Qubit™ dsDNA HS Assay Kit (Invitrogen, 
Thermo Fisher Scientific). Approximately 100 ng of DNA was PCR amplified and 
prepared for sequencing using the Nextera DNA Flex Library Prep Kit (Illumina, Inc.). 
The amplified library was purified and enriched for amplicons ~350 bp, then sequenced 
using an S1 Flowcell on the Illumina NovaSeq 6000. Reads were exported as fastq files, 
quality assessed using FastQC (Andrews, 2010), trimmed with Trimmomatic (Bolger et 
al., 2014), and mapped against the human genome (Hg38) using Bowtie2 (Langmead and 
Salzberg, 2012). Human reads were discarded, and the remaining unmapped reads were 
utilized in downstream analyses. Taxonomy was assigned with Kaiju (Menzel et al., 
2016) and reads were assembled into contigs using MetaSPAdes (Nurk et al., 2017). 
Functional annotation was determined based on alignment to the SEED database 
(Overbeek et al., 2014). Downstream statistical analysis was performed with core R 
packages, as well as Aldex2, vegan, MaAsLin2, and LEfSe (Fernandez et al., 2013; 
Morgan et al., 2012; Oksanen et al., 2019; R Core Team, 2019; Segata et al., 2011). 
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Table 5. Study participant inclusion and exclusion criteria 
Kidney stone patients 
Inclusion Exclusion 
At least 18 years of age Taking/taken any antibiotic during the 
previous 30 days 
Scheduled for PCNL or URS as treatment 
of urinary stone disease 
Has an active gastro-intestinal infection 
Able and willing to provide informed 
consent 
Previously enrolled in this trial 
Able and willing to provide urine, saliva, 
and stool samples 
In the opinion of the treating urologist, it is 
not in the patient’s best interest to 
participate 
Able and willing to complete diet 
questionnaire at home 
 
Healthy control participants 
Inclusion Exclusion 
At least 18 years of age Taking/taken any antibiotic during the 
previous 30 days 
Able and willing to provide informed 
consent 
Has an active gastro-intestinal infection 
Able and willing to provide urine, saliva, 
and stool samples 
Has Crohn’s disease 
Able and willing to complete diet 
questionnaire at home 
Has ulcerative colitis 
Undergo renal ultrasound to confirm stone-
free status 
Has had gastric bypass surgery 
Has a history of urinary stone disease 
Has a history of urosepsis in the past year 
(365 days) 
Has a urinary diversion 
Has an indwelling catheter 
Performs clean intermittent catheterization 
Has previously enrolled in this trial 
In the opinion of the treating urologist, it is 
not in the subject’s best interest to 
participate 
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Table 6. HPLC running conditions 
 Creatinine quantification Oxalate quantification 
Flow rate 1 mL/minute 1 mL/minute 
Mobile phase 60% ACN / 40% 5 mM KHPO4 
(pH 2.8) 
15% ACN / 85% 50 mM KHPO4 
(pH 7.0) 
Column Poroshel 120 HILIC (4.6 × 150 
mm, 4μm) – ambient 
temperature (Agilent) 
Poroshel 120 EC-C18 (4.6 × 150 
mm, 4μm) – ambient temperature 
(Agilent) 
Injection volume 5 μL 5 μL 
Detector 215, 4 (ref = 320, 120) 312. 4 (ref = 355, 50) 
Retention time ~2.2 minutes ~ 2.7 minutes 
Run time 4 minutes 4 minutes 
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Table 7. Primer and barcode sequences 
Name Sequence (5’ – 3’) 
Left Illumina adapter ACACTCTTTCCCTACACGACGCTCTTCCGATCT 
Right Illumina adapter CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT 
Left primer (515F) GTGCCAGCMGCCGCGGTAA 
Right primer (806R) GGACTACHVGGGTWTCTAAT 
Barcode #1 TGCATACACTGG 
Barcode #2 ACTCACAGGAAT 
Barcode #3 GTAGGTGCTTAC 
Barcode #4 CAGTCGTTAAGA 
Barcode #5 CACTACGCTAGA 
Barcode #6 GCTCGAAGATTC 
Barcode #7 TGAACGTTGGAT 
Barcode #8 ATGGTTCACCCG 
Barcode #9 CGAGGGAAAGTC 
Barcode #10 TACTACGTGGCC 
Barcode #11 GTTCCTCCATTA 
Barcode #12 ACGATATGGTCA 
Barcode #13 TATCGACACAAG 
Barcode #14 AGCATGTCCCGT 
Barcode #15 CCAGATATAGCA 
Barcode #16 GTGTCCGGATTC 
Barcode #17 ATCGCACAGTAA 
Barcode #18 CAGCTCATCAGC 
Barcode #19 GCATATGCACTG 
Barcode #20 TGTAGGTGTGCT 
Barcode #21 ACGAGACTGATT 
Barcode #22 CATCAGTACGCC 
Barcode #23 GTATCTGCGCGT 
Barcode #24 TGCGTCAGCTAC 
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3.4 Results 
3.4.1 Study recruitment and participant demographics 
Participant recruitment began in August of 2015 and was completed in January of 2019 
after the inclusion of 30 healthy control (HC) participants and 83 stone-forming (SF) 
patients. This yielded 178 urine samples, 113 oral swabs, 36 environmental (OR) control 
samples, 47 stone fragments, and 102 fecal samples. Healthy controls were matched to 
stone patients on the basis of age, BMI, and comorbidities, but differed in their smoking 
status and antibiotic history (Table 8). The stone patients were evenly divided between 
those that received percutaneous (PCNL) compared to ureteroscopic (URS) surgery. 
3.4.2 Urinary oxalate quantification 
The urinary oxalate concentration was measured in ppm with HPLC and normalized to 
creatinine concentration. The urinary oxalate/creatinine ratio was significantly higher in 
the SF patients at the pre-operative time point compared to both healthy controls and SF 
at the OR timepoint (Figure 10).  
3.4.3 Diet history analysis 
HC and SF participants did not significantly differ in their estimated intake of any of the 
216 measured features from the diet history questionnaire after multiple testing correction 
with Bonferroni adjustment. Similarly, no differences were statistically significant 
between study participants when they were grouped by their history of stones (i.e. no 
history of urolithiasis versus recurrent stone formers). Dietary metrics of interest that may 
play a role in stone formation (including water consumption, caffeine, Vitamins B6, C, D, 
and K, calcium, sodium, potassium, and oxalate) are displayed in Figure 11.  
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Table 8. Demographic and clinical data of study participants 
Metric  Healthy controls Stone patients P value* 
No. enrolled  30 83 NA 
Sex  n (%) n (%)  
 Female 11 (37) 32 (39)  
 Male 19 (63) 51 (61) 0.99 
Age  M (SD) M (SD)  
  55 (11.25) 58 (11.5) 0.29 
BMI  M (SD) M (SD)  
  27.6 (7.1) 30.2 (5.0) 0.06 
Other health features n (%) n (%)  
History of stones 
0 (0) 70 (84) <0.0001 
History of UTI  
9 (30) 43 (51) 0.06 
Smoking status 
   
 Current smoker 
0 (0) 12 (14.8)  
 Non-smoker 
30 (100) 71 (85.7) 0.03 
Comorbidities Cardiac 
3 (10) 8 (9.5) 0.99 
 Hypertension 
8 (27) 32 (38) 0.37 
 Diabetes 
3 (10) 16 (19) 0.39 
 Hypothyroidism 
3 (10) 9 (10.7) 0.99 
Years since antibiotic use M (SD) M (SD)  
  
5.53 (4.0) 3.5 (6.7) 0.04 
Stone removal procedure  n (%) 
 
 PCNL 
 40 (48.2) NA 
 Ureteroscopy 
 43 (51.8) NA 
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Urinary oxalate concentrations [ppm] were determined with HPLC and normalized to 
creatinine levels [ppm]. SF Pre-Op urine had the highest oxalate concentrations 
(Kruskall-Wallis test with Dunn’s multiple comparisons). HC = healthy control 
participants (n = 29); Pre-Op = SF urine at preoperative timepoint (n = 83); OR = SF 
intraoperative urine (n = 55). * P < 0.05, ** P < 0.01. 
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Figure 10. Urinary oxalate levels are higher in stone formers than healthy controls 
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Approximate daily values of macronutrients of interest were compared between patient 
groups; no macronutrients were significantly different by two-tailed Mann Whitney test. 
HC = healthy control participants (n = 14); SF = stone former (n = 64); NHS = no history 
of stones (n = 22); RSF = recurrent stone forming patients (n = 56). 
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Figure 11. Dietary macronutrients are comparable between cohorts 
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3.4.4 16S rRNA gene sequencing 
Microbiota sequencing was performed on urine, stone, and OR control samples with the 
Illumina MiSeq platform. There was a total of 277 samples that yielded 14,989,061 reads, 
ranging from 148 to 774,051 reads per sample. An average of 19.58% reads were 
removed from each sample following quality filtration performed utilizing the DADA2 
pipeline (Callahan, et al., 2017). The remaining filtered reads (13,766,536) were assigned 
taxonomy with the SILVA (v132) training set. Samples and sequence variants (SVs) 
were then further pruned such that the final dataset utilized in all downstream analyses 
retained samples with greater than 1,000 reads, SVs present at greater than 1% abundance 
in any sample, and SVs with greater than 10,000 total reads across all samples. This 
cleaning reduced the dimensions of the dataset from 935 SVs and 277 samples down to 
83 SVs and 232 samples. Two additional SVs were removed due to their alignment to 
human mitochondrial sequences. Due to the low-abundance nature of the samples, 
additional stringent assessment using the decontam R package was performed to assess 
the presence of likely contaminant sequence variants (Davis et al., 2018). After assessing 
prevalence, frequency, and combined metrics of contaminant detection with decontam, 
one additional SV was determined to be a potential contaminant and removed from 
downstream analyses (Figure 12). 
The most proportionally abundant genera in urine and stone samples were Escherichia 
(29.7%), Lactobacillus (12.8%), Staphylococcus (10.3%), Gardnerella (7.3%), and 
Streptococcus (7.3%). The sequence counts were centre log ratio (CLR) transformed, 
generating sample-wise Aitchison distances, which were analyzed with principal 
components analysis (PCA) (Gloor et al., 2017). The PCA biplot displays modest 
clustering of samples based on sample type (Figure 13A). Sample types also differed by 
alpha diversity, whereby SF urine taken during stone-removal surgery (OR urine) had the 
lowest diversity, and the HC and pre-operative SF urine samples had the highest diversity 
(Figure 13B). 
Significant confounders of microbiota variation were determined using the envfit function 
within the R package ‘vegan’ for various sample group comparisons (Table 9). General 
linear models (GLM) were then utilized in MaAsLin2 to further determine significant 
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effectors of microbial community variation whilst accounting for the confounders. With 
this technique, the relative abundance of several genera was determined to be discordant 
when evaluating the three urine sample types (HC, SF pre-operative, and SF-OR) (Figure 
14A). Within stone patients, Lactobacillus and Prevotella spp. were relatively more 
abundant at the pre-operative time point, and Acinetobacter, Escherichia, and 
Gardnerella spp. were more abundant in the OR (Figure 14 B-F). Notably, Gardnerella 
spp. were relatively more abundant in HC compared to SF pre-operative samples (Figure 
14G).  
Samples from the SF cohort were determined to differ by sample type (Table 9) and 
several genera were determined to be significantly discordant using a GLM (accounting 
for relevant confounders) when comparing the urine and stone samples (Figure 15A). 
Stones had relatively more Gardnerella spp. and less Acinetobacter spp. compared to SF-
OR urine (Figure 15B-C). Stones had relatively more Atopobium, Gardnerella, and 
Staphylococcus spp. and relatively less Dialister, Lactobacillus, and Prevotella than SF 
Pre-Op urine (Figure 15D-I). 
Finally, stone samples were investigated to determine if microbial communities differed 
by stone composition. The time since participants’ most recent UTI was determined to be 
a confounder of stone microbiota (Table 9), however when this was accounted for in a 
GLM, there were no significant differences in stone microbiota based on stone 
composition (Figure 16). Several stone samples were also cultured utilizing the EQUC 
method as a proof of principle that the microbiota composition determined with 16S was 
indeed due to living, culturable bacteria present within the stone. Table 10 illustrates that 
several colonies were grown from stone fragments and largely correlated with the 16S 
rRNA gene sequencing findings. 
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SVs were assayed with decontam “prevalence”, “frequency”, and “combined” methods. 
SVs determined to be contaminants are blue and “true” SVs are pink. One SV (circled in 
black) was detected in all three methods and subsequently removed from the downstream 
analyses. 
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Figure 12. Determination of contaminant sequence variants 
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A) PCA was performed on CLR-transformed Aitchison distances of all urine and stone 
samples. Each coloured point represents a sample. Distance between samples on the plot 
represents differences in microbial community composition, with 17.6% of total variance 
being explained by the first two components shown. Strength and association for genera 
are depicted by the length and direction of the gray arrows, respectively. Points are 
coloured by sample type and ellipses represent the 95% confidence intervals of sample 
types. B) Shannon’s Index of alpha diversity was compared between sample groups. OR 
urine samples from stone patients had the lowest diversity (Kruskall-Wallis test with 
Dunn’s multiple comparisons, * P < 0.05, ** P < 0.01, *** P < 0.001). 
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Figure 13. Compositional analysis of all urine and stone samples 
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Table 9. Significant covariates of microbiota variation at genus level PCA 
ordination 
Samples tested Metadata Feature P value* 
HC and SF Pre-Op urine Time since most recent UTI (years) 0.04995 
SF Pre-Op and SF-OR urine Time of sampling (Pre-Op vs. OR) 0.00099 
SF Pre-Op urine and Stone Sample type 0.00999 
SF- OR urine and Stone Sample type 0.00099 
PCNL or URS 0.03196 
History of orthopedic conditions 0.00999 
Stone samples Time since most recent UTI (years) 0.04895 
* P values calculated using the envfit function within the vegan R package 
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A)  PCA was performed on CLR-transformed Aitchison distances of all urine samples. 
Each coloured point represents a sample. Distance between samples on the plot 
represents differences in microbial community composition, with 18.4% of total variance 
being explained by the first two components shown. Strength and association for genera 
are depicted by the length and direction of the gray arrows, respectively. Points are 
coloured by sample type and ellipses represent the 95% confidence intervals of sample 
types. B-F) Significantly altered genera between stone formers’ preoperative (PreOp) and 
OR urine, and G) stone formers preoperative (PreOp) and healthy control (HC) urine 
samples, as determined with general linear models accounting for significant covariates. 
* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Figure 14. Compositional differences in urine samples 
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A) PCA was performed on CLR-transformed Aitchison distances of all urine samples. Each 
coloured point represents a sample. Distance between samples on the plot represents 
differences in microbial community composition, with 18.2% of total variance being 
explained by the first two components shown. Strength and association for genera are 
depicted by the length and direction of the gray arrows, respectively. Points are coloured by 
sample type and ellipses represent the 95% confidence intervals of sample types. B-C) 
Significantly altered genera between stone formers’ OR urine and stones, and D-I) stone 
formers preoperative (PreOp) and stone samples, as determined with general linear models 
accounting for significant covariates. CLR-transformed relative abundances are plotted. * P < 
0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. 
  
Figure 15. Compositional differences in stone-former samples 
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PCA was performed on CLR-transformed Aitchison distances of all stone samples. Each 
coloured point represents a sample. Distance between samples on the plot represents 
differences in microbial community composition, with 36.1% of total variance being 
explained by the first two components shown. Strength and association for genera are 
depicted by the length and direction of the gray arrows, respectively. Samples are coloured 
by stone composition (major component shown for stones with mixed composition). 
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Table 10. Proof-of-principle culture results of stone fragments 
Participant ID Culture 
+/- 
Stone 
composition 
Colony 
characteristics: 
16S ID* 
Dominant 
genus by 16S** 
171 + Calcium 
oxalate 
Yeast (not 
sequenced) 
N/A, below 
filter cut-off 
175 + Struvite Short Gram 
negative rods: 
Proteus mirabilis 
Proteus 
177 + Uric acid Gram negative 
rods: Escherichia 
coli 
Escherichia 
178 + Calcium 
oxalate 
Gram negative rods 
(not sequenced)  
Gardnerella 
181 - Calcium 
oxalate 
N/A N/A, below 
filter cut-off 
182 + Calcium 
oxalate 
Gram positive 
cocci and Gram 
negative rods (not 
sequenced) 
Staphylococcus 
and Klebsiella 
* Generic 16S colony identification with pA-pH primers 
** 16S rRNA gene microbiota sequencing 
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3.4.5 Whole shotgun metagenomic sequencing 
One hundred and two fecal samples were collected from which DNA was extracted. Of these, 
61 were selected to be sequenced with whole shotgun metagenomics. These comprised 
samples from 25 healthy controls, and 36 confirmed calcium oxalate (CaOx) stone forming 
patients, all with high enough DNA yield (100 ng of ds DNA) and quality (260/280 between 
1.8-2.0) for sequencing library preparation. After quality filtering and discarding reads that 
mapped to the human genome, samples contained an average of 21,805,652 reads from 4342 
taxa (including bacterial, archaeal, and viral annotations). After aligning filtered reads to 
functional outputs within SEED, 9299 gene products were annotated (Overbeek et al., 2014). 
The total proportional abundance of unclassified reads ranged from 5.0% to 24.8% (mean 
11.7%). The most abundant taxa were Bacteroides, Clostridium, Alistipes, Faecalibacterium, 
and Prevotella. The 100 most abundant taxa are shown in Figure 17, where each sample 
(column) is clustered by a hierarchical dendrogram based on Aitchison distance. With this 
method, samples that are more similar in composition are closer together on the tree; 
branches of the dendrogram were coloured based on cohort, but samples did not group by HC 
(purple) or SF (orange). 
Based on the findings that samples did not group based on cohort, an investigation was 
performed to determine what participant factors explained the microbiota variability. 
Significant confounders were determined using the envfit function within the R package 
‘vegan’ on all the gut metagenome samples from both taxonomic and functional annotations 
(Table 11). This pointed to samples being segregated by participant age as well as whether or 
not they were recurrent stone formers. Of all the patients in the SF cohort, nine were first 
time stone formers with no previous history of urolithiasis. Due to the findings that stone 
recurrence was a large driver of microbiota variation, further downstream analyses 
considered patients based on this feature, rather than just whether they were originally 
classified as HC or SF. Of note, dietary intake was not significantly different between 
participants with no history of stones (NHS) and recurrent stone formers (RSF) (Figure 11). 
Alpha diversity of the gut samples was determined with Shannon’s Diversity Index based on 
taxonomic annotation. Notably, SF samples were not significantly different from HC, but 
participants with NHS had significantly higher diversity than RSF (Figure 18).  
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General linear models (GLM) were then utilized in MaAsLin2 to further determine 
significant effectors of microbiome variation whilst accounting for the confounders (Table 
11). With this technique, the relative abundance of several genera and functional pathways 
was determined to be discordant between participants on the basis of stone history. Linear 
discriminant analysis was performed with LEfSe (Segata et al., 2011), and features with an 
effect size greater than 2 that also achieved a q value (FDR corrected P value) in MaAsLin2 
of <0.05 were retained (Morgan et al., 2012). 
Recurrent stone formers were found to have a higher relative abundance of several genera 
within the family Enterobacteriaceae, including Escherichia, Klebsiella, Shigella, and 
Citrobacter, among other taxa, compared to those with no history of stones (Figure 19). In 
contrast, study participants with no history of stones had higher relative abundance of 
Prevotella, Faecalibacterium, Roseburia, and Clostridium, among other taxa, compared to 
recurrent stone formers (Figure 19). 
Recurrent stone formers were elevated in the relative abundance of many functional 
pathways of interest, including resistance to antibiotics and toxic compounds, organic sulfur 
assimilation, osmotic stress, and quinone cofactors (Figure 20). In contrast, study participants 
with no history of stones had higher relative abundance in general cellular metabolism 
pathways including protein biosynthesis, DNA repair, and transcription, amongst others 
(Figure 20). Specific proteins of interest with differential relative gene abundance between 
the groups are illustrated in Figure 21. Recurrent stone formers had increased relative 
abundance of genes associated with heavy metal resistance, antibiotic and antiseptic 
resistance, osmoprotectants, and L-ascorbate utilization, and lower relative abundance of 
pyridoxine metabolism and synthesis relative to participants with no history of stones (Figure 
21). Interestingly, no differences in relative abundance of Oxalobacter formigenes (Figure 
22) were detected between groups. Enzymes involved in oxalate degradation such as formyl-
CoA transferase, oxalyl-CoA decarboxylase and oxalate decarboxylase were not annotated 
with SEED, however analysis is ongoing with a custom metagenomic database to annotate 
the relative abundance of these gene pathways between groups (Abratt and Reid, 2010; NCBI 
Resource Coordinators, 2018; Ticinesi et al., 2018). 
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CLR-transformed values of the 100 genera with highest average relative abundance are 
displayed. Samples (columns) are clustered according to average linkage clustering of per-
sample Aitchison distance, and branches of the resulting dendrogram are coloured by 
participant cohort. Phylum and genus (or otherwise lowest available taxonomic assignment) 
are listed. 
  
Figure 17. Bacterial composition of healthy and stone former gut microbiome 
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Table 11. Significant covariates of gut microbiome variation 
PCA ordination level Metadata Feature P value* 
Taxonomic mapping of metagenomic reads 
Genus Age 0.007 
Genus History of stones 0.007 
Genus Approximate number of previous stones 0.007 
Functional mapping of metagenomic reads 
SEED subsystem1 History of stones 0.002 
History of surgical treatment of stone disease 0.002 
Approximate number of previous stones 0.002 
SEED subsystem2 Approximate number of previous stones 0.008 
SEED subsystem3 Approximate number of previous stones 0.007 
SEED subsystem4 Approximate number of previous stones 0.003 
* P values were calculated using the envfit function within the vegan R package on all gut 
metagenome samples 
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 Shannon’s index of alpha diversity was compared between cohorts and between patients 
based on their history of stone formation: those with a history of stones had significantly 
lower intestinal diversity than those without a history of stone formation (Two tailed Mann-
Whitney U test, P = 0.016). 
Figure 18. Microbial diversity is different between participants with and without 
a history of stones, rather than between cohorts 
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Bacterial genera (or otherwise lowest available taxonomic assignment) with significantly 
altered relative abundance between stone history groups. Taxa with LDA effect size greater 
than 2 are plotted and coloured based on patient group of enrichment.  
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Figure 19. Differential genera between stone history groups 
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Functional pathways with significantly altered abundance between stone history groups. 
Pathways are summarized based on SEED subsystem 2. Those with LDA effect size greater 
than 2 are plotted and coloured based on patient group of enrichment. 
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Figure 20. Differential functional pathways between stone history groups 
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Proteins of interest with significantly differential abundance (LDA effect size >2 [LEfSe] and 
q score < 0.05 [MaAsLin2]) between stone history groups. Group median is plotted, and all 
values were normalized to the average frequency in participants with no history of stones. 
Genes are coloured by functional implication. 
  
Figure 21. Differential proteins between stone history groups 
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Relative abundance of the genus Oxalobacter was not different between the healthy control 
and stone former cohorts, nor between participants with no history of stones and recurrent 
stone formers (by two tailed Mann-Whitney U test). 
  
Figure 22. Relative abundance of Oxalobacter sp. is not different between participant 
groups 
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3.5 Discussion 
Nephrolithiasis is a pervasive pathology, affecting upwards of 10% of the population in 
North America and increasing in prevalence (Scales Jr., et al., 2012; Tasian et al., 2016). 
Previous studies investigating the bacterial contribution to this disease have focussed on 
intestinal bacteria that degrade oxalate, primarily Oxalobacter formigenes (Jiang et al., 2011; 
Liu et al., 2017; Miller et al., 2019; Prokopovich et al., 2007). Several more recent studies 
have evaluated the gut microbiota in stone disease and describe generalized “dysbiosis” but 
have been unsuccessful at coming to a consensus with their findings (Miller et al., 2019; 
Stern et al., 2016; Suryavanshi et al., 2018; Tang et al., 2018; Zampini et al., 2019). 
Moreover, studies into the urinary and stone microbiota of stone formers has been prefatory, 
involving few patients or lacking a healthy control comparison group (Barr-Beare et al., 
2015; Dornbier et al., 2019; Xie et al., 2020; Zampini et al., 2019). Based on these 
knowledge gaps left unaddressed by previous investigations, it remained unclear i) exactly 
how the gut is altered, ii) whether O. formigenes colonization is a driving factor, and iii) how 
the urinary and stone microbiota may contribute to nephrolithiasis. The aim of the current 
study was to define the urinary and gut microbiome’s involvement in stone disease in the 
largest multi-omics -based investigation to date.  
The results of the current study describe the urinary, stone, and gut microbiota of stone 
formers and healthy controls. It was confirmed that stone patients had higher urinary oxalate 
concentrations and an altered urinary microbiota composition compared to healthy controls. 
The urinary microbiota was enriched in inflammation-associated microbes during surgical 
stone treatment. A sequence-positive microbiota was found in all stone crystalline 
compositions and was derived from urogenital microbes, yet compositionally distinct from 
both pre-operative and intraoperative urine. A lower relative abundance of O. formigenes in 
the gut of stone formers was not found, however, novel functional changes were detected 
indicative of risk of stone formation which was not dictated by altered dietary consumption. 
Pathways conferring resistance to toxic compounds were elevated in the gut of stone formers. 
These findings suggest that the gut is a reservoir of resistance, and likely the root of systemic, 
aberrant microbial interactions leading to stone formation. 
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Participant recruitment began in August of 2015 and was completed in January of 2019 after 
the enrolment of 30 healthy control (HC) participants and 83 stone-forming (SF) patients. 
The intent was to recruit 200 stone patients however the lower study enrolment rate was a 
direct reflection of the available patient pool and was still within a sample size suitable to 
draw conclusions. Despite the Urology Clinic at St. Joseph’s Hospital seeing upwards of 200 
stone patients per year, many had taken antibiotics within the last 30 days constituting an 
exclusion criterion for study participation. In contrast to the lower than expected participant 
eligibility, the recruitment rate of stone patients approached for study participation was above 
90%. Those that declined to participate cited lack of interest. 
A full assemblage of samples was collected from 36 out of 83 stone patients; a limiting factor 
was intraoperative stone collection, since stone fragments were collected only from SF 
patients who underwent PCNL, rather than ureteroscopic stone removal. All HC participants 
provided complete sample sets. The dietary questionnaire was introduced as an amendment 
to the study protocol in 2016 under the guidance of a registered dietician, and therefore the 
HC and SF participants who had been recruited within the first year prior to its adoption did 
not complete this. Although this is a limitation, this study was the largest of its kind and 
involved the most extensive sample and participant characterization. 
The urinary oxalate concentrations were significantly higher in SF compared to HC. Urinary 
levels were calculated to be (mean ± SE) 0.56 ± 0.07 mM, 0.84 ± 0.08 mM, and 0.37 ± 0.04 
mM for HC, SF (PreOp), and SF (OR), respectively, after comparing against the 
concentrations of the known oxalate and creatinine standards. These values are slightly 
higher than documented urinary levels in healthy and hyperoxaluric patients, indicating a 
potential error in quantitation due to urinary ascorbate breakdown throughout storage 
(Baadenhuijsen and Jansen, 1975; Fry and Starkey, 1991; Lemann et al., 1996; Thompson 
and Fennema, 1971). We therefore did not utilize the exact molarity measurements of urinary 
oxalate. Instead, the ratio of oxalate [ppm]/creatinine [ppm] was reported, assuming the 
erroneous methodology was applied to both participant cohorts evenly. With these 
assumptions in mind, it was concluded that the SF urine was significantly higher in the 
relative proportion of oxalate compared to HC. 
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Urinary oxalate is a product of both exogenous dietary consumption of the compound and 
endogenous production as a terminal product of metabolism (Holmes and Assimos, 1998; 
Holmes et al., 2001). It is estimated that 20-50 % of urinary oxalate results from dietary 
consumption (Holmes et al., 2001). However, in concordance with previous studies, the 
present study demonstrated that dietary oxalate consumption was not different between SF 
and HC (Taylor and Curhan, 2007). Estimates of other relevant nutrients that may play a role 
in stone formation including water, caffeine, Vitamins B6, C, D, and K, calcium, sodium, or 
potassium intake were also not different between cohorts (Han et al., 2015). Although some 
diet questionnaires tend to exhibit measurement errors due to under-reporting, it was 
confident that the dietary questionnaire utilized in this study provided accurate assessments 
of nutrient intake as it has been independently validated (Subar et al., 2001; Subar 2003). 
Because endogenous oxalate production is largely affected by body size and in this study the 
cohorts were matched for these characteristics, altered endogenous production was unlikely 
to be responsible for the elevated oxaluria in SF (Lemann et al., 1996). These findings 
instead point to altered absorption or bacterial breakdown of dietary oxalate, or its 
precursors, between cohorts as the divergent factor. 
Characterization of the urinary and stone microbiota was completed with 16S rRNA gene 
sequencing of the V4 region. Whole shotgun metagenomic sequencing is significantly more 
expensive than 16S rRNA gene sequencing and also requires a much higher DNA yield. 
Therefore, the urinary samples which were of much lower microbial biomass than the gut 
samples were assessed with 16S (Hillmann et al., 2018; Whiteside et al., 2015). The urinary 
microbiota was significantly distinct between HC and SF, and in SF throughout their course 
of treatment. It has been postulated that both commensal and pathogenic Gardnerella 
vaginalis strains exist (Harwich et al., 2010). Although this organism is recognized as a 
pathogen in the vagina, it is often detected in the urine of healthy individuals, and here it was 
of higher relative abundance in healthy subjects compared to PreOp SF (Gottschick et al., 
2017; Mueller et al., 2018). In SF when urine was collected in the OR, the relative abundance 
of Gardnerella fell along with Lactobacillus and Prevotella spp., while that of Acinetobacter 
and Escherichia spp. increased significantly compared to the PreOp samples. Explanations 
for these alterations could include variations in the sampling methodology, the effect of pre-
operative and peri-operative antibiotics, or that the urological procedure may have disrupted 
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and flushed out the Acinetobacter and Escherichia spp. If the latter, it implies that some 
genera may be deeply embedded within the uroepithelium (Goneau et al., 2015). Escherichia 
and Acinetobacter are known to be associated with infection and inflammation, so their 
increased detection might lead to additional or longer antibiotic administration (Flores-
Mireles et al., 2016; Govender et al., 2019). Lactobacillus and Prevotella on the other hand 
are present in typical urotypes of healthy individuals, so their depletion may allow for 
resistant, deep-seated pathogens to take over the niche (Goneau et al., 2015; Mueller et al., 
2018). Such beneficiaries could be pathogenic G. vaginalis strains with enhanced adherence 
and virulence properties (Harwich et al., 2010; Mueller et al., 2018). For such substantial 
urinary microbiota changes to occur in a short time frame, efforts should be made to 
understand the reasons and clinical implications.  
Although historically only struvite stones were associated with bacteria, recent studies using 
both culture and molecular techniques have identified their presence in non-struvite kidney 
stones (Barr-Beare et al., 2015; Dornbier et al., 2019; Tavichakorntrakool et al., 2012; 
Zampini et al., 2019). Concordantly, after stringent filtering, the present study detected a 
sequence-positive microbiota in 34 out of 47 stone samples, only 3 of which were composed 
of struvite. The presence of live bacteria was confirmed with extended quantitative urine 
culture in a limited number of samples, the results of which were in agreement with the next 
generation sequencing. Such confirmation is important to overcome criticisms that simply 
detecting bacterial DNA does not prove the presence of living bacteria (Emerson et al., 
2017).  
Several genera including Staphylococcus and Streptococcus have been detected in stones 
previously (Dornbier et al., 2019; Tavichakorntrakool et al., 2012). This was confirmed in 
the present study along with numerous novel stone-associated taxa such as Gardnerella and 
Atopobium spp. The finding that the stone-associated microbiota was dominated by urinary 
microbes but was compositionally distinct from both the PreOp and OR SF urine indicates 
that bacteria inside calculi likely do not derive out of coincidental entrapment in the growing 
stone matrix, or the resulting community would more closely resemble the PreOp urine. 
Instead, the results suggest that specific microbes are intimately involved in stone 
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development, potentially exacerbating crystal nidus formation through inflammation and 
crystal aggregation (Barr-Beare et al., 2015; Chutipongtanate et al., 2013).  
Dogma has held that intestinal colonization by O. formigenes lowers oxaluria and 
consequently the risk of stone formation, however recent studies have failed to detect 
differences in the colonization rates between stone-formers and non-formers (Batagello et al., 
2018; Kaufman et al., 2008; Kwak et al., 2003; Siener et al., 2013; Ticinesi et al., 2018). In 
congruence with these studies, we did not detect a difference in the relative abundance of this 
bacterium in fecal samples from HC and calcium oxalate (CaOx) SF by whole shotgun 
metagenomic sequencing (Magwira et al., 2012; Miller et al., 2019; Tang et al., 2018; 
Ticinesi et al., 2018). These results suggest that perhaps the previous emphasis put on O. 
formigenes colonization has been overstated. It appears that Western society is collectively 
losing carriage of this bacterium, but this may just be a sign of a progressively ailing 
population, or the influence of medical practices and prevalent antibiotic use, as opposed to a 
direct causal factor in stone prevalence (Barnett et al., 2016; PeBenito et al., 2019). 
Alpha diversity as well as overall gut microbiota variation were divergent between study 
participants based on their history of CaOx stone disease and previous stone treatment, rather 
than between HC and SF cohorts. Indeed, those with a previous history of stones (recurrent 
stone formers, RSF) had higher relative abundance of various Enterobacteriaceae and the 
opportunistic pathogens Pseudomonas and Finegoldia, compared to those with no history of 
stones (NHS) (de Bentzmann and Plésiat, 2011; Goto et al., 2008; Sassone-Corsi et al., 
2016). This may be a marker of microbiota damage, precipitated by the repetitive 
antimicrobial therapy and surgical interventions experienced by the RSF (Ng et al., 2013; 
Sassone-Corsi et al., 2016; Winter et al., 2013). RSF also had lower relative abundance of 
the known gut commensal genera Prevotella, Faecalibacterium, and Roseburia compared to 
NHS (Mangalam et al., 2017; Marchesi et al., 2016; Martín et al., 2014; Tamanai-Shacoori et 
al., 2017).  
Beyond taxonomic differences, many functional changes in the gut of RSF and NHS cohorts 
were noted. Mapping shotgun metagenomic reads to the SEED database allowed for 
detection of changes at the level of individual protein encoding genes, as well as from a 
higher-level view of subsystems, or functionally related protein families (Overbeek et al., 
133 
 
 
 
2014). With this approach, RSF samples were found to be enriched compared to NHS in 
osmotic stress-related proteins marked by higher relative abundance of aquaporins and 
choline/betaine transporters. Bacterial aquaporins were first described in 1995, but their 
characterization to-date remains scant (Calamita et al., 1995, Tong et al., 2019). These 
membrane channels facilitate the diffusion of water and solutes across cellular membranes, 
though a role for these proteins in kidney stone disease is undocumented beyond human renal 
aquaporins and their activation by urinary calcium (Earm et al., 1998). Prokaryotic 
aquaporins may play a role in bacterial persistence in harsh environments, virulence, and 
rapid growth in hypoosmotic conditions, and have been characterized in many bacteria 
including Escherichia, Pseudomonas, and Shigella spp., which were similarly enriched in 
RSF (Calamita et al., 1998; Kaenjak et al., 1993; Tanghe et al., 2006; Tong et al., 2019). 
Whether this enrichment in osmotic stress response has a pathogenic role in nephrolithiasis 
or is a result of altered gut osmolality or toxification warrants further research. 
Higher relative abundance of ascorbate utilization and depleted pyridoxine metabolism 
functional pathways in RSF may be of great consequence, as both of these pathways impact 
serum and urinary oxalate levels. These pathways may have been previously overlooked by 
groups solely focussed on direct oxalate breakdown. Ascorbate, or vitamin C, is a precursor 
to oxalate and its intake is associated with risk of incident kidney stones (Ferraro et al., 
2016). Elevated utilization of vitamin C by bacteria in the RSF gut may lead to higher 
intestinal levels of absorbable oxalate, despite no difference in vitamin C or oxalate dietary 
consumption between cohorts in this study (Baxmann et al., 2003; Eddy and Ingram, 1953; 
Stack et al., 2020). This ascorbate utilization has been documented in Pseudomonas and 
Acinetobacter spp. among others, both of which were elevated in (R)SF patients (Stack et al., 
2020). Thus, for some people suffering from recurrent stone formation, the levels of gut 
microbiota mediated ascorbate utilization (by qPCR or ELISA) might be worth determining. 
Pyridoxine, also known as vitamin B6, is a cofactor necessary for the enzyme alanine-
glyoxylate aminotransferase’s conversion of glyoxalate to glycine. Deficiency of this vitamin 
has been associated with elevated oxaluria (Curhan et al., 1999; Ferraro et al., 2017). 
Bacteria can biosynthesize B6, and also convert it to the active form, pyridoxal 5’ phosphate 
(PLP) (Dempsey, 1967; Eliot and Kirsch, 2004; Magnúsdóttir et al., 2015; Strohmeier et al., 
134 
 
 
 
2006). Gut colonizing species within the genera Prevotella, Corynebacterium, and 
Clostridium are capable of B6 and PLP biosynthesis, and these genera were of relatively 
higher abundance in the gut of NHS compared to RSF (Jochmann et al., 2011; Magnúsdóttir 
et al., 2015; Yoshii et al., 2019). The finding that antibiotic use can lead to B6 deficiency 
again raises the issue of the extent to which antibiotics influence recurrence of stone 
formation (Levy, 1969; Meletis and Zabriskie, 2007; Snider, 1980). Although vitamin B6 
intake was not different between participant cohorts, RSF may have reduced 
microbiologically synthesized pyridoxine, or lower levels of the microbiologically activated 
PLP, ultimately leading to increased urinary oxalate. Despite B6 supplementation being 
previously tested as a therapy for nephrolithiasis with some success, its use has not been 
widely implemented, nor has the microbial contribution to this vitamin been evaluated in the 
context of stone formers (Mitwalli et al., 1988; Pearle et al., 2014; Prien and Gershoff, 1974; 
Rao and Choudhary, 2005). Serum and fecal PLP concentration should be collected in future 
studies of the gut microbiome and nephrolithiasis to identify the keystone microbes necessary 
for host pyridoxine acquisition and confirm whether these are depleted in RSF. 
The gut microbiota of RSF was enriched in functional pathways associated with resistance to 
toxic compounds including heavy metals and a variety of antibiotic and antiseptic classes. 
Specifically, the cobalt/zinc/cadmium efflux system encoded on the czcCBA operon was 
significantly enriched in RSF (Liu et al., 2015). Interestingly, both zinc and cadmium 
exposure have been associated with elevated stone risk (Guo et al., 2018; Tang et al., 2012). 
Although biological levels of these metals were not investigated in the present study, because 
serum levels of these metals are largely derived from dietary consumption, they were likely 
not different between the cohorts due to their comparable diets (Canada Environmental 
Protection Act, 2007; Dabeka and McKenzie, 1992). However, if the gut microbiota of RSF 
effluxes more of these metals into the intestinal lumen instead of providing a “quenching” 
effect as some bacteria do, increased amounts may be bioavailable for unfavourable 
absorption by the host (Bisanz et al., 2014; Daisley et al., 2018). For this reason, heavy 
metals should be evaluated in future studies of the gut microbiome and stone formation; if 
cadmium-resistant bacteria in the gut such as Pseudomonas spp. are contributing to a 
biologically relevant increase of serum levels in stone formers, this cadmium may be 
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aggravating crystal precipitation and stone formation in the kidney (Liu et al., 2015; Thomas 
et al., 2013). 
The cmeABC operon encodes a multidrug efflux pump of the RND superfamily and confers 
resistance to a broad range of antibiotics including ciprofloxacin (Fernando and Kumar, 
2013; Lin et al., 2002; Yan et al., 2006). This operon as well as genes encoding resistance to 
β-lactams, macrolides, polymyxins, and the topical antiseptic acriflavine were significantly 
elevated in RSF compared to NHS. It is known that the use of antibiotics, particularly in 
early life, can have lasting impacts on the microbiome, host metabolism, and immunity (Cho 
et al., 2012; Cox et al., 2014; Ruiz et al., 2017). The recent report of a direct link between 
oral antibiotic use and the risk of nephrolithiasis highlighted sulfas, cephalosporins, 
fluoroquinolones, nitrofurantoin, and β-lactams as problematic, especially with recent and 
younger age exposures (Tasian et al., 2018).  
Although neither cohort had used antibiotics within 30 days prior to providing their fecal 
sample in the present study, antibiotics were prescribed significantly more recently in SF 
than HC. Indeed, throughout the course of surgical stone treatment, patients were treated with 
perioperative antibiotics, and those with planned PCNL additionally took pre-surgical 
prophylactic antibiotics. The data suggest this practice may be enriching for 
Gammaproteobacteria including Enterobacteriaceae and antibiotic-resistance in the gut of 
RSF subjects, as they were administered antibiotics at each previous surgical stone treatment. 
As the gut is a bacterial reservoir for the urinary tract, antibiotic-resistant strains may have 
ascended from the rectum (Magruder et al., 2019; Yamamoto et al., 1997). In support of this, 
Acinetobacter spp. (of class Gammaproteobacteria), often multidrug resistant and considered 
serious uropathogens with increasing nosocomial disease burden, were enriched in SF OR 
urine (Bergogne-Bérézin et al., 1996; Di Venanzio et al., 2019; Jiménez-Guerra et al., 2018). 
Therefore, patients with previous surgical intervention for calculi have likely experienced 
antibiotic-induced, functional changes to their gut microbiota resulting in the enrichment of 
potentially pathogenic, multidrug resistant microbes.  
We therefore propose, based on these collective findings and in corroboration with the work 
of others, that antibiotics induce a widespread assault on the gut and urinary microbiota, 
driving the depletion of beneficial gut microbes such as Faecalibacterium and Lactobacillus 
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spp., while simultaneously enriching for antibiotic resistant uropathogens. This ultimately 
leads to disrupted oxalate homeostasis due to altered microbiota-mediated micronutrient 
biosynthesis and utilization, intestinal toxin accumulation, and the blooming of uropathogens 
in the bladder via the interconnected pelvic floor microbiota (Moreno et al., 2006; Thomas-
White et al., 2018; Yamamoto et al., 1997). These biological consequences all collectively 
impact stone formation, and the repeated microbiome assaults inflicted by surgical stone 
treatment and its accompanying antibiotic use perpetuate the cyclic recurrence of the disease. 
With this in mind, future management of nephrolithiasis should comprise both prevention of 
microbiome disturbance and the use of agents for subsequent restoration of homeostasis. 
Antibiotic stewardship is a first and obligatory step in preventing the unnecessary disruption 
of microbial balance (Mossanen et al., 2014; Siemens and Nickel, 2015). Although often 
required to avert systemic infection, there is still debate over antibiotic prophylaxis for PCNL 
in low-risk patients (Chew et al., 2018). In such cases, avoidance of antibiotics may reduce 
the progression of microbial dysbiosis and its subsequent ramifications for stone formation. 
In addition, microbial restoration therapies such as probiotics and prebiotics could replenish 
organisms associated with a healthy urinary tract and may offer relief to recurrent stone 
formers that have already experienced substantial microbiota damage (Bustamante et al., 
2020; Collins et al., 2018; Falagas et al., 2006; Stapleton et al., 2011). Such restoration may 
even include fecal microbiota transplant (FMT), based on early evidence of efficacy against 
recurrent urinary tract infection (Hocquart et al., 2019; Tariq et al., 2017). Where previous 
studies implementing supplementation of a single microbe (as has been attempted with O. 
formigenes) have yielded mixed results, FMT may hold promise (Duncan et al., 2002; Ellis 
et al., 2015; Jairath et al., 2015; Stern et al., 2019). Future studies should investigate the 
therapeutic potential of FMT for nephrolithiasis, where it may restore the robust community 
and interactive network of beneficial microbes that becomes depleted in recurrent stone 
formers (Miller et al., 2017; Stern et al., 2019). It would also be important to validate how 
long the effects of an FMT persist in stone formers, and the extent to which altering the gut 
microbiome spills over to the urinary tract. 
In conclusion, the results of the current study demonstrate how antimicrobial use inherent in 
surgical stone management depletes beneficial microbes in the gut and urinary tract, causing 
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a decreased capacity to maintain oxalate homeostasis and the development of an intestinal 
reservoir of antibiotic resistant uropathogens. That these microbes are detected within stone 
fragments further suggests that elevated urinary oxalate in concert with the presence of 
inflammation-mediating microbes in the upper urinary tract leads to the development of 
crystal nidi and aggravates recurrent stone development. We postulate that the previous 
emphasis of direct oxalate degradation and O. formigenes colonization status in the gut has 
been overstated. Rather, a novel, inconspicuous method of oxalate homeostasis is causative 
and dependent on microbial micronutrient metabolism and biosynthesis. If the diversity and 
robust functional potential of the healthy human microbiome is repeatedly assaulted by the 
average Westernized lifestyle via diet, antibiotic use, and other environmental factors, then 
kidney stone prevalence will continue to increase (Lozupone et al., 2012; Tasian et al., 
2016). Reversing this trend through microbiome-targeted therapeutic applications should be 
studied as a means to prevent this debilitating condition. 
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Chapter 4  
4 Characterizing the microbial communities associated with 
ureteral stents 
4.1 Abstract 
Ureteral stents are commonly used in urological practice and can often become bacterially 
colonized and encrusted, leading to clinical complications. Despite recent discovery and 
characterization of the healthy urinary microbiota, stent-associated bacteria and their impact 
on encrustation are largely underexplored. We profiled the bacterial communities of ureteral 
stents and mid-stream urine from a single clinical centre over a one-year period. 16S rRNA 
gene sequencing was utilized to determine factors that impacted variation in the microbial 
communities. Two hundred and forty-one patients were examined, including typical short-
term stent insertion cases, as well as atypical cases of bilateral stenting, long-term indwelling 
stents, patients with multiple sequential stents over time, and antegrade stent placement. 
Indwelling time, age, and various patient comorbidities including diabetes and IBS/IBD 
impacted the stent microbiota, whereas antibiotic treatment, UTI, and stent placement 
method did not. The stent microbiota originates from adhesion of urinary microbes and 
subsequently diverges to a distinct and reproducible population, thereby negating the urine as 
an accurate biomarker for stent encrustation or microbiota. Urological practice should 
reconsider standalone prophylactic antibiotic use in favour of tailored therapies based on 
patient comorbidities in efforts to minimize bacterial burden, encrustation, and complications 
of ureteral stents. 
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4.2 Introduction 
Ureteral stents are hollow conduits placed in the ureter from the renal pelvis to the bladder 
and are commonly used in urological practice to maintain urine drainage, which can be 
impeded by obstruction caused by urolithiasis, stricture, or malignancy. Termed double 
pigtail or double J, typical stents involve a curl at either end to prevent displacement. They 
are typically composed of polyurethane, silicon, and new combination polymers (Chew and 
Denstedt, 2004; Mosayyebi et al., 2018). Due to constant contact with the urine, deposition 
of urinary crystals and formation of bacterial biofilms on stents are common (Reid et al., 
1992; Zumstein et al., 2017). The formation of these encrustations can lead to complications 
including infection, failure of the stent to drain urine, more frequent device exchanges, and 
subsequent difficulty with removal. Indwelling ureteral stents have been associated with the 
development of urinary tract infections (UTIs), and in more severe cases, pyelonephritis or 
urosepsis which may be related to single species or polymicrobial biofilms attached to the 
stent (Lange et al., 2015).  
The urinary tract harbours a unique microbiota which is distinct from that of the gut in 
composition and is of much lower abundance (Whiteside et al., 2015; Wolfe et al., 2012). 
Based on recent evidence, it is likely that the different sites and tissues throughout this 
system have different microbiotas (Barr-Beare et al., 2015; Cavarretta et al., 2017; Wolfe et 
al., 2012). The biofilms that form on stents may originate from this microbiota or 
contamination during insertion of the device. Regardless of their origin, the development of 
biofilms on these devices illustrates that even very low numbers of bacteria can quickly take 
advantage of the niche-altering foreign material to expand their populations. Previous studies 
in stent patients have identified bacterial colonization rates from 70 – 90% (Rahmann et al., 
2010; Reid et al., 1992). Bacteriuria can be common in upwards of 20% of patients with 
stents, and Escherichia coli is often the most commonly cultured and identified organism 
(Rahmann, et al., 2010). Bacterial isolates derived from stent biofilms of clinical origin often 
demonstrate resistance to multiple antibiotics, and antibiotic prophylaxis or concomitant 
antibiotic administration does not appear to reduce the incidence of stent-related symptoms 
or urinary tract infection incidence or severity (Chatterjee et al., 2014; Chew and Lange, 
2009; Moltzahn et al., 2013; Paz et al., 2005). Due to these findings, the use of antibiotic 
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prophylaxis for stents is controversial, and it is unclear how these compounds may impact the 
urinary microbiota during stenting.  
The purpose of this study was to elucidate how the urinary microbiota and other host factors 
impact bacterial colonization and encrustation of indwelling ureteral stents. As such, we 
utilized 16S rRNA gene sequencing and scanning electron microscopy to characterize the 
urine and stent microbiota from 241 patients that were sampled from a single urology centre. 
The large sample size and complementary nature of the samples provide the first high 
resolution insight into bacterial attachment to ureteral stents under different clinical 
scenarios. This work may help clinicians and scientists to have a better understanding of 
what types of bacteria colonize or adhere to ureteral stents, factors that increase or decrease 
the likelihood of stent colonization and encrustation, and provision of best management 
practises. 
4.3 Materials and Methods 
4.3.1 Study design and clinical sample collection 
Ureteral double-J stent patients were recruited from the Urology Department at St. Joseph’s 
Hospital in London, Ontario. Ethical approval for the study was granted by Lawson Health 
Research Institute and the Health Sciences Research Ethics Board at the University of 
Western Ontario (REB #107941, Appendix C) in London, Ontario. Written consent was 
obtained from all the study participants at the time of study inclusion and the methods were 
carried out in accordance with the approved guidelines. 
The study proposed to recruit up to 500 participants over a 2-year period; at study conclusion 
241 participants had been enrolled. Inclusion and exclusion criteria for the participants are 
provided in Table 12. All patients that met the inclusion criteria were recruited to the study 
during regularly scheduled clinic appointments. Upon recruitment, patients were asked about 
relevant demographic and medical history including antibiotic usage and their history of 
urinary tract infections. Following enrolment, participants provided a mid-stream urine 
sample. Stents were collected during cystoscopy (either in-clinic or OR) and placed by the 
surgeon into a sterile urine collection cup (Figure 23). 
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4.3.2 Clinical sample processing and DNA extraction 
Urine samples were processed in two portions within 6-hours of their collection. Where 
possible, 10 mL of whole urine was collected and frozen at -20 °C for future high-
performance liquid chromatography (HPLC) analyses of urinary metabolites. The remainder 
was stored for future 16S rRNA gene sequencing: the entire remaining volume of urine was 
centrifuged for 10 minutes at 5,000 x g, after which the supernatant was decanted off and the 
pellet was stored dry at -20 °C until DNA extraction. If the total urine volume was under 25 
mL, only 2 mL of whole urine was reserved for calcium oxalate quantitation by HPLC. The 
urine volume that resulted in the pellet for 16S rRNA gene sequencing was recorded to 
identify confounding factors in the downstream sequencing analysis associated with 
processing conditions.  
Within 6 hours of their collection, stents were frozen at -20 °C and stored until DNA 
extraction. On the day of DNA extraction, the stents were thawed and processed in a sterile 
biosafety hood. A scalpel sterilized with RNase AWAY™ (Thermo Scientific, Waltham, 
MA, USA) was utilized to slice two x 1 cm portions from both the proximal and distal curls 
of the stents (Figure 23). One 1 cm slice from each curl was utilized for 16S rRNA gene 
sequencing: using tweezers sterilized with RNase AWAY™, 1 mL of nuclease free water 
(Ambion, Mississauga, ON, CAN) was gently rinsed over the external surface of the stent 
and into the inner lumen of the stent where possible (this was sometimes inhibited by 
encrustation). The rinsed cut was then directly transferred into the bead plate of the DNeasy 
PowerSoil HTP 96 Kit utilized for DNA extraction (Qiagen, Toronto, ON, CAN). A second 1 
cm cut segment was reserved for scanning electron microscopy (SEM): both the internal 
lumen and exterior of the stent were of interest for imaging so the stent cut was sliced 
lengthwise and both halves were transferred to a sterile 1.5 mL Eppendorf tube for SEM 
preparation. 
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Table 12. Inclusion and exclusion criteria for study participation 
Inclusion Criteria Exclusion Criteria 
At least 18 years of age In the opinion of the treating urologist, it is 
not in the patient’s best interest to 
participate 
Has a ureteric stent scheduled for removal 
Able and willing to provide informed 
consent 
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Stents were collected by the surgeon and placed into a sterile urine collection cup. A sterile 
scalpel was utilized to slice two x 1 cm portions from both the proximal and distal curls of 
the stents. One 1 cm slice from each curl was utilized for SEM imaging, the other for 16S 
rRNA gene sequencing. The portion for 16S sequencing was gently rinsed externally and 
internally where possible with nuclease-free water over a sterile reservoir and added directly 
to the DNA extraction plate. Image templates from Servier Medical Art by Servier were used 
and modified under the Creative Commons Attribution 3.0 Unported License. 
  
Figure 23. Schematic of stent sample processing 
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For DNA extraction, frozen urine pellets were thawed and suspended in 100 uL of nuclease-
free water (Ambion), then pipetted into individual wells of the PowerSoil HTP bead plate 
with PCR-grade filter tips (FroggaBio, Toronto, ON, CAN). Two wells in every plate were 
left empty and acted as negative controls. Two positive controls, or spikes, were added to 
each plate and were 100 μL of pure bacterial culture: Spike 1 was Escherichia coli strain 
DH5α, and Spike 2 was Staphylococcus aureus strain Newman. For preparation of the 
spikes, a single colony of the bacteria was inoculated into 10 mL of Luria-Bertani (LB) broth 
and grown overnight at 37 °C. One hundred 100 μL aliquots of the overnight cultures were 
portioned into 1.5 mL Eppendorf tubes and frozen at -80 °C. For each DNA extraction plate, 
a single tube of both spikes was thawed and pipetted directly into the PowerSoil HTP bead 
plate with PCR-grade filter tips. 
DNA was isolated from urine and stent samples using the DNeasy PowerSoil HTP 96 Kit 
according to the manufacturer’s instructions. Briefly, 750 μL of bead solution and 60 μL of 
Solution C1 were added to the bead plate loaded with all samples and controls. Plates were 
shaken for 20 minutes at speed 20 using the MoBio 96-well plate shaker (Qiagen), then 
centrifuged for 10 minutes (all centrifuge steps were conducted at room temperature at 2250 
x g). Five hundred μL of the supernatant was added to a fresh plate with 250 μL Solution C2 
and mixed by pipetting. The plates were incubated at 4 °C for 10 minutes followed by 
centrifugation for 10-minutes. The resulting supernatant was then transferred to a fresh plate 
and the centrifugation step was repeated. Approximately 600 μL of the solution was then 
transferred to a fresh plate containing 200 μL Solution C3 and mixed by pipetting. The plate 
was incubated at 4 °C for 10 minutes followed by centrifugation for 10-minutes. The entire 
volume, with the exception of the pellet, was again transferred to a fresh plate for 
centrifugation. Carefully avoiding the loose residual pellet, 650 μL was transferred from each 
well to a fresh plate containing 1300 μL Solution C4. The plates were then sealed with 
sealing tape and stored at 4°C overnight. The following day the plates were briefly 
centrifuged and sealing tape was removed. Solution in the wells was then mixed by pipetting 
and 500 μL was transferred to a Spin Plate, which was centrifuged for 5 minutes. The flow-
through was discarded, and this step was repeated until the entire sample-Solution C4 mix 
was processed through the Spin Plate. A volume of 500 μL Solution C5-D was then added to 
the Spin Plate and centrifuged twice for ten minutes, where the flow-through was discarded 
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between spins. 100 μL Solution C6 was then added to the Spin Plate, incubated at room 
temperature in the biosafety hood for 10 minutes and the resulting DNA was eluted to a 
Microplate via centrifugation for 15 minutes. DNA was stored at -20 °C until PCR 
amplification. 
4.3.3 16S rRNA gene amplification and sequencing 
PCR amplification was completed using the Earth Microbiome universal primers, 515F and 
806R, which are specific for the V4 variable region of the 16S rRNA gene (Figure 4). 
Primers contained an Illumina adapter, followed by four random nucleotides, one of 24 
unique 12-mer barcodes, and the annealing left or right primer (Figure 4) (Parada et al., 
2016). Primers and barcode sequences are listed in Table 7. PCR reagent set-up was 
performed using a Biomek® 3000 Laboratory Automation Workstation (Beckman-Coulter, 
Mississauga, ON, CAN). Ten μL of each left and right- barcoded primers (3.2 pMole/μL) 
were arrayed in 96-well plates (Axygen-Corning, Oneota, NY, USA) such that each well 
contained a unique combination of left- and right- barcodes (up to a maximum of 576 unique 
combinations). Two μL of DNA template was added to the primer plate, followed by 20 μL 
of Promega GoTaq hot-start colourless master mix (Promega, Madison WI, USA). The 
reaction was briefly mixed by pipetting, then plates were sealed with foil plate covers 
(Axygen-Corning) and centrifuged for 2 minutes at room temperature at 2250 x g. 
Amplification was carried out using an Eppendorf thermal cycler (Eppendorf, Mississauga, 
ON, CAN), where the lid temperature was maintained at 104 °C. An initial warm-up of 95 °C 
for 4 minutes was utilized to activate the GoTaq, followed by 25 cycles of 1 minute each of 
95 °C, 52 °C, and 72 °C. 
DNA extraction was completed across a total of 11 x 96-well plates, as in some cases stent 
samples were extracted in parallel with samples from other experiments. Due to the total 
number of samples exceeding the number of unique barcode combinations, two Illumina 
MiSeq runs were completed to accommodate the sequencing of all the samples (Illumina 
Inc., San Diego, CA, USA). In order to identify potential batch effects between the two 
sequencing runs, several samples and controls were sequenced on both runs. In total, 
accounting for doubly sequenced samples, 822 samples were sequenced across 9 PCR plates 
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(5 x 96-well plates containing 438 samples on the first MiSeq run, 4 plates containing 384 
samples on the second). Sequencing was carried out at the London Regional Genomics 
Centre (http://www.lrgc.ca; London, ON, CAN). Amplicons were quantified using pico 
green (Quant-It; Life Technologies, Burlington, ON) and pooled at equimolar concentrations 
before cleanup (QIAquick PCR clean up; Qiagen, Germantown, MD). Using the 600-cycle 
MiSeq Reagent Kit (Illumina Inc.), paired-end sequencing was carried out as 2 × 260 cycles 
with the addition of 5% ɸX-174 at a cluster density of ~1100. Data was exported as raw fastq 
files (uploaded to NCBI Sequence Read Archive, BioProject ID #PRJNA601180). 
From the two sequencing runs, run 1 contained 438 samples and yielded a total of 16,211,576 
reads, ranging from 419 to 358,493 reads per sample. Run 2, containing 384 samples, yielded 
a total of 10,424,180 reads, ranging from 168 to 400,010 reads per sample. An average of 
20.8% and 18.8% of reads were removed from each sample in Runs 1 and 2, respectively, 
following quality filtering performed utilizing the DADA2 pipeline (Callahan et al., 2016). 
The remaining filtered reads from the two runs (14,477,624 and 9,697,990) were then 
merged by amplicon sequence variants (SVs). SVs that were only detected in one of the two 
runs were removed. Samples and SVs were then further pruned such that the final dataset 
utilized in all downstream analyses retained samples with greater than 1,000 filtered reads, 
SVs present at 1% relative abundance in any sample, and SVs with greater than 10,000 total 
reads across all samples in both runs. This cleaning reduced the dimensions of the dataset 
from 460 SVs and 822 samples down to 43 SVs and 711 samples. The remaining 43 SVs 
were assigned taxonomy with the SILVA (v132) training set, and a further 5 SVs were 
removed due to their alignment to human mitochondrial sequences (Quast et al., 2013). 
Downstream analysis was performed with ALDEx2, MaAslin2, Vegan, and core R packages 
(Fernandes et al., 2013; Morgan et al., 2012; Oksanen et al., 2019; R Core team, 2019).  
4.3.4 Scanning electron microscopy and X-ray diffraction 
spectroscopy 
One-centimetre stent sections were cut open lengthwise with a sterile razor and mounted 
upon aluminum stubs such that one half exposed the inner lumen, and the other half exposed 
the external surface. They were then gently rinsed with DI water to remove salt precipitation 
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prior to SEM and X-ray diffraction spectroscopy analysis at the Western University 
Nanofabrication Facility (https://nanofab.uwo.ca). 
4.4 Results 
4.4.1 Study recruitment and participant demographics 
Participant recruitment began in July of 2016 and concluded in May of 2017 after the 
recruitment of 241 stent patients. Their average age was 59 years; 122 were female and 119 
were male. Patient demographic characteristics are summarized in Table 13. The majority of 
samples were collected from typical stenting events, where one double-J stent links between 
one of the kidneys and the bladder. However, cases of bilateral (stents between both the left 
and right kidney to the bladder), longitudinal (receiving multiple consecutive devices), 
antegrade (placed downwards from the kidney percutaneously rather than upwards from the 
urethra), uncommonly long indwelling times, and various encrustation levels were also 
examined. The majority of study participants had an indwelling stent placed for treatment 
related to stone disease, though in 22 participants stents were necessitated for other reasons 
including radiation-induced ureteral stricture and the presence of retroperitoneal masses. 
Stent indwelling time ranged from 2 to 394 days. 
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Table 13. Demographic and clinical characteristics of study participants 
Participant characteristic N = 241 (%) 
Age 59.01 ± 13.84 (range 22 – 90) 
Sex 122 females (50.6), 119 males (49.4) 
Indwelling time 22.79 ± 34.61 days (range 2 – 394) 
BMI 31.04 ± 7.64 (range 17.00 – 60.00) 
Reason for stent placement: Urolithiasis 219 (90.9) 
 Stricture 5 (2.1) 
 Mass 10 (4.1) 
 Other 7 (2.9) 
Stent placement method: Retrograde 219 (90.9) 
 Antegrade 22 (9.1) 
Patients with bilateral stents  11  
Patients with multiple sequential stents over time 11 (9 patients with 2 devices, 2 
patients with 3 devices) 
Time between sequential stent placements 63.5 ± 28.6 days (range 25 – 105) 
Use of antibiotics within the last 30 days from stent 
collection 
225 (93.4) 
Previous history of UTI 99 (41.1) 
UTI within 7 days of stent placement or whilst 
indwelling 
37 (15.4) 
Diabetes 54 (22.4) 
Hyperlipidemia 99 (41.1) 
Hyperuricemia 16 (6.6) 
Hypertension 122 (50.6) 
IBS 17 (7.1) 
IBD 28 (11.6) 
Crohn’s disease 8 (3.3) 
Ulcerative colitis 20 (8.3) 
Pulmonary disease 72 (29.9) 
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4.4.2 16S rRNA gene sequencing 
Stringent bioinformatic filtering was performed such that 711 samples and 43 amplicon 
sequence variants (SVs) were maintained for downstream analysis. The most abundant SVs 
in stent and urine samples corresponded to the bacterial genera Staphylococcus, 
Enterococcus, Lactobacillus, and Escherichia (Table 14). The clinical samples (not including 
positive and negative controls) contained an average of 13.5 SVs, ranging from 3 to 31. 
There was a positive correlation between read count and observed SVs (Figure 24A); the 
correlation coefficient was 0.44 (P < 0.0001, 95% CI 0.38 - 0.50). Urine samples had 
significantly more SVs observed (Figure 24B) and higher total read count (Figure 24C) 
compared to stent samples (P = 0.0063 and P < 0.0001, respectively). 
The sequence counts were centred log ratio (CLR) transformed, generating sample-wise 
Aitchison distances (Gloor et al., 2017). A heatmap representing the relative abundance of 
CLR-transformed samples was generated based on the Aitchison distance average linkage 
clustering (Figure 25). The differences in microbiota composition at the genus level were not 
driven by sex or sample type (urine or stent). This was confirmed with a Benjamini-
Hochberg corrected Welch’s t-test and principal component analysis (PCA) performed on the 
log-ratio transformed data at SV-level (Figure 26), where all samples and sex subsets did not 
separate by sample type (Figure 27A). These findings demonstrate that the same microbes 
dominate both stent and urine samples from a single patient, and therefore the stent 
microbiota is likely to be urinary derived. 
Although sample types were dominated by similar organisms, stent samples were further 
compared based on curl position to determine if the two curls (proximal curl in the kidney, 
and distal in the bladder) had a distinct microbial profile compared to that of the patient’s 
urine (Figure 27B). Specifically, beta diversity was measured by Aitchison distance to 
evaluate the distance between proximal and distal curls from each stent, as well as between 
the stent curls and the urine. Stent curls had significantly shorter distances between proximal 
and distal curls versus the further distance between stent curls to the urine sample. Thus, 
microbiota composition of the stent curls was more similar to each other than either curl to 
the urine, indicating the presence of a stent-specific microbiota that doesn’t directly reflect 
the composition of the urine. 
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From the devices recovered from participants with multiple sequentially placed stents, many 
of the same organisms were detected within the same individual over time (Figures 28 and 
29). Upon PCA, samples from the same individual generally clustered together (Figure 29A). 
Distance between samples from the same participants at different time points was shorter 
than between samples from different participants (Figure 29B, Kruskall-Wallis test with 
Dunn’s multiple comparisons, P = 0.022). There were no significant effects of visit number 
on the samples (Benjamini-Hochberg corrected Wilcoxon rank sum test, data not shown). 
Thus, on a per-patient basis, the stent microbiota is a reproducible community over time, 
even over the course of up to 150 days. 
The microbiota of bilateral stents did not differ significantly, as determined from eleven 
subjects (Figures 30 and 31). Within patients, both proximal and distal ends of bilateral stents 
clustered separately from the urine (Figure 31A). Intraindividual samples were closer 
together than interindividual samples (Figure 31B). There was greatest spread between stent 
and urine samples from the same individual, and the distance between stent samples was the 
shortest (Figure 31B), again indicating the presence of a distinct and reproducible stent-
specific microbiota. 
To determine if patient and sample attributes (metadata) drove microbiota variation, CLR-
transformed sample-wise Aitchison distances were evaluated (Oksanen et al., 2019). With 
this approach, several metadata factors were determined to be microbiota confounders, 
including stent indwelling time and patient comorbidities (Table 15). These confounders 
were subsequently adjusted for, and several statistically significant drivers of microbiota 
variation remained between metadata characteristics and taxonomic features as determined 
using a general linear model, including patient age, BMI, stent indwelling time, pulmonary 
disease, hypertension, diabetes, IBS, IBD, and hyperlipidemia (Table 16) (Morgan et al., 
2012). 
To determine how the degree of encrustation impacted microbial composition, stents were 
categorized based on visible encrustation level (Table 17). There was a correlation between 
the degree of stent encrustation and the amount of time stents were indwelling (Figure 32A); 
the correlation coefficient was 0.32 (P < 0.0001, 95% CI 0.20 – 0.37). Shannon’s index of 
alpha diversity was negatively correlated with the degree of stent encrustation (Figure 32B); 
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the correlation coefficient was -0.14 (P = 0.0005, 95% CI -0.22 – -0.03). Shannon’s index 
was also significantly lower in grade-3 encrusted stents compared to grade-0 (Figure 32C; 
Kruskall-Wallis with Dunn’s multiple comparisons, P = 0.027). This suggests that the longer 
a stent is indwelling, the more likely it will be to become encrusted by a less diverse 
microbial community. 
Ten study participants had stents indwelling for greater than two months; these participants 
were determined to be outliers, having stents significantly longer than the average indwelling 
time of 23 days (“ROUT” method of outlier detection, Q = 0.1%) (Motulsky and Brown, 
2006). Microbial communities of participants with “long-term” stents indwelling for 60 or 
more days were evaluated (Figure 33). The microbiota of these patients was not significantly 
different when compared to all samples, or to samples from the ten participants with the 
shortest indwelling durations (Benjamini-Hochberg corrected Wilcoxon rank sum test, data 
not shown). However, as indwelling time increased, relative abundance of the genera 
Finegoldia and Porphyromonas increased, and Enterococcus and Escherichia decreased 
(Table 16). 
Antibiotic usage was widespread amongst participants; about 93% had used antibiotics 
within 30 days of sample collection (Table 13). However, the microbiota of the few 
participants without recent antibiotic usage was not significantly different than the majority 
(Table 16, Figure 34A and by Benjamini-Hochberg corrected Wilcoxon rank sum test, data 
not shown). These participants also did not differ by encrustation grade or alpha diversity 
(Figure  34B-C; Mann-Whitney U test, P = 0.091 and P = 0.25 respectively). 
Stents were evaluated based on their placement method. The majority (90.9%, Table 13) of 
stents were placed in a retrograde manner, however the microbiota of the stents placed 
antegrade (i.e. during percutaneous nephrolithotomy or nephroscopy) was not significantly 
different than those placed retrograde (Table 16, Figure 34D). These participants also did not 
differ by encrustation grade or alpha diversity (Figure 34E-F; Mann-Whitney U test, P = 0.90 
and P = 0.95 respectively). 
About 15% of patients had culture positive UTIs within 7 days of stent placement, or 
throughout the stent indwelling period (Table 13). The microbiota and degree of stent 
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encrustation in these patients was not significantly different than those without UTIs (Figure 
34G and H), however alpha diversity was lower for patients with UTIs (Figure 34I, Mann-
Whitney U test, P = 0.002).
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Table 14. Ten most abundant sequence variants in urine and stent samples 
Urine samples 
Rank Sequence Variant Corresponding Genus Average abundance (%) 
1 SV_603 Staphylococcus 18.09 
2 SV_705 Enterococcus 17.53 
3 SV_709 Lactobacillus 11.75 
4 SV_213 Escherichia 11.61 
5 SV_695 Lactobacillus 6.13 
6 SV_713 Lactobacillus 5.20 
7 SV_108 Prevotella 2.42 
8 SV_60 Pseudomonas 2.28 
9 SV_40 Ureaplasma 2.10 
10 SV_208 Citrobacter 1.63 
Stent samples 
Rank Sequence Variant Corresponding Genus Average abundance (%) 
1 SV_705 Enterococcus 21.43 
2 SV_603 Staphylococcus 18.73 
3 SV_213 Escherichia 16.21 
4 SV_709 Lactobacillus 9.15 
5 SV_713 Lactobacillus 4.98 
6 SV_695 Lactobacillus 4.24 
7 SV_60 Pseudomonas 3.67 
8 SV_208 Citrobacter 2.34 
9 SV_40 Ureaplasma 1.90 
10 SV_648 Veillonella 1.66 
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A) Sample read count was positively correlated with the number of observed SVs, as 
calculated by the Spearman correlation coefficient (r = 0.44, P < 0.0001). R2 was 
calculated as the least-squares fit of the semilog line. B) The number of SVs observed 
was higher in urine samples compared to stents (Mann-Whitney U test, P = 0.0063). C) 
The total read count was higher in urine samples compared to stents (Mann-Whitney U 
test, P < 0.0001). Box plot whiskers represent minimum and maximum. 
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Figure 24. Assessment of sample read count and microbiota richness as measured by 
the number of observed sequence variants 
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Figure 25. Heatmap and cluster dendrogram of relative abundances of CLR-
transformed samples 
Samples are plotted left to right and ordered by the dendrogram. The dendrogram was 
generated from CLR-transformed read counts grouped by genera, based on the average 
linkage clustering of per-sample Aitchison distance. Branches of the dendrogram are 
coloured by sample type (stents are navy, urine are orange). The heatmap represents the 
relative abundance of genera within samples (more abundant genera are lighter in 
colour). Colour coding below the heat map corresponds to patient sex (females are pink, 
males are blue). An excerpt from the fourteen left-most branches of the tree illustrates 
that in general, samples from the same individual group nearby on the dendrogram.  
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A PCA was performed on CLR-transformed Aitchison distances. Each coloured point 
represents a sample. Distance between samples on the plot represents differences in 
microbial community composition, with 20.5% of total variance being explained by the 
first two components shown. Strength and association for genera (sequence variants) are 
depicted by the length and direction of the gray arrows, respectively. Points are coloured 
by sample type (stents are navy, urine are orange); ellipses represent the 95% confidence 
interval of the sample types. All samples are shown in A) and shaped by participant sex 
(females are circles, males are triangles); female patients are shown in B), and males are 
shown in C). 
 
  
Figure 26. Principal component analysis of all samples 
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A) Aitchison distance was greater between samples from different participants than 
within samples from the same participant (Bonferroni corrected Mann-Whitney U test, P 
< 0.0001). B) Aitchison distance was greater from stent samples to urine within (W) the 
same participant than between proximal to distal stent curls of the same stent (Bonferroni 
corrected Mann-Whitney U test, P < 0.0001). Aitchison distance was greatest between 
(B) urine of one participant to stent samples from the other participants (Bonferroni 
corrected Mann-Whitney U tests, P < 0.0001). Box plot whiskers represent minimum and 
maximum. 
Figure 27. Microbiota similarity between samples assessed with beta diversity 
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Each vertical bar represents the relative SV abundance within a single sample. Samples are grouped by participant. Relative 
abundance of SVs is coloured by genera, with common genera shown in the legend. Sample and participant attributes are described in 
the legend and coloured accordingly (participant sex, grade of stent encrustation, sample type, and the visit number). Stents from the 
left side are denoted by “L” and from the right side by “R”, while urine are denoted by “U”. Days between sample collections are 
listed in the green visit code.
Figure 28. Microbial communities in longitudinally collected samples 
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A) PCA was performed on CLR-transformed Aitchison distances of longitudinally 
collected samples. Each coloured point represents a sample. Distance between samples 
on the plot represents differences in microbial community composition, with 24.9% of 
total variance being explained by the first two components shown. Strength and 
association for genera (sequence variants) are depicted by the length and direction of the 
gray arrows, respectively. Points are coloured by participant and shaped by visit number. 
B) Aitchison distance was greater between interindividual samples of the same type than 
between samples from the same participant of the same type at different visits (Mann-
Whitney U test, P < 0.0001). Box plot whiskers represent minimum and maximum.
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Figure 29. Principal component analysis of longitudinal samples 
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Figure 30. Microbial communities of bilateral stents 
Each vertical bar represents the relative SV abundance within a single sample. Samples are grouped by participant. Relative abundance 
of SVs is coloured by genus, with common genera shown in the legend. Sample and participant attributes are described in the legend 
and coloured accordingly (participant sex, grade of stent encrustation, sample type). Stents from the left side are denoted by “L” and 
from the right side by “R”; Urine are denoted by “U”. 
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A) PCA was performed on CLR-transformed Aitchison distances of samples from patients 
with bilateral indwelling stents. Each coloured point represents a sample. Distance between 
samples on the plot represents differences in microbial community composition, with 29.3% 
of total variance being explained by the first two components shown. Strength and association 
for genera (sequence variants) are depicted by the length and direction of the gray arrows, 
respectively. Points are coloured by participant and shaped by sample type. B) Aitchison 
distance was compared between interindividual and intraindividual samples. S = distance 
between stent samples from the same participant, U vs S = distance between urine and stent 
samples from the same participant, All =  all samples from a single participant. All 
intraindividual comparisons had significantly shorter distances than the distance between 
samples from different individuals (Kruskall-Wallis test with Dunn’s multiple comparisons, P 
<0.0001). In intraindividual comparisons, the distance was shortest between stent samples and 
furthest from urine to stent samples (P = 0.022). Box plot whiskers represent minimum and 
maximum. 
Figure 31. Principal component analysis of bilateral stents 
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Table 15. Significant covariates of microbiota variation at genus level PCA 
ordination 
Metadata P- value 
Stent indwelling time 0.008 
Pulmonary disease 0.001 
Hypertension 0.001 
Diabetes 0.001 
IBS 0.002 
Procedure (e.g. ureteroscopy, ESWL) 0.007 
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Table 16. Significant correlations between metadata attributes and the microbiota 
after adjusting for confounders 
Metadata Genus Coefficient FDR 
Age Campylobacter 0.250 0.034 
Lactobacilli -0.370 0.002 
Veillonella 0.457 0.002 
BMI Actinotignum 0.499 0.048 
 Morganella 0.546 0.049 
Stent indwelling time Enterococcus -0.292 0.008 
 Escherichia -0.309 0.034 
 Finegoldia 0.202 0.034 
 Porphyromonas 0.245 0.001 
Pulmonary disease Campylobacter 0.627 0.004 
 Ezakiella 0.498 0.034 
Hypertension Campylobacter -0.595 0.013 
 Klebsiella 0.592 0.034 
 Moryella 0.349 0.035 
Diabetes Citrobacter -1.653 0.002 
 Enterococcus 1.086 0.034 
IBS Prevotella 0.046 0.001 
 Veillonella 0.041 0.020 
IBD                Crohn’s Lactobacillus -0.112 0.023 
 Staphylococcus 0.009 0.061 
Ulcerative Colitis Veillonella 0.036 0.020 
Hyperlipidemia Aerococcus -0.424 0.049 
 Ureaplasma -0.816 0.003 
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Table 17. Classification of stent encrustation 
Grade of encrustation Visual characteristics Number 
0 Like-new 84 
1 Discolouration only 308 
2 Mild encrustation (≤1 mm thick) 135 
3 Heavy encrustation (>1 mm thick) 10 
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Figure 32. Relationship of stent encrustation to indwelling time and alpha diversity 
A) Indwelling time was positively correlated with the degree of stent encrustation, as calculated 
by the Spearman correlation coefficient (r = 0.3221, P < 0.0001). B) Shannon’s index of alpha 
diversity was negatively correlated with the degree of stent encrustation, as calculated by the 
Spearman correlation coefficient (r = - 0.1378, P = 0.0005). C) Shannon’s index was lower for 
grade-3 encrusted stents compared to grade-0 (Kruskall-Wallis test with Dunn’s multiple 
comparisons, P = 0.027). 
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Figure 33. Microbial communities of long-term stents 
Each vertical bar represents the relative SV abundance within a single sample. Samples are grouped by participant. Relative abundance 
of SVs is coloured by genus, with common genera shown in the legend. Sample and participant attributes are described in the legend 
and coloured accordingly (participant sex, grade of stent encrustation, sample type). Stents from the left side are denoted by “L” and 
from the right side by “R”, while urine are denoted by “U”. Stent indwelling time is stated under each participant (from 62 to 394 days). 
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PCA was performed on CLR-transformed Aitchison distances. Each coloured point 
represents a sample. Distance between samples on the plot represents differences in 
microbial community composition, with 20.5% of total variance being explained by the 
first two components shown. Strength and association for genera (sequence variants) are 
depicted by the length and direction of the gray arrows, respectively. Samples are 
coloured based on (A) whether the study participant had used antibiotics within the last 
30 days prior to sample collection (blue) or not (pink), (D) whether the stents were placed 
in a retrograde (purple) or antegrade (orange) manner, and (G) whether the participant 
had a UTI within 7 days of stent placement or throughout the indwelling period (orange), 
or not (green). Ellipses represent the 95% confidence interval. (B, E, H) The degree of 
stent encrustation was compared between groups of interest. Groups were not 
significantly different by two-tailed Mann-Whitney U test. Shannon’s index of alpha 
diversity was not significantly different between antibiotic (C) or placement (F) groups, 
but patients with a UTI had lower diversity than those without (I, two-tailed Mann-
Whitney U test, P = 0.002). Box plot whiskers represent minimum and maximum.  
Figure 34. Stent microbiota and encrustation are unchanged by antibiotics, device 
placement method, and UTI 
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4.4.3 SEM imaging of stents 
SEM imaging of stent samples revealed characteristic crystal phases and the presence of 
bacterial biofilms (Figure 35). Where bacteria-like structures were visualized, their 
morphology showed concordance which the genera that were present in the sample based 
on microbiota sequencing (Figure 35, samples 014 and 195). The predominant substances 
on the stent surfaces consisted of organic deposits and crystals. X-ray diffraction of 
crystalline structures confirmed the presence of calcium oxalate monohydrate in oval and 
multiple-twinning morphologies, calcium oxalate dihydrate, calcium phosphate (Figure 
35), uric acid, and struvite (not shown).  
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Representative scanning electron micrographs of stent encrustations illustrating typical 
bacterial biofilms and crystal morphologies. Based on microbiota sequencing, bacteria 
visible (white arrowheads) likely correspond the genera (014) Lactobacillus and (195) 
Enterococcus. X-ray diffraction of crystalline microstructures (white arrows) correspond 
to calcium oxalate dihydrate (010 and 019a), calcium oxalate monohydrate in oval (022) 
and multiple-twinning (095) morphologies, and calcium phosphate (019b and 195). Scale 
bars = 20 µm. 
Figure 35. Scanning electron micrographs of stents 
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4.5 Discussion 
This study is the first to characterize the urinary microbiota of ureteral stent patients and 
the largest of its kind to evaluate the microbiota present on the surface of ureteral stents. 
Importantly, we identified several novel patient factors and comorbidities as drivers of 
stent microbiota composition and demonstrated that sex, antibiotic use, and stent 
placement method did not have a significant impact on the urinary or stent microbiota. 
Our findings also demonstrate consistency in stent microbial community over time in 
patients with multiple stent placements, and in both left and right sides during bilateral 
stent placement, solidifying the true presence of a reproducible stent microbiota. 
Interestingly, intraindividual microbiotas of proximal and distal stent ends were more 
similar than either stent end compared to the urine, indicating that although the same 
genera may be present in the urine, it is not proportionally representative of the bacterial 
community colonizing the stent. 
Previous culture-based studies have shown that removed stents are frequently culture 
positive despite patients exhibiting a culture-negative urine profile (Kehinde et al., 2004; 
Riedl et al., 1999). Corroborating these findings, we demonstrated that urinary and stent 
microbiotas were dominated by similar bacterial genera; however, when investigating the 
patterns on a per-patient basis, both proximal and distal ends of the stent, as well as left 
and right bilateral stents, were more similar to each other in microbiota composition than 
to the urine. Additionally, culture confirmed UTI was not associated with increased 
encrustation level in this cohort. This illustrates that urine is not an accurate biomarker of 
stent encrustation, nor representative of the stent-adhered microbiota. Instead, the degree 
of stent encrustation was positively correlated with indwelling time and negatively 
correlated with microbial diversity, indicating that the longer a stent is indwelling, the 
greater the likelihood of it becoming encrusted and colonized with a less diverse 
microbial community. 
The urinary microbiome may extend as far as the renal collecting system. This renal 
microbiota may contribute to the microbial community of the proximal stent curl, or 
bacteria residing in the bladder could adhere to the proximal stent curl during retrograde 
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insertion (Barr-Beare et al., 2015; Tavichakorntrakool et al., 2017). Bacteria are also 
thought to ascend from the distal curl during movement of the stent whilst indwelling, or 
by utilizing active motility, a process that can occur quite rapidly (Chew et al., 2007; 
Lane et al., 2007; Nickel et al., 1992; Reid et al., 1992; Siitonen and Nurminen, 1992; 
Tenke et al., 2012). Our findings support these previous studies and suggest that the 
stent-associated microbiota is derived from the urinary bladder based on the fact that no 
difference was observed in microbial composition between antegrade or retrograde 
placement method (though only 9% of stents were inserted in an antegrade fashion). 
Further validation is provided by the stent-associated microbiota being dominated by 
common urinary bacteria which is unlikely to have originated from skin or gut 
contamination during placement (Gottschick et al., 2017). Taken together, our findings 
suggest that although the urinary microbiota may originally seed onto the stent, the stent 
microbial community is shaped and enriched for competitively adherent bacteria, and 
eventually diverges significantly from the urine. 
A previous microbiota study of stent encrustations demonstrated a lack of association 
between “urotype” and patient conditions including age, gender, BMI, diabetes, urinary 
crystals, and other factors (Buhmann et al., 2019). The current study differed by utilizing 
a non-partisan analysis method, whereby arbitrary community groups, or “urotypes” were 
not used and instead the entire dataset was tested against all patient and sample 
characteristics. With this approach, confounders were adjusted for and significant 
associations between eight metadata features and genus-level microbiota changes were 
established.  
In concordance with previous studies, age was determined to be significantly associated 
with decreased Lactobacillus spp. and increased Veillonella spp. (Liu et al., 2017; Rowe 
and Juthani-Mehta, 2013). In humans, Veillonella spp. are commensals of the oral cavity, 
gastrointestinal and urogenital tracts, with the potential to cause opportunistic infections, 
including UTI (Aujoulat et al., 2014; Berenger et al., 2015; Mashima and Nakazawa, 
2014; Scheiman et al., 2019; van de Wijgert et al., 2014). Veillonella spp. are also 
commonly associated with a more diverse urinary microbiota, an attribute often 
accompanied with urological disorders (Pearce et al., 2015; Thomas-White et al., 2017). 
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In contrast, Lactobacillus spp. are commensals, with a robust body of evidence detailing 
their beneficial effects in the healthy urinary tract of both men and women (Aragon et al., 
2018; Gottschick et al., 2017; Whiteside et al., 2015). It is unclear how the ageing 
process alters the urinary microbiota, however the observed decrease in protective urinary 
lactobacilli may account for common stent associated UTI and encrustation in older 
populations (Akay et al., 2007; Altunal et al., 2017).  
Patients with IBS and IBD had increased stent and urinary presence of Prevotella and 
Veillonella species, and decreased lactobacilli. These findings are consistent with 
previous literature on the gut microbiota in these conditions (Lee and Tack, 2010; Sha et 
al., 2013; Shankar et al., 2013). These genera have also been implicated in urogenital 
infections and disorders such as pelvic inflammatory disease (Brook, 2004; Haggerty and 
Taylor, 2011). Our findings add further credence to the hypothesis that the gut microbiota 
is a reservoir for the genito-urinary microbiota (Magruder et al., 2019; Yamamoto et al., 
1997). In the same manner that gut colonization with uropathogenic Escherichia coli 
(UPEC) increases the risk of UPEC UTI, the concurrence of inflammatory urinary tract 
symptoms in patients with IBS may be explained (Magruder et al., 2019; Matsumoto et 
al., 2012; Moreno et al., 2006; Moreno et al., 2008; Zingone et al., 2017). A limitation of 
the current study was that lower urinary tract symptoms were not evaluated in the stent 
patient population, but future studies should evaluate this if urological patients with 
IBS/IBD experience increased stent-associated complications in addition to the 
documented urinary tract symptoms. 
Of the various comorbidities that significantly impacted the stent microbiota, it was 
notable that they originated from distant sites (pancreas, respiratory tract, liver, and 
gastrointestinal tract), suggesting some common physiological denominator. Potentially, 
it is the gastrointestinal tract that is altered by these conditions, with systemic 
consequences of bacterial translocation. For this reason, it is feasible that microbiota-
based treatment including oral consumption of probiotic lactobacilli, or even fecal 
microbiota transplantation could be of therapeutic potential to stent patients. In addition 
to many other maladies, these treatments have shown efficacy against IBS/IBD 
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symptoms, urogenital infections in the elderly, and recurrent UTI (Ducrotte et al., 2012; 
Hocquart et al., 2019; Kim and Park, 2017; Tariq et al., 2017). 
The majority of stents imaged by SEM revealed encrustations composed of organic 
material and urinary crystals, while bacteria were only visualized in a small number of 
cases. This was expected due to the high proportion of urolithiasis patients amongst the 
study participants, as well as the low bacterial load present in urinary samples (Dyer and 
Nordin, 1967; Lewis et al., 2013). If these organisms were involved in crystal deposition 
on the biomaterial, the urologist should ensure device removal within 3 weeks, given the 
positive correlation between indwelling time and stent encrustation. 
Due to the low bacterial biomass nature of the samples collected, this study utilized 
stringent pre-sequencing processing methods in addition to the application of 
conservative bioinformatic cut-offs and analysis tools in order to minimize contamination 
effects (Karstens et al., 2019; Minich et al., 2019). In future studies, quantification of 
total 16S rRNA gene copies by qPCR or the use of extended quantitative urine culture 
may complement and validate microbiota analysis of urinary samples (Hilt et al., 2014; 
Buhmann et al., 2019). Nevertheless, the detection of reproducible, patient-specific, stent 
microbiota signatures provides confidence that our findings are not due to contamination. 
In summary, this study has characterized the urinary and stent microbiota of ureteral stent 
patients from a single centre over a one-year period, uncovering the importance of patient 
characteristics in explaining microbiota variation. Actions taken by the physician such as 
antibiotic treatment and stent placement method had little to no impact on the microbiota 
in these samples, but comorbidities and patient age did. The stent microbiota appears to 
originate from patient-specific adhesion of urinary microbes, and subsequently diverges 
to a distinct reproducible population, thereby negating the urine as an accurate biomarker 
for stent encrustation or microbiota status. These findings suggest that timely stent 
removal is likely the most important action to be taken by the treating urologist. Stent-
specific antibiotic administration practices need recalibration, perhaps interchanging 
prophylactic oral antibiotic use with targeted intravesical antimicrobial instillation during 
device placement (Pietropaolo et al., 2018). Elderly patients or those diagnosed with 
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pulmonary disease, hypertension, diabetes, or IBS/IBD may need closer evaluation to 
minimize stent- and microbiota-associated complications. 
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Chapter 5  
5 Utilization of a Drosophila melanogaster model of stone 
formation to explore host-microbe interactions in 
nephrolithiasis 
5.1 Abstract 
The prevalence of nephrolithiasis in North America has risen to approximately 10% and 
is associated with significant morbidity. The microbiota is known for its role in human 
health and disease, including in kidney stone formation. Intestinal colonization with 
Oxalobacter formigenes has been suggested to protect against formation of calcium 
oxalate (CaOx) stones by reducing urinary oxalate, and kidney stones are known to 
harbour uropathogenic bacteria. In stone patients, probiotic supplementation with 
oxalate-degrading bacteria has been suggested as a potential preventive therapy, but 
clinical trials with O. formigenes have been limited and inconclusive. The aims of this 
study were to investigate the oxalate-degrading properties of Bacillus subtilis 168 
(BS168) as a potential probiotic candidate and to characterize how uropathogens may be 
contributing to stone formation using an established Drosophila melanogaster (DM) 
model of urolithiasis and in vitro cell line experiments. Flies administered BS168 
developed lower fecal and Malpighian tubule crystal burden compared to flies without 
bacterial treatment and had increased survival. Uropathogenic Escherichia coli strain 
UTI89 increased stone burden but did not impact DM survival, whereas Proteus mirabilis 
PM175 decreased survival irrespective of lithogenesis. In vitro cell line experiments with 
BS168 did not exhibit increased crystal aggregation, suggesting this strain is a promising 
probiotic candidate to reduce stone formation through degradation of oxalate. 
Conversely, uropathogenic E. coli but not P. mirabilis may increase stone burden through 
its capacity to increase CaOx crystal adhesion and aggregation. As strains of B. subtilis 
have been used safely to promote digestive health, strain BS168 is worthy of testing in 
humans to determine if it can reduce the incidence of recurrent nephrolithiasis. 
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5.2 Introduction 
The prevalence of nephrolithiasis, or kidney stone disease, in North America has risen to 
approximately 10% over recent decades. The condition is associated with significant 
patient morbidity and severe economic losses to the health care system. The human 
microbiota, defined as the microorganisms present in a certain environment, is 
recognized as an important facet in health and disease, including nephrolithiasis for 
several reasons (Whiteside et al., 2015). One reason involves the gut microbiota’s 
capacity to influence serum oxalate levels, a terminal metabolite implicated in 
approximately 80% of all kidney stones (Moe, 2006). Another reason deals with the 
urinary microbiota and how it may interact with stone formation at the site (Barr-Beare et 
al., 2015). 
The most common kidney stones are composed of calcium oxalate, of which oxalate is 
the limiting factor (Moe, 2006). Urinary oxalate is derived from both dietary and 
endogenous sources, where estimates of the relative contributions vary widely; studies 
have suggested that the proportion of dietary derived urinary oxalate ranges from 10-50% 
(Taylor and Curhan, 2008; Holmes et al., 2001). Dietary oxalate can be absorbed by both 
trans- and paracellular mechanisms in its soluble form, excreted in the feces as an 
insoluble crystal, or degraded by members of the gut microbiota. The bacterium 
Oxalobacter formigenes utilizes oxalate as its sole carbon source, and when present in the 
intestine, subjects have been reported to have lower urinary oxalate levels and are 
subsequently at lower risk of developing stones (Kaufman et al., 2008; Jiang et al., 
2011). Other members of the gut microbial community including lactobacilli and 
bifidobacteria are capable of degrading oxalate, though to a lesser extent (Miller and 
Dearing, 2013). In kidney stone patients, supplementation with oxalate-degrading 
bacteria has been suggested as a potential preventive therapy, however trials thus far have 
been limited and inconclusive (Hoppe et al., 2006; Siener et al., 2013; Klimesova et al., 
2014). 
As with O. formigenes, Bacillus subtilis strain 168 (BS168) can degrade oxalate (Tanner 
and Bornemann, 2000). The strain’s oxalate decarboxylase gene, YvrK, is acid- induced 
and encodes a ~43 kD manganese-requiring enzyme that converts oxalate to formate and 
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CO2 (Tanner et al., 2001). Some Bacillus subtilis strains have recently been identified for 
potential probiotic use for gastrointestinal disorders and have the added benefit of being 
highly heat and pH resistant due to spore formation (Sorokulova et al., 2008; 
Poormontaseri et al., 2017). It is for these reasons that BS168 may have therapeutic 
potential in nephrolithiasis treatment. 
Struvite stones have long been known to be associated with urinary tract infection by 
urease-producing organisms such as Proteus, Pseudomonas, or Klebsiella spp., whereas 
other stone compositions have historically not been thought to involve a bacterial 
component (Flannigan et al., 2014). However, recent culture-dependent and -independent 
studies have identified the presence of bacteria within non-struvite kidney stones (Barr-
Beare et al., 2015; Dornbier et al., 2019; Golechha and Solanki, 2001; Sohshang et al., 
2000; Tavichakorntrakool et al., 2012; Wang et al., 2014; Zampini et al., 2019). Whether 
these bacteria are coincidentally entrapped in the growing stone matrix, or if they are 
playing an active role in stone formation remains to be elucidated. 
In this study, the aim was to investigate the role of both pathogenic and non-pathogenic 
bacteria in nephrolithiasis. An established Drosophila melanogaster (DM) model of stone 
formation was used to evaluate stone burden after supplementation with both BS168 and 
uropathogenic bacteria (Chen et al., 2011). In addition, Madin-Darby renal epithelial cell 
culture was used to determine the impact of the microbes on calcium oxalate crystal 
adhesion and aggregation. Furthermore, to better assess the impact of various treatments 
on stone disease in the DM model, method development of an X-ray micro computed 
tomography (µCT) imaging protocol was undertaken. It was hypothesized that based on 
its safe nature and oxalate-degrading ability, that BS168 would reduce stone burden and 
promote markers of heath, in contrast to uropathogens.  
5.3 Materials and Methods 
5.3.1 Bacterial culture and growth curves 
Bacillus subtilis strain 168 (ATCC 23857, designated here as BS168), Escherichia coli 
UTI89 (Mulvey et al., 2001) and a clinical kidney stone isolate of Proteus mirabilis 
(referred to here as PM175, Table 10), were routinely cultured at 37 °C in Luria-Bertani 
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(LB) broth (Table 18). BS168 growth in oxalate was assayed in 96-well plates prepared 
as dilutions of sodium oxalate (NaOx) in LB broth with stationary-phase bacteria added 
at a final dilution of 1/100. Plates were incubated for 24 hours at 37 °C with optical 
density (OD) readings every 30 minutes using an Eon microplate spectrophotometer 
(BioTek, Winooski, VT, USA). NaOx concentrations were selected based on physiologic 
intestinal oxalate concentrations reported in the literature (Prokopovich et al., 2007). 
Statistical analyses of growth curves were performed with the R package Growthcurver 
(Sprouffske and Wagner, 2016). 
Bacteria were cultured from whole DM after homogenization. Fruit flies were surface 
sterilized with 70% ethanol and homogenized in 0.01 M PBS using a motorized pestle. 
Homogenates were then serially diluted and plated onto agar. Based on the known 
microbiota of DM, LB, MRS, and Mannitol agars were used to culture BS168, 
Lactobacillus spp., and Acetobacter spp., respectively (Table 18). LB and Mannitol plates 
were incubated aerobically at 37 °C, and MRS plates were incubated using an anaerobic 
gas pack (BD, Mississauga, ON, CAN) in a sealed jar at 37 °C. Colony forming units 
(CFU) were enumerated after 48-hours of incubation. Variation was observed between 
biological replicates, so oxalate-fed fly CFU counts were normalized to control diet-fed 
fly CFU counts.  
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Table 18. Bacterial media compositions 
Media Component Amount 
Luria-Bertani  DI water  1000 mL 
Tryptone 10 g 
NaCl 10 g 
Yeast extract 5 g 
Agar (omit for broth) 15 g 
MRS agar DI water 1000 mL 
Difco MRS Lactobacilli broth (BD) 55 g 
Agar 15 g 
Mannitol agar DI water 1000 mL 
Mannitol 25 g 
Yeast extract 5 g 
Peptone 3 g 
Agar 15 g 
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5.3.2 Drosophila melanogaster husbandry 
As insects, the use of Drosophila melanogaster (DM) in this study did not require 
institutional ethical review board approval. The DM stock used in this study was Canton-
S. Standard cornmeal-based media was utilized (Table 19), and the lithogenic diet 
included 0.1 or 1.0 % weight/volume NaOx (Chen et al., 2011). Food was generated by 
gently boiling the water on a hot plate, and slowly adding all components except the acid 
mix and NaOx (if including), being sure to bring to the boil in between additions. The 
food was then cooled to 55 °C, at which point the acid mix and oxalate were added and 
mixed well. The media was portioned to approximately 50 mL per bottle or 10 mL per 
vial and stored at 4 °C until use. Grape juice agar was made by boiling the water, agar, 
and juice in a microwave, cooling to 55 °C at which point the Tegosept was added and 
the solution was poured into Petri dishes. DM were maintained in a 25 °C incubator with 
60% humidity and a 12 h light-dark cycle. For maintenance, DM stocks were transferred 
to fresh 50 mL media bottles every two weeks; for experiments, DM were transferred to 
fresh 10 mL media vials every two days. Lifespan measurement was performed as 
previously described (Linford et al, 2013).  
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Table 19. Drosophila melanogaster media and chemicals 
Recipe Ingredient Amount 
Standard media DI water 1000 mL 
 Agar 15 g 
 Dried yeast 17.3 g 
 Cornmeal 73 g 
 Corn syrup 76 mL 
 Acid mix (50 mL propionic acid with 3.2 mL 
phosphoric acid) 
5.8 mL 
Grape juice agar DI water 750 mL 
 Agar 30 g 
 Welch’s grape juice 250 mL 
 Tegosept (10 % solution in ethanol) 10 mL 
Yeast paste DI water 6 mL 
 Dried yeast 3 g 
Carl’s solution DI water 28 mL 
 95% ethanol 17 mL 
 Formalin 6 mL 
 Glacial acetic acid 2 mL 
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5.3.3 Determining the effect of bacterial supplementation in the 
DM stone model 
An experimental timeline is displayed in Figure 36. At five days of age, adult DM were 
sorted into cohorts and supplemented with 5% sucrose solution with or without bacteria 
for 24 hours. Bacteria were prepared for supplementation to DM as follows: 25 mL 
overnight broth culture of BS168, UTI89, or PM175 (~ 108 CFU/mL) was pelleted by 
centrifugation at 5000 rpm for 5 minutes. The supernatant was decanted, and the pellet 
was completely resuspended in 25 mL sterile PBS by vortexing. The process was 
repeated whereby the PBS and BS168 was centrifuged at 5000 rpm for 5 minutes, after 
the supernatant was decanted, and the pellet was resuspended in 25 mL sterile PBS for a 
total of two PBS washes. The remaining pellet after the second PBS wash was 
completely resuspended in 25 mL of 5% weight/volume sucrose solution by vortexing. 
DM were transferred to polypropylene vials containing a cotton ball moistened with 3 
mL of 5% sucrose ± bacteria. After 24 hours, DM were transferred to standard media ± 
1.0% NaOx for BS168, or 0.1% NaOx for the uropathogen experiments.  
For larval exposure to bacteria, on Day 0 approximately 200 adult DM were mated in 
standard media bottles containing 1 cm x 1 cm x 0.25 cm grape juice agar and 1 cm 
diameter of yeast paste (water and yeast mixed to the consistency of smooth peanut 
butter) (Table 19). DM were allowed to lay eggs for 3 hours, after which all adults were 
removed along with the grape agar and any remaining yeast paste. Five hundred µL of 
5% sucrose ± bacteria (processed as above) was then pipetted on the top of the standard 
media. On Day 2, 100 mL of room temperature 20% sucrose solution was added to 
completely submerge the media in the bottles and float the larvae for 20 minutes. The 
sucrose solution containing larvae was then gently poured over a sterile cell strainer. The 
larvae collected in the strainer were briefly rinsed once with 70% ethanol, then twice with 
DI water. Cleaned larvae were added with a paintbrush to vials of standard media ± 1.0% 
NaOx.  
Stone burden was evaluated in adult DM Malpighian tubules on day 7. Briefly, DM were 
narcotized with CO2, treated for 2 minutes in Carl’s solution (Table 19) in a small glass 
petri dish, and transferred to a dissecting dish with cold sterile PBS. Using a Nikon 
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SMZ800N stereomicroscope, DM Malpighian tubules were dissected in the cold PBS, 
fixed in 4% formaldehyde/PBS for one hour at room temperature, and mounted on 
microscope slides in 50:50 PBS and glycerol. Clear nail polish was used to seal the 
coverslip to the microscope slides prior to polarized light microscopy. Birefringence 
microscopy of the dissected tubules was performed with a Nikon Ts2R inverted 
microscope, and NIH ImageJ software was utilized to determine the degree of 
birefringence per tubule (particle analysis function). Fecal excreta from adult DM was 
also evaluated for the presence of birefringent crystals throughout the duration of the 14-
day BS168 survival analysis, as previously described, Figure 37 (Ali et al., 2018). 
Briefly, glass cover slips were inserted into the fly vial plugs during the 14-day 
incubation period, then fixed to microscope slides with clear nail polish and imaged with 
polarized light (Nikon) to determine the percentage of excreta containing birefringent 
crystals. 
Stone burden was evaluated in third instar DM larvae on day 4 by means of a crawling 
assay; larval crawling is an indicator of behavioural and locomotor health in DM 
(Nichols et al., 2012; Gunther et al., 2016). Twenty mL of room temperature 20% 
sucrose solution was added to each media bottle for 20 minutes, during which larvae 
floated to the top. The solution was then poured over a sterile cell strainer, where the 
collected larvae were washed twice with DI water. A paint brush was used to transfer 
larvae from the strainer to a 15 mL petri dish containing 2% agar where they acclimatized 
for 10 minutes. A second petri dish of 2% agar was positioned over a 0.5 cm graph paper 
grid (Figure 37). A six mm diameter paper disk was submerged in apple cider vinegar 
and positioned near one side of the plate, and larvae were positioned at a starting point 4 
cm away. The time it took each larva to travel 3 cm from the starting point towards the 
vinegar stimulant was recorded. 
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Figure 36. Drosophila melanogaster experimental timeline 
Schematic outline of experimental design. A) Adults were supplemented +/- BS168, 
UTI89, or PM175 in 3 mL of 5% sucrose via cotton balls in empty vials on Day 0. On 
Day 1 they were transferred to standard media vials with or without 1.0% or 0.1% NaOx 
(weight/volume). Deaths were recorded daily, and dead flies were removed every two 
days during transfer to fresh food. Fecal excreta were assayed throughout the 14-day 
BS168 experiment by transferring the coverslip-embedded vial plug with each food 
transfer. Lifespan analysis of DM uropathogen experiments was conducted until the 
expiration of all DM (approximately 60 days). B) Adult DM mated for three hours in 
standard media bottles, after which they were removed and 500 uL of 5% sucrose +/- 
BS168, UTI89, or PM175 was pipetted over the top of the media. They were transferred 
via 20% sucrose suspension to standard media +/- 1.0% NaOx on Day 2 and their 
crawling was assayed on Day 4.  
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Figure 37. Assays of stone burden and DM health 
A) Fecal excreta assay. Microscope coverslips remained inserted in the vial plug 
throughout the duration of the 14-day adult DM survival experiment and were evaluated 
for crystal birefringence with polarized light microscopy.  B) Larval locomotion assay. 
Larvae were stimulated to crawl towards the apple cider vinegar attractant; the time taken 
to travel 6 squares (3 cm) was recorded. 
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5.3.4 Development of a µCT scanning protocol in DM 
As human kidney stones are normally assessed with computed tomography (CT) 
imaging, we sought to develop a mechanism of live imaging DM for the purpose of 
evaluating stone burden, in collaboration with the Robarts Research Institute Micro-CT 
lab (Assimos et al., 2016; Poinapen et al., 2017). A custom scanning apparatus was 
designed to house flies throughout the duration of scanning (Figure 38). Flies were 
imaged with a constant flow of CO2 anesthesia (0.5 mL/min) and X-ray radiation (90 
kVp; 70 uA; 0.3 degree incremental angle over 360 degrees) using the GE Locus MS 
scanner (GE Healthcare, Mississauga, ON, CAN). Image analysis was performed using a 
threshold of 700 Hounsfield units (HU) as the minimum density of stone particles 
(Shahnani et al., 2014). Particles greater than 10 voxels in size were retained for stone 
quantification analysis. Adult flies treated with BS168 and 1.0% NaOx as described 
above were imaged on Day 3 and Day 7. 
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Figure 38. DM µCT scanning apparatus 
A) Acrylic apparatus developed for live µCT imaging of anesthetized DM. The DM 
chamber (B) was mounted on the rotating base inside the CO2 chamber. Four DM were 
placed into wells on each of two foam scanning platforms, separated by cohort. 
Desiccation was prevented by the addition of hydrated foam, and a water-filled capillary 
was utilized for scan calibration. 
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5.3.5 CaOx crystal adhesion to renal epithelial tissue culture 
Cell culture experiments were performed in Madin-Darby canine kidney (MDCK) 
epithelial cells (Bigelow et al., 1998; Yamaguchi et al., 2002), which were initially 
isolated from the normal renal tubules of an adult male cocker spaniel dog (Gaush et al., 
1966), and were acquired from the American Type Culture Collection (ATCC). Cells 
were maintained in T75 flasks in a 5% CO2 tissue culture incubator with minimum 
essential medium (MEM; Gibco, Burlington, ON, CAN) supplemented with 10% fetal 
bovine serum (FBS; Gibco) and 2 mM L-Glutamine (Gibco), the combination of which is 
hereafter referred to as MEM. Cells were routinely passed when confluency reached 80% 
and above. To pass the cells, the spent MEM was removed from the flask and cells were 
washed with warmed phosphate buffered saline (PBS), followed by trypsinization for 
approximately 10 minutes at 37 °C and 5% CO2 by addition of 0.25% trypsin-
ethylenediaminetetraacetic acid (Trypsin-EDTA; Gibco). After 10 minutes the cells were 
observed under the microscope for 90% detachment, when MEM was added to inactivate 
the typsin. For cell maintenance, cell suspension was seeded to new flasks at a 
subcultivation ratio of 1:6 with fresh MEM. For experiments, an aliquot of the cell 
suspension was mixed 1:1 (v/v) with 0.4% trypan blue (Invitrogen, Carlsbad, CA, USA) 
and 10 μL of sample mixture added to the chamber of a Countess Cell Counting Chamber 
Slide (Invitrogen) for use with a Countess II Automated Cell Counter (Invitrogen). Cell 
suspensions were centrifuged at 2,000 rpm for 5 minutes, reconstituted in culture media, 
and subsequently seeded to 6-well tissue-culture treated plates (Sarstedt, Nümbrecht, 
Germany) at 1 x 105 cells/mL. Plates were incubated as above until the monolayer 
reached confluency, at approximately 48 hours. 
Utilizing a method adapted from Bigelow et al., calcium oxalate monohydrate (COM) 
crystal adhesion and aggregation was investigated in the MDCK cells (Bigelow et al., 
1998; Yamaguchi et al., 2002). An overnight broth culture of BS168, UTI89, or PM175 
was processed as described earlier but the bacterial pellet was reconstituted in MEM at a 
concentration of ~5 x 103 CFU per mL. Confluent monolayers of MDCK cells in 6-well 
plates were washed twice with warmed sterile PBS, then incubated with 2 mL MEM ± 
bacteria for 20 minutes at 37 °C and 5% CO2. Cells were then washed twice with warmed 
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sterile PBS and incubated with 2 mL of artificial urine ± 0.5 mg/mL COM for 20 minutes 
at 37 °C and 5% CO2 (Brooks and Keevil, 1997). The urine was then removed, and cells 
were gently washed with PBS. Two mL MEM was added, and cells were immediately 
imaged with light microscopy using a Nikon Ts2R inverted microscope. Crystal 
attachment was quantitated with ImageJ. 
Statistical analysis for DM and cell culture experiments was conducted with GraphPad 
Prism (version 8.1.2) for Mac OSX (GraphPad Software, San Diego CA, USA). Results 
were considered significant as follows: ****, P<0.0001; ***, P< 0.001; **, P < 0.01; *, P 
< 0.05. 
5.3.6 16S rRNA gene sequencing 
Analysis of the adult DM microbiota was determined by 16S rRNA gene sequencing of 
10 individual flies per cohort on Day 7. Specifically, five sex-separated vials were 
prepared per treatment group containing approximately 20 flies, and one fly (either male 
or female) was used from each. DNA was extracted from the single whole flies in 
accordance with the Earth Microbiome Project standard protocols, using the Qiagen 
DNeasy PowerSoil 96-well kit (Qiagen, Toronto, ON, CAN). A Biomek 3000 laboratory 
automation workstation (Beckman-Coulter, Mississauga, ON, CAN) was utilized for 
PCR reagent set up. Amplifications of the V4 region of the 16S ribosomal RNA gene 
were carried out with the primers (5′-3′) 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNxxxxxxxxxxxxGTGCC 
AGCMGCCGCGGTAA and (5′-3′) CGGTCTCGGCATTCCTGCTGAACCG 
CTCTTCCGATCTNNNNxxxxxxxxxxxxGGACTACHVGGGTWTCTAAT wherein 
xxxxxxxxxxxx is a nucleotide barcode and the preceding sequence is a portion of the 
Illumina adapter sequence for library construction (Parada et al., 2016). Two μL of DNA 
template was added to a 96-well plate containing 10 μL of both forward and reverse 
primers (3.2 pMole/μL) where unique barcode pairs were utilized for each sample. 20 μL 
of Promega GoTaq® Colourless Master Mix (Promega, Maddison, WI) was added to the 
DNA template and primers. The final plate was firmly sealed with a foil PCR plate cover. 
This plate was placed in the Eppendorf Mastercycler® thermal cycler (Eppendorf, 
Mississauga, ON), where the lid was kept at 105 °C. An initial warm-up temperature of 
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95 °C was used for 2 min to activate the GoTaq®. Afterwards, the volumes underwent 25 
cycles of 95 °C for 1 min, 52 °C for 1 min, and 72 °C for 1 min. After completion, the 
temperature of the thermal cycler was held at 4 °C, and amplicons were then stored at 
−20 °C.  
Processing of DNA samples and DNA sequencing was conducted at the London Regional 
Genomics Centre at Robarts Research Institute (London, ON). Amplicons were 
quantified using pico green (Quant-It; Life Technologies, Burlington, ON) and pooled at 
equimolar concentrations before cleanup (QIAquick PCR clean up; Qiagen, 
Germantown, MD). The final samples were sequenced using the MiSeq by Illumina® 
platform, with 2 × 260 bp paired-end chemistry. The returned reads were then analyzed 
using R, DADA2, the SILVA database (version 132), and ALDEx2 (R Core Team, 2019; 
Callahan et al., 2016; Quast et al., 2013; Fernandez et al., 2013).  
5.3.7 qPCR-based quantification of microbial communities in DM 
DNA template from the Qiagen DNeasy PowerSoil kit was also utilized for qPCR- based 
quantification. Bacterial loads were determined by qPCR using the Power SYBR Green 
kit (Applied Biosystems) following the manufacturer’s instructions. Universal 16S rRNA 
gene, genus-, and species-specific primer sets used in this study are listed in Table 20. All 
qPCR reactions were performed in DNase- and RNase-free 384-well microplates on a 
Quant Studio 5 Real-Time PCR System (Applied Biosystems) and analyzed with 
associated software. Copy numbers of target 16S rRNA genes were calculated as 
previously described using established primer efficiencies and limits of detection 
(Daisley et al., 2019; Walker et al., 2017). 
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Table 20. Primers used for qPCR 
Target Primer Sequence (5’>3’) Reference 
Host endogenous 
control 
DRO_B-act_F GGAAACCACGCAAATTCTCAGT Elgart et 
al., 2016 DRO_B-act_R CGACAACCAGAGCAGCAACTT 
Host endogenous 
control 
DRO_RpLP0_F CCGAAAAGTCTGTGCTTTGTTCT Daisley et 
al., 2017 DRO_RpLP0_R CGCTGCCTTGTTCTCCCTAA 
Universal bacteria 
BAC_UNI_F ACTCCTACGGGAGGCAGCAGT Hartman 
et al., 
2009 BAC_UNI_R ATTACCGCGGCTGCTGGC 
Acetobacter spp. BAC_Aceto_F TAGTGGCGGACGGGTGAGTA Elgart et al., 2016 BAC_Aceto_R AATCAAACGCAGGCTCCTCC 
Lactobacillus spp. BAC_Lacto_F AGGTAACGGCTCACCATGGC Elgart et al., 2016 BAC_Lacto_R ATTCCCTACTGCTGCCTCCC 
Wolbachia spp. BAC_wsp_F CATTGGTGTTGGTGTTGGTG Newton et al., 2015 BAC_wsp_R ACCGAAATAACGAGCTCCAG 
Bacillus subtilis 
BAC_B-
subtilis_F GCGGCGTGCCTAATACATGC 
Lahlali et 
al., 2013 
BAC_B-
subtilis_R CTCAGGTCGGCTACGCATCG 
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5.4 Results 
5.4.1 Increasing concentration of oxalate promotes the growth of 
BS168 
As oxalate can be toxic to bacteria, even those capable of degrading it, the viability of 
BS168 was assessed upon exposure to oxalate concentrations ranging from 50 μM to 50 
mM (Suryavanshi et al., 2016). Representative growth curves are presented in Figure 39. 
There was a significant, dose-dependent increase in growth when BS168 was 
supplemented with NaOx (Figure 39D).  
5.4.2 Effect of dietary oxalate on culturable DM microbiota 
DM reared on 0.1% or 1.0% w/v NaOx-containing media for seven days harboured 
significantly less (two-way ANOVA with Tukey’s multiple comparisons test, P < 
0.0001) culturable bacteria compared to normal food controls (Figure 40). NaOx had a 
dose-dependent effect towards DM microbes cultured on LB and the Acetobacter spp. 
cultivated on Mannitol agar (P = 0.0008 and P = 0.0049, respectively). BS168 was 
detected by culture on LB agar from pulverized adult DM up to 5 days following 
supplementation (data not shown). 
  
222 
 
 
 
 
Figure 39. Increasing concentration of oxalate promotes the growth of BS168 
A) Growth is represented as the increase in optical density at 600 nm over the course of 
24 hours. BS168 was grown in LB broth with NaOx at the stated concentrations. Three 
biological replicates were performed; the mean of 10 representative replicates and SD are 
plotted. B) Area under the logistic curve from A), n = 10. C) Time at curve inflection 
from A), n = 10. D) Significant NaOx concentration comparisons between BS168 growth 
by Kruskall-Wallis test with Dunn’s multiple comparisons. All other comparison pairs 
were not significant. 
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Adult DM consumed normal food, or media with 0.1% or 1.0% (weight/volume) of 
NaOx for 7 days. DM were homogenized and plated onto Luria-Bertani (LB), de Man, 
Rogosa, Sharpe (MRS), or Mannitol agars. CFU from lithogenic groups were normalized 
to CFU from normal food groups to simplify variation from biological replicates. 
Average CFU/ fly for normal food cohorts was 2 X 102, 4 X 104, and 5 X 104 for LB, 
MRS, and Mannitol agars, respectively. Three biological replicates were performed, n = 
15. Significance was determined with Tukey’s multiple comparisons test. Box plots 
illustrate the median, quartiles, minimum and maximum. ** P < 0.01, *** P < 0.001, 
**** P < 0.0001. 
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Figure 40. Lithogenic diet significantly depletes the culturable DM microbiota 
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5.4.3 Effect of BS168 on stone burden in DM 
Stone burden and health were assayed in the DM model of urolithiasis after 
supplementation with NaOx and BS168; adult survival, adult Malpighian tubule crystal 
birefringence, adult fecal excreta birefringence, and larval locomotion were all evaluated 
(Figure 41). Kaplan-Meier survival analysis of adult DM (Figure 41A) demonstrated that 
the detrimental effects of the highly lithogenic 1% NaOx diet were improved with 
supplementation of BS168 (logrank test, P = 0.0057). Larval crawling was significantly 
increased in 4-day old larvae treated with BS168 on lithogenic media when compared to 
untreated controls (Parametric, D’Agostino-Pearson test; vs. normal media controls, two-
way ANOVA with Tukey’s multiple comparisons, P = 0.0073; vs. lithogenic controls, 
two-way ANOVA with Tukey’s multiple comparisons, P = 0.0013) (Figure 41B). On day 
7, dissected adult Malpighian tubules (Figure 41C) from BS168-treated DM had 
significantly less CaOx crystal deposition compared to untreated lithogenic controls 
(Nonparametric, D’Agostino-Pearson test; Wilcoxon rank-sum test, P < 0.0001) (Figure 
41D). The percentage of fecal excreta containing birefringent particles from adult DM 
vials after 14 days was significantly reduced in the BS168-treated cohorts relative to 
untreated lithogenic controls (Nonparametric, D’Agostino-Pearson test; Wilcoxon rank-
sum test, P = 0.0039) (Figure 41E). 
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A) Kaplan Meier survival analysis of five-day old DM that were supplemented with 2 X 
108 CFU of BS168 on Day 0, then transferred to normal or lithogenic media on Day 1 
and followed for 14 days. Error bars represent SE. n ≥ 100 per group from 4 biological 
replicates of n = 20-30 flies. B) Larval locomotion was determined on Day 4 after larvae 
were supplemented with 0.5 X 108 CFU of BS168 on Day 0 and transferred to normal or 
lithogenic media on Day 2, n = 19-24 larvae per group from 3 biological replicates. C) I- 
IV) CaOx crystals were imaged in dissected Malpighian tubules from adult DM on Day 7 
and quantitated with ImageJ particle analysis, n =21-29 adults per group from 3 
biological replicates. (D). C) V) Birefringent fecal excreta from coverslips in adult vials 
on Day 14 were imaged and the fraction that contained birefringent crystals was 
quantitated, n = 16-20 cover slips per group from 3 biological replicates. (E). Legend for 
group colours in A) is relevant for figures B), D), and E). Scale bar in C) is relevant for I-
IV. F) Microbial composition of adult urolithiasis DM model exposed to BS168. DNA 
was extracted from whole adult DM after 7 days consuming normal or lithogenic media 
following ± BS168 supplementation on day 0. 16S rDNA was sequenced using the 
Illumina platform. Each column represents a single fly and each colour corresponds to a 
different bacterial genus. Five females and five males, each from separate vials, were 
included in each treatment group. Reads corresponding to Wolbachia were removed. All 
box plots illustrate the median, quartiles, minimum and maximum. ** P < 0.01, **** P 
<0.0001. 
  
Figure 41. Effect of BS168 on DM model of urolithiasis 
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5.4.4 16S rRNA gene sequencing assessment of DM microbiota 
Microbial composition of whole pulverized adult DM was assessed after 7 days on 
normal or lithogenic media following BS168 treatment on Day 0. A common insect 
endosymbiont, Wolbachia, dominated the sequencing depth of all samples but was not 
significantly different between cohorts (Clark et al., 2005). Although Wolbachia is 
known to impact fertility, viral infection susceptibility, and longevity among other traits 
in DM, the bacterium is not known to play a role in the DM urolithiasis model, so reads 
corresponding to the genus were removed from downstream analysis (Clark et al., 2005; 
Teixeira, et al., 2008; Fry and Rand, 2002).  
After omitting sequencing control samples (based on their distinct clustering apart from 
DM samples, Figure 42) the DM microbiota dataset contained 1,974,659 total reads, 
ranging from 10,945 to 76,733 reads across the 40 samples. An average of 2.72 % of 
reads were removed from each sample following quality filtration performed utilizing the 
DADA2 pipeline (Callahan, et al., 2017). The remaining filtered 1,922,688 reads were 
assigned taxonomy with the SILVA (v132) training set. After filtering sequence variants 
to maintain those present at >1% in any sample, 69 sequence variants remained.  
A bar plot representing the relative proportions of genera in the samples is represented in 
Figure 41F. These results are consistent with past surveys of the DM microbiota which 
exhibit a distinct and low-diversity microbiota dominated by the genera Lactobacillus 
and Acetobacter, which was observed here in DM consuming normal media (Wong et al., 
2011). In the lithogenic diet cohorts the relative proportion of sequence variant 127, 
which based on sequence homology likely corresponds to Acetobacter tropicalis, was 
significantly decreased relative to normal media controls (Benjamini-Hochberg corrected 
Wilcoxon rank sum test, P = 0.0075), while lactobacilli proportions were unchanged. 
There were no differences in abundance of any bacterial groups when comparing BS168-
treated with -untreated groups. No sequences corresponding to the genus Bacillus were 
detected from the flies in any cohort.  
The sequence counts were centred log ratio (CLR) transformed, generating sample-wise 
Aitchison distances which were subsequently used to perform a principal component 
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analysis (PCA) (Figure 43A). Principal components 1 and 2 were plotted and represent 
36.8% of the total variance in the data (Figure 43A). Samples did not partition into 
distinct groups based on treatment (coloured points), however subtle drivers in the data 
separation across principal component 1 were noted for diet groups and denoted with 
95% confidence ellipses. Sequence variants driving separation of the dataset are depicted 
by the dark gray arrows and associated taxonomy. Differences in diversity metrics 
(Shannon’s Index of alpha diversity, Figure 43B, and Aitchison distance determination, 
Figure 43C) due to exposure to the lithogenic diet were observed in the un-supplemented 
controls but were mitigated when DM were supplemented with BS168. 
  
229 
 
 
 
Principal Component Analysis (PCA) plot of sequencing control and adult DM samples. 
A PCA was performed on CLR-transformed Aitchison distances. Distance between 
samples on the plot represents differences in microbial community composition, with 
34.9% of total variance being explained by the first two components shown. DM samples 
are coloured by treatment groups, and sequencing control samples are red. The black 
ellipse represents the 95% confidence interval of the DM samples. Sequence variants are 
depicted by the gray numbers.  
  
Figure 42. Sequencing controls distinctly separate from DM microbiota 
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A) Principal Component Analysis (PCA) plot of adult DM exposed to lithogenic media 
and BS168 supplementation. A PCA was performed on CLR-transformed Aitchison 
distances. Distance between samples (coloured points) on the plot represents differences 
in microbial community composition, with 36.3% of total variance being explained by 
the first two components shown. Strength and association for genera (sequence variants) 
are depicted by the length and direction of the gray arrows, respectively. Individual 
samples are coloured by treatment groups, and ellipses represent the 95% confidence 
interval of the diet groups. NF = Control diet, OX = 1.0% oxalate diet. B) Shannon’s 
Index of alpha diversity was calculated for each individual sample and plotted by 
treatment group. C) Intra-group Aitchison distance was determined within treatment 
groups. The distance of every individual sample to all others within the same treatment 
group was averaged to obtain a single distance value per sample. (B-C) Box plots 
illustrate the median, quartiles, and 5-95% confidence intervals. ** P < 0.01, **** P 
<0.0001).  
  
Figure 43. Exploratory analysis of DM microbiota 
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5.4.5 qPCR-based assessment of DM microbiota 
No differences were determined between fly sexes for any taxonomic comparisons (data 
not shown), so pooled sex data were illustrated in Figure 44. Total bacterial and 
Wolbachia spp. loads were unchanged between treatment groups (Figure 44A and 44B, 
respectively). Abundance of the genus Lactobacillus was not significantly changed, 
however the genus Acetobacter was significantly decreased in the lithogenic diet groups 
(Figure 44C and 44D, respectively). Intra-individual ratio of Lactobacillus to Acetobacter 
was increased by the lithogenic diet (P = 0.0007); however, this phenomenon was 
rescued with BS168 supplementation (1% Ox- BS168 was not significantly different 
from untreated controls; P = 0.048 between 1% Ox- NA and 1% Ox- BS168) (Figure 
44E). Species-specific primers were utilized to assess the load of Bacillus subtilis; 
BS168-treated groups trended towards increased loads, but these findings were not 
statistically significant (Figure 44F). 
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Molecular quantification of total bacteria, bacterial genera, and species in whole-body 
DM adults (A-F). Intra-individual ratios of Lactobacillus : Acetobacter loads were 
compared in (E). All comparisons were made after normalizing to total host DNA. Data 
are depicted as mean ± standard deviation. Significance was determined with Tukey’s 
multiple comparisons tests. Each point represents a single adult DM, each from a separate 
experimental vial (n = 10, three technical replicates were performed). Sexes are pooled. * 
P < 0.05, *** P < 0.001. 
  
Figure 44. qPCR-based assessment of DM microbiota 
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5.4.6 Effect of uropathogenic bacteria on stone burden in DM 
Stone burden and health were assayed in the DM model of urolithiasis after 
supplementation with NaOx, UTI89, and PM175; adult survival, adult Malpighian tubule 
crystal birefringence, and larval locomotion were all evaluated (Figure 45). Kaplan-Meier 
survival analysis of adult DM (Figure 45A) demonstrated that UTI89 did not impact DM 
survival, however PM175 decreased DM survival irrespective of dietary lithogenesis. 
Larval crawling was not impacted by treatment with either uropathogen (Figure 45B). On 
day 7, dissected adult Malpighian tubules from UTI89-treated DM had significantly 
increased crystal deposition compared to untreated and PM175-treated DM (Kruskall-
Wallis test with Dunn’s multiple comparisons, P < 0.0001 and P = 0.001, respectively) 
(Figure 45C-D). 
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A) Kaplan Meier survival analysis of five-day old DM that were supplemented with 2 X 
108 CFU of UTI89 or PM175 on Day 0, then transferred to normal or lithogenic media on 
Day 1 and followed until expiration. n ≥ 80 per group from 3 biological replicates of n = 
20-30 flies. B) Larval locomotion was determined on Day 4 after larvae were 
supplemented with 0.5 X 108 CFU of UTI89 or PM175 on Day 0 and transferred to 
normal or lithogenic media on Day 2, n = 20 larvae per group from 3 biological 
replicates. C) CaOx crystals from polarized light microscopy of dissected Malpighian 
tubules were quantitated with ImageJ particle analysis, n =20-25 adults per group from 3 
biological replicates. D) Representative polarized light images of dissected Malpighian 
tubules from adult DM on Day 7 treated with 0.1% NaOx (i), 0.1% NaOx + UTI89 (ii) or 
0.1% NaOx + PM175. The scale bar in D-iii) is applicable to all of D). All box plots 
illustrate the median, quartiles, minimum and maximum. *** P < 0.001, **** P <0.0001. 
  
Figure 45. The effect of uropathogens on stone burden in DM 
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5.4.7 Impact of microbes on renal calcium oxalate crystal 
adhesion and aggregation 
MDCK renal epithelial cells were utilized to assess the effect of BS168, UTI89, and 
PM175 on adhesion and aggregation of calcium oxalate monohydrate (COM) crystals 
(Figure 46A). Cells that were pre-treated with BS168 prior to treatment with COM 
crystals in artificial urine did not show an increase in crystal adhesion compared to cells 
that were pre-treated with a media control (Figure 46B). The average crystal size was not 
significantly different between BS168 and PM175 treated groups and the untreated 
control, indicating that BS168 did not encourage aggregation (Figure 46C). In contrast, 
cells treated with UTI89 had significantly increased crystal adhesion and aggregation 
(Kruskall-Wallis test with Dunn’s multiple comparisons, P = 0.016 and 0.021, 
respectively) (Figure 46B-C). 
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A) Crystal aggregates were visualized with light microscopy after MDCK monolayers 
were pre-treated with MEM ± bacteria, followed by artificial urine ± 5 mg/mL COM 
(Ox). Scale bars are 200 µm. B) Amount of adhered COM crystals to MDCK cells was 
not significantly different between Ox-BS168 or Ox-PM175 treated groups compared to 
Ox alone but was significantly higher for Ox-UTI89 (Kruskall-Wallis test with Dunn’s 
multiple comparisons). C) Average crystal aggregate size was not significantly different 
between Ox-BS168 or Ox-PM175 treated groups compared to Ox alone but was 
significantly higher for Ox-UTI89 (Kruskall-Wallis test with Dunn’s multiple 
comparisons). Three technical and three biological replicates were performed (n = 9). 
Box plots illustrate the median, quartiles, minimum and maximum. *P < 0.05. 
  
Figure 46. Effect of microbes on COM crystal adhesion to renal epithelial cells 
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5.4.8 Development of a live imaging µCT scanning protocol of DM 
The fruit flies tolerated three but not six or eight hours of constant flow of CO2 anesthesia 
in combination with X-ray radiation exposure throughout the µCT acquisition. During 
this time, the optimal scanning protocol achieved DM survival and minimal image-noise 
(Figure 47A). With this method, successful 3D reconstruction and visualization of DM 
adults were reproduced at 5.72 µm isotropic voxel spacing with stones clearly present; 
thus, this protocol was utilized for experimental scans.  
Adult DM were exposed to 1.0% Ox lithogenic media and BS168 supplementation as 
described above. Four adult males from each group were then selected for repeated µCT 
to validate the live, repeated scanning methodology (Figure 47C). After scanning it was 
apparent that the µCT detected calcification in the DM legs, head, and thorax, which was 
photoshopped out of the images prior to analysis, such that stone quantification only 
involved calcification within the abdomen. The calculated stone volume was unchanged 
in the 1% Ox group between scans, but surprisingly was decreased on day 7 compared to 
day 3 in the 1% Ox + BS168 group (P = 0.48 by unpaired, two tailed t-test) (Figure 47B). 
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A) DM survived less than six hours of CO2 anesthesia (n = 8 for each timed scan). 
Images were acquired under constant flow of CO2 (0.5 mL/min), over 360° (0.4° 
incremental angle). Survival was counted immediately after the scan and DM were 
followed for 3 days. On day 6 and 10, DM that had undergone a 3h scan had 100% 
survival. B) Quantification of stone burden in DM. Stone volume was calculated as the 
sum of all pixels >700 HU within the 3D CT reconstructed images. Stone size was 
unchanged between scans for OX-NA cohort but decreased from Day 3 to Day 7 scans in 
the OX-BS168 cohort by unpaired, two tailed t-test. n = 4 DM per cohort, one 
experimental replicate performed. C) Representative 3D CT reconstruction of live 
anesthetized male DM demonstrating the feasibility of repeated scanning of the same 
individual flies longitudinally. 3D volume representations were reconstructed at 5.7-
micron isotropic voxel size. Colour code is Hounsfield Units (HU), with structures >700 
HU coloured red. Calcification outside the abdomen (not stones) are visible in all groups. 
Box plots illustrate the median, quartiles, minimum and maximum. *P < 0.05. 
  
Figure 47. Repeated live imaging by µCT demonstrates stone burden in DM 
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5.5 Discussion 
This study is the first to characterize the role of both beneficial and pathogenic microbes 
in a Drosophila melanogaster (DM) model of urolithiasis, in a step towards 
understanding the host-microbe interactions involved in kidney stone disease. The 
Bacillus subtilis strain 168 (BS168) ameliorated stone burden in DM. Notably, growth of 
BS168 increased in the presence of sodium oxalate, and BS168 increased adult DM 
survival, increased markers of health in DM larvae, decreased stone burden in DM 
Malpighian tubules and fecal excreta, as well as altered the adult DM microbiota. In 
contrast, a clinical kidney stone isolate of Proteus mirabilis (PM175) decreased DM 
survival irrespective of lithogenesis, and the uropathogenic Escherichia coli (UTI89) 
increased stone burden in DM and aggravated crystal deposition to renal epithelial cells 
in vitro. A novel, sensitive, live imaging modality was developed for DM using µCT. 
Collectively, the in vivo, in vitro, and imaging findings suggested that BS168 may 
mitigate and UTI89 may contribute to, urolithiasis development and severity. This further 
supports a potential role for BS168 as a future therapeutic adjunct in the treatment of 
human nephrolithiasis. 
Oxalate is a toxin consumed in the diet and produced endogenously in the liver (Hatch 
and Freel, 2008). It can act as a chelating agent of metallic cations and can impart toxic 
effects by means of altered gene expression, membrane disruption, and production of 
reactive oxygen species, among other methods (Hess et al., 1998; Jonassen et al., 2005; 
Miller and Dearing, 2013). Humans are incapable of degrading oxalate and instead rely 
on excretion and microbial degradation (Miller and Dearing, 2013); accordingly, it is a 
common component in kidney stones (Moe, 2006). Many species of bacteria are able to 
degrade the compound; however, oxalate can still exert toxicity over bacterial cells and 
many gut commensals cannot tolerate high levels of oxalate (Suryavanshi et al., 2016). 
Here, it was demonstrated that BS168 exhibited prolific growth in media with up to 50 
mM NaOx present, which is expected to far exceed physiological relevance based on an 
approximated 2.0 mM daily dietary oxalate ingestion (Holmes and Assimos, 2004). 
Alongside its ability to form endospores, resist bile salts, and tolerate low pH conditions, 
these results suggest that BS168 would likely survive well in the human intestinal tract 
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despite even the highest levels of dietary oxalate consumption (Jeon et al., 2017). Hatch 
and colleagues (2011) demonstrated that the gut commensal bacterium Oxalobacter 
formigenes not only degrades oxalate, but also promotes enteric oxalate excretion from 
circulation. Future work on BS168 should investigate this potential and evaluate the 
degree to which BS168 may lower serum and urinary oxalate concentrations. 
In the well-established DM model of urolithiasis, BS168 was able to transiently colonize 
the intestinal tract for up to 5 days following a single treatment yet it could elicit marked 
improvements to DM survival during at least 14 days of lethal oxalate exposure (Ali et 
al., 2018; Chen et al., 2011; Miller et al., 2013). These findings suggest that, in addition 
to directly metabolizing oxalate, BS168 may reduce oxalate toxicity indirectly through 
priming of host cell physiology (Tanner and Bornemann, 2000). It is well known that 
renal oxalate toxicity is primarily mediated via mitochondrial dysfunction and excessive 
reactive oxygen species (ROS) generation propagated by phospholipase A2 (PLA2) 
activation (Cao et al., 2004). This process leads to inflammation and damage to the renal 
epithelium, which can become a crystal deposition site, accelerating stone formation 
(Albert et al., 2020; Miller et al., 2000; Zuo et al., 2011). Notably, B. subtilis can 
biosynthesize lipopeptides that are potent inhibitors of PLA2, which have been 
demonstrated in vivo to decrease inflammation (Selvam et al., 2009; Volpon et al., 2000). 
This suggests that the survival benefits afforded by BS168 in oxalate-exposed DM may 
be partly due to the prevention of oxalate-induced mitochondrial dysfunction via blunting 
of the PLA2-facilitated ROS signaling cascade. 
In corroboration with these findings, BS168 increased psychomotor activity, indicative of 
improved metabolic energy conversion and neuronal development, in both oxalate-
exposed and non-exposed DM larvae (Clark et al., 2018; Jakubowski et al., 2012; Yang 
and Hultmark, 2017). Given the integral role of PLA2 in modulating oxidative stress-
related degenerative diseases in DM, these results indicate that BS168-mediated 
modulation of PLA2 activity may represent a key mechanism of indirect protection 
against oxalate-based stone disease (Iliadi et al., 2018). Utilizing alternative mechanisms, 
recent evidence has also shown that B. subtilis from fermented foods can decrease 
mitochondrial dysfunction, oxidative stress, and DNA damage associated with metabolic 
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dysfunction (Prazdnova et al., 2015; Do et al., 2015; Boyd et al., 2018). Given the links 
between metabolic syndrome and urolithiasis, the conserved and multipronged ability of 
B. subtilis strains to promote mitochondrial health may offer a simple and effective 
solution for attenuating oxalate-induced renal damage in patients with recurrent stone 
formation (Boyd et al., 2018; Ramaswamy and Shah, 2014). 
Oxalate has been shown to alter the microbiota in humans, however, how this influences 
the microbiota in nephrolithiasis is still unclear (Miller and Dearing, 2013; Suryavanshi 
et al., 2016). For this reason, the simplicity of the DM urolithiasis model was 
advantageous for evaluating the effect of the lithogenic diet on the microbiota. Indeed, it 
was found that oxalate consumption could exact significant effects to the DM microbiota, 
some of which were mitigated by supplementation with BS168. DM exposed to the 
lithogenic diet yielded significantly lower culturable bacterial CFU; this was in contrast 
to unchanged total bacterial loads that were determined by qPCR. However, the flies 
were known to be heavily colonized by intracellular insect commensal Wolbachia spp. 
which accounts for this discrepancy, as this genus accounts for the majority of the qPCR 
load but is not cultivable in standard bacterial culture, instead requiring propagation in 
insect cell lines (O’Neill et al., 1997). Consumption of the lithogenic diet by adult DM 
also led to significant alterations in the microbial alpha and beta diversity, and 
additionally altered the ratio of the two dominant bacterial genera of the DM microbiota, 
Lactobacillus and Acetobacter. In both instances, BS168 was able to rescue these 
phenotypes. These findings suggest that BS168 exerts its protective effects without 
saturating the DM microbiota. Supporting this, BS168 was undetectable by culture from 
DM beyond experimental Day 5, while on Day 7, no sequence variants corresponding to 
Bacillus spp. were detected with 16S rRNA gene sequencing, and by qPCR, the B. 
subtilis loads were nearing the limits of detection and comparable between all groups. 
This is an important feature of B. subtilis, because as an oxalate-tolerant spore former, the 
potential existed for it to overtake the endogenous microbiota in a manner reminiscent to 
Clostridium difficile infection in humans, however this was not observed (Voth and 
Ballard, 2005). 
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For decades, struvite stones have been referred to as “infectious” stones, due to their 
association with urinary tract infections (UTIs) (Thompson and Stamey, 1973). 
Organisms such as Proteus mirabilis, Klebsiella spp., Pseudomonas aeruginosa, 
Staphylococcus saprophyticus, and Ureaplasma urealyticum produce urease, an enzyme 
that cleaves urea to ammonia and CO2, which subsequently elevates urinary pH and 
precipitation of magnesium ammonium phosphate hexahydrate crystals (Das et al., 2017; 
Thompson and Stamey, 1973). Until more recently, bacteria were not thought to 
contribute to the formation of non-struvite stone compositions (Coe et al., 1992; 
Schwaderer and Wolfe, 2017). Groups have now validated the presence of live bacteria 
within stones of various compositions with both culture and molecular techniques, and 
we have corroborated these findings (Chapter 3) (Barr-Beare et al., 2015; Dornbier et al., 
2019; Golechha and Solanki, 2001; Sohshang et al., 2000; Tavichakorntrakool et al., 
2012; Wang et al., 2014; Zampini et al., 2019). Based on results from our group and 
others, E. coli appears to be the most commonly isolated microbe from non-struvite 
stones, followed by Pseudomonas and Staphylococcus spp. Whether these microbes play 
an intimate role in stone formation, or if they are just passive bystanders, has not been 
well described. The concept of such well-known pathogens being bystanders is hard to 
imagine. Potentially, while not being metabolically active enough to induce a classical 
infection, they could still be causing an element of harm to the host. For example, very 
low abundances of Pseudomonas, E. coli and other pathogens have been identified in 
breast tissue of women with cancer despite no infectious process taking place (Urbaniak 
et al., 2014). 
The DM urolithiasis model proved useful in revealing that PM175 had a detrimental 
effect on DM survival, irrespective of lithogenesis as both PM175 alone and 0.1% Ox + 
PM175 groups had similar mortality, and 0.1% Ox + PM175 did not have increased stone 
formation compared to 0.1% Ox alone. This was unexpected, as P. mirabilis is not a 
known pathogen of DM (although its close relatives Providencia spp. are) and it was only 
supplemented at the initial Day 0 timepoint (Galac and Lazzaro, 2012; Ma et al., 2012). It 
is possible that this microbe exerts a pathogenic role on DM during a key developmental 
window in young adult flies, which could result in subsequent mortality effects later in 
life regardless of stone formation (Clark et al., 2015). In contrast to the findings in 
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PM175, we found UTI89 to significantly increase stone deposition in a manner that did 
not affect DM survival. This may indicate that the DM urolithiasis model is already quite 
severe, and although UTI89 impacts stone formation, it may not manifest worse mortality 
beyond that of the lithogenic diet alone (Miller et al., 2013). 
Previous studies with uropathogenic E. coli (UPEC) have demonstrated that they 
aggregate on and around CaOx monohydrate (COM) crystals, significantly more so than 
other crystal compositions (Barr-Beare et al., 2015; Chutipongtanate et al., 2013). Other 
groups have shown the ability for COM to adhere to MDCK renal epithelial cells, but the 
role of bacteria in this process had not been previously explored (Bigelow et al., 1998; 
Yamaguchi et al., 2002).  
It is unlikely that a large quantity of BS168 would be present in the kidney after oral 
administration, even though the gut is a reservoir for the urogenital microbiota 
(Yamamoto et al., 1997). However, as gut colonization with UPEC has been shown to 
increase the risk of UPEC UTI, experiments were performed here to address how BS168 
may impact the urinary tract and stone development should some cells traffic there 
(Moreno et al., 2006; Moreno et al., 2008). Here, BS168 did not encourage aggregation 
nor adherence of COM crystals to the MDCK cells. Accordingly, these in vitro findings 
suggest that if any orally consumed BS168 cells did migrate to the urinary tract, 
increased morbidity would be unlikely.  
Conversely, in agreement with previous UPEC work by Barr-Beare et al. and 
Chutipongtanate et al., UTI89 demonstrated the ability to aggregate COM crystals and 
encourage their adherence to renal epithelial cells (2015; 2013). This demonstrates how 
UPEC, unlike other uropathogens such as PM175 which had no appreciable effect on the 
COM crystals, could be actively involved in CaOx stone growth through its ability to 
potentiate crystal deposition. This may be the consequence of active bacterial adhesion to 
the crystals, charge interactions between the bacterial cell surface and urinary ions, or the 
expression of enzymes such as citrate lyase, which through its ability to convert citrate to 
acetyl-CoA can increase urinary CaOx supersaturation (Bayer and Sloyer, 1990; 
Chutipongtanate et al., 2013; Quentmeier et al., 1987; Zuckerman and Assimos, 2009). 
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Future research should investigate the microbes present in non-struvite kidney stones in 
the context of urine chemistry to determine if hypocitraturia is a significant, uropathogen-
induced factor leading to stone formation or recurrence (De Ferrari et al., 1996). 
Finally, this study was the first to demonstrate the ability to live image DM using a novel 
anesthetic and µCT protocol. Just as CT scans are used to visualize stones in humans, 
previous studies have utilized X-ray µCT to evaluate stones in narcotized, wax-embedded 
DM (Assimos et al., 2016; Hirata et al., 2012). Unfortunately, anatomical structures are 
often difficult to appreciate in narcotized flies and this method precludes longitudinal 
studies. Here, the successful application of an acrylic scanning apparatus enabled 
anesthesia and full-body immobilization of up to 16 flies at a time, with 100% recovery 
after two 3-hours scans. This methodology enabled repeated scanning and the capability 
of time course studies in DM. Although as an overall urolithiasis model DM are 
exceedingly economical, the use of flies as a high-throughput screening tool for the 
assessment of expensive pharmaceutical or nutraceutical stone therapies can still amount 
to significant costs (Miller et al., 2013). The ability to repeatedly scan DM and follow 
stone progression longitudinally throughout life is a significant advancement to the field. 
In summary, this study has characterized the beneficial properties of BS168, and the 
uropathogenic stone-promoting effects of UTI89 in the context of nephrolithiasis, as 
assayed in a DM model of the disease and in vitro cell culture experiments. This validates 
that in the capacity of both probiotics and pathogens, microbes can play an instrumental 
role in stone prevention and formation, respectively. Although probiotics are classically 
Lacotobacillus spp. or Bifidobacterium spp., strains of Bacillus subtilis are generally 
regarded as safe, gaining favour as probiotics for gut-related maladies, and are 
components of several fermented foods (Kim et al., 2014; Poormontaseri et al., 2017; 
Sorokulova et al., 2008). To date, studies employing various formulations of probiotics in 
nephrolithiasis patients have largely been inconclusive due to the broad variety of 
preparations tested alongside ill-defined strain selection, thereby making it unclear how 
efficacious this approach could be (Abratt and Reid, 2010; Campieri et al., 2001; Duncan 
et al., 2002; Jairath et al., 2015; Lieske et al., 2010; Okombo and Liebman, 2010). 
Instead, future studies should carefully evaluate mechanistically validated strains which 
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can be delivered effectively to the gut, such as BS168. Based on our seminal findings, 
this microbe may prove a novel therapeutic adjunct to reducing the incidence of recurrent 
CaOx nephrolithiasis in high-risk patients.  
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Chapter 6  
6 General Discussion 
The study of the human microbiome is regarded as one of the most pivotal scientific 
developments of the 2010’s (Nature, 2019). The advances in human microbial ecology 
have been aided by the information revolution, the advent of next generation sequencing 
(NGS) technologies, and big data analysis (Malla et al., 2018). Thanks to these 
innovations, we now know that the microbial “organ” living within us (the microbiota), 
and its genes and products (the microbiome), are intimately involved in human health and 
disease (Malla et al., 2018; Whiteside et al., 2015). In this thesis I provide evidence that 
the human microbiota at multiple anatomical sites is implicated in kidney stone formation 
and can be exploited in this disease’s treatment and prevention. 
6.1 Towards standards in microbiota studies 
Along with the rapidly developing discipline of microbiota research has come a wide 
variety of study methodologies, none of which are standardized across the field 
(Goodrich et al., 2014; Hiergeist et al., 2016). These differences in protocols extend from 
study inception and span through to the final publication, with areas of potential bias at 
every step along the way. These can come from sample collection (further diversified by 
biological sample type), sample processing and storage, DNA extraction, PCR 
amplification, sequencing, and bioinformatic analysis. Coupled with the sensitivity of 
NGS, these factors can make cross-comparison between studies very difficult, and meta-
analyses nearly impossible. In this thesis, urinary, gut, medical device, and in vivo model 
samples were investigated, all with the aim of making the highest fidelity 16S rRNA and 
whole shotgun metagenomic sequencing feasible. With these factors in mind, careful 
consideration was taken at all levels of study design and performance to yield next 
generation sequencing analysis to the very best of our ability. 
Previous studies in our lab by Dr. Yige Bao worked towards optimizing the handling of 
urine samples, as well as similar clinical samples with high host- and low microbial- 
biomass (Bao, 2018; Minich et al., 2019; Wolfe et al., 2012). These findings suggested 
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that voided urine retained optimal microbial resolution for studies with 16S rRNA gene 
sequencing when samples were greater than or equal to ten millilitres in volume and were 
centrifuged, with the supernatant discarded, retaining a pellet for frozen storage at -80 °C. 
Employing this method resulted in consistent, high quality sequencing results even after 
samples spent two years in frozen storage (Bao, 2018). Therefore, this method was 
utilized for the urine sample collection in Chapters 3 and 4 of this thesis. 
Although the bacterial biomass of feces is high, unlike most urinary samples, these 
samples present a different set of challenges (Sender et al., 2016). Study subjects are 
usually willing to provide urine samples, but less so fecal samples “on demand” per se, so 
at-home collection is commonly required. This was the case in the kidney stone study 
(Chapter 3), where fecal samples were to be collected prior to commencing pre-surgical 
antibiotic prophylaxis, as these drugs would affect the microbiota composition with 
consequences for the subsequent analysis. At-home collection is usually more amenable 
to participants than in-clinic deep rectal swabs, although both methods appear to 
approximate the gut microbiota comparably (Biehl et al., 2019; Liang et al., 2020). 
Whether participants collect a full fecal sample, just a portion on toilet paper, or a swab 
thereof is a second point of review, although again method acceptance by the participant 
should be considered to optimize study recruitment (especially where monetary 
incentives aren’t offered, as in the clinical studies performed in Chapters 2, 3, and 4) 
(Gilbert et al., 2014; Liang et al., 2020). Further confounders include interim storage of 
these samples and whether same-day lab delivery, or perhaps mailing of a sample is 
sufficient (Gilbert et al., 2014; Liang et al., 2020; Voigt et al., 2015). For this reason, 
Chapter 2 evaluated the feasibility of soiled toilet paper collection and storage for the 
purpose of NGS. Fecal samples were homogenized and transferred evenly to toilet paper, 
then stored dry or in the preservative agent RNAlater® at various temperatures and for 
various lengths of time. This study validated that unpreserved fecal samples collected on 
soiled toilet paper and stored in sterile sample bags are appropriate for NGS after being 
mailed. Specifically, it was determined that the length of time and temperatures 
experienced by unpreserved samples mailed via Canada Post would still resemble the 
origin with minimal variation. This methodology has since been utilized in numerous 
clinical studies from our group, including those of the gut microbiota in irritable bowel 
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syndrome, multiple sclerosis, non-alcoholic fatty liver disease, schizophrenia, chronic 
pain, and of course, nephrolithiasis (Craven et al., 2020). 
6.2 The microbiota of recurrent nephrolithiasis patients 
diverges from a healthy state 
A primary purpose of this thesis was to characterize how the microbiota is altered in 
kidney stone patients in order to elucidate whether bacteria are implicated in stone 
formation. Utilizing the methods established in earlier work, Chapter 3 involved a 
microbiota-targeted clinical study of both healthy adults and kidney stone patients 
receiving surgical treatment. Despite the publication of several studies aimed at 
addressing similar or associated questions since the onset of this thesis, a certain 
consensus has not been reached by others (Barr-Beare et al., 2015; Batagello et al., 2018; 
Dornbier et al., 2019; Magwira et al., 2012; Miller et al., 2019; Stern et al., 2016; 
Suryavanshi et al., 2018; Tang et al., 2018; Tavichakorntrakool et al., 2012; Ticinesi et 
al., 2018; Xie et al., 2020; Zampini et al., 2019). These studies have few similarities and 
many discrepancies between their design and results, epitomizing how the lack of 
standards in the microbiome research field can lead to faulty conclusions. To avoid such 
issues, this thesis sought to combine the individual strengths of several of these studies 
(large sample size, sampling at multiple timepoints and anatomic sites, dietary 
consideration, the combination of both 16S rRNA gene and whole shotgun metagenomic 
sequencing, and scrupulous bioinformatic analysis) into a single investigation that should 
stand up against re-examination with reproducibility in future studies. 
In this study, stone patients were found to have higher urinary oxalate concentrations 
compared to healthy subjects, despite similar dietary micronutrients consumption by both 
cohorts. In an effort to understand this finding, further investigation showed that the 
urinary and gut microbiota were distinct in kidney stone formers compared to healthy 
subjects. Based on the differential features, the microbiota is believed to play a 
significant role in nephrolithiasis. During the time period of surgical stone management, 
the urinary microbiota was enriched by bacterial genera known to be associated with 
inflammatory responses. In addition, a sequence-positive microbiota was detected within 
all crystalline compositions of kidney stones examined. Based on literature expectations, 
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it was surprising to not detect a lower relative abundance of Oxalobacter formigenes in 
the gut microbiota of stone formers. This further questions the correlation between this 
species and prevention of stone formation. 
A novel finding was the higher relative abundance of antibiotic resistance factors and 
uropathogenic bacteria, as well as previously unreported functional changes involved in 
oxalate homeostasis indicative of metabolic stone formation. Together, these findings 
implicate the gut as a reservoir for the urinary tract and stone formation. Interestingly, 
surgical stone management, which invariably includes antibiotic use, significantly 
disrupted the urinary and gut microbiota and led to blooming of antibiotic resistant 
uropathogens in the urinary tract, facilitating further crystal nidi development and disease 
recurrence, a finding observed epidemiologically (Johnson et al., 1979; Koşar et al., 
1999; Vaughan et al., 2019). 
6.3 The microbiota and kidney stone disease 
management 
A key step in applying microbiome findings to the clinic is to understand how the 
microbiota might influence kidney stone disease management. An almost ubiquitous 
component of such care involves ureteral stent placement. These stents along with 
urinary catheters are the most commonly used medical devices in urological practice and 
the most common source of device and hospital-acquired infections (Chatterjee et al., 
2014; Lo et al., 2014). In spite of the risk of infection, encrustation, and the morbidity 
associated with ureteral stent placement, they are used for nearly all nephrolithiasis 
patients at some point throughout their treatment, most routinely following surgical stone 
intervention (Assimos et al., 2016; Dyer et al., 2002; Haleblian et al., 2008). Thus, in 
Chapter 4, the goal was to characterize the microbiota adhering to ureteral stents and 
determine which, if any, patient factors influenced the microbiota composition and stent 
encrustation. 
Upon attempting to evaluate all ureteral stents removed from our centre over a one-year 
period, ultimately 241 patients were enrolled, of which 91% were receiving treatment for 
urolithiasis. Both mid-stream urine and ureteral stents were collected and characterized 
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with 16S rRNA gene sequencing. The presence of a reproducible, patient-specific stent 
microbiota was validated, even in visibly un-encrusted devices. Device indwelling time, 
patient age and comorbidities such as metabolic syndrome, irritable bowel syndrome, 
inflammatory bowel disease, and pulmonary disease were all significantly associated 
with stent and urinary microbial community variation. Unexpectedly, the use of 
antibiotics by participants throughout the course of stent placement did not alter the 
microbial community composition, microbial diversity, or degree of stent encrustation. 
Because antibiotics are often prescribed alongside stent placement and removal in an 
attempt to curb urinary tract infections (UTIs) and device encrustation, these findings 
raise questions about the necessity of this standard practice (Abbott et al., 2016; Riedl et 
al., 1999).  
6.4 The ramifications of disrupting the microbiome 
The finding that recurrent kidney stone formers have altered bacterial community 
composition in both the intestinal and urinary tracts markedly correlates with recent 
findings that oral antibiotics increase the risk of nephrolithiasis (Tasian et al., 2018). 
Moreover, findings in stent patients revealed that antibiotic use did not create a health-
associated urinary microbiota devoid of uropathogens, nor did it decrease device 
encrustation. Instead, the overall results raised potential disadvantages and long-term 
consequences of antibiotic use in urological practice. This is not to suggest that 
antibiotics do not fulfill a necessary and invaluable role in disease treatment (López 
Romo and Quirós, 2019; Paterson et al., 2016). However, the use of these agents remains 
debated for many urological scenarios — a particularly consequential fact given that 
urologists have higher antibiotic prescription rates than providers from any other surgical 
specialty (Durkin et al., 2017). Additionally, antimicrobial use by urologists is often 
discordant to the best practice guidelines published by the American Urological 
Association (AUA) (Khaw et al., 2018; Wolf et al., 2008). Clearly, the reasons for this 
must be examined given the knowledge emerging from microbiome studies, including 
those described here. 
Urinary tract infection is the second most common indication for all antibiotic 
prescriptions behind respiratory infections (Shively et al., 2018). In studies of antibiotic 
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use for acute uncomplicated UTIs, randomized placebo-controlled trials have 
demonstrated that patients given placebo exhibit significant symptom improvement and 
cure of bacteriuria after just days. Thus, uncomplicated UTIs are often cleared without 
drug treatment (Christiaens et al., 2002; Ferry et al., 2004; Little et al., 2010). 
Furthermore, antibiotic use does not provide significant benefit for UTI prevention in 
ureteral stent patients with normal risk profiles, yet they are still commonly prescribed for 
this indication (Abbott et al., 2016; Khaw et al., 2018; Lee et al., 2019). Similar 
controversy surrounds antibiotic use in ureteroscopic lithotripsy, transurethral resection 
of the prostate, and even PCNL (Baten et al., 2019; Deng et al., 2017; Khaw et al., 2018; 
Potretzke et al., 2016). Further, none of these studies have considered the damage 
incurred by antibiotics to the microbiome and to the patient’s health as a consequence of 
this. 
It is known that the use of antimicrobials can cause pronounced and long-lasting 
microbiota remodelling, which can have implications for host health for years to come 
(Cho et al., 2012; Cox et al., 2014; Dethlefsen and Relman, 2011; Korpela et al., 2016; 
Ruiz et al., 2017). Although much literature has focussed on oral antibiotic prescription, 
this is not where the assault to our microbiome ends (Lozupone et al., 2012). In Western 
society, people are constantly bombarded by antimicrobial substances, from prescription 
and over-the-counter medications, to preservatives in food, and even contaminants in 
drinking water (Khan and Nicell, 2015; Lozupone et al., 2012; Maier et al., 2018; Nash, 
2012). Many negative consequences of microbiome-disrupting substances have been 
reported to affect host metabolic syndrome, psoriasis, asthma, allergies, and intestinal 
diseases, among many others (Brown et al., 2013; Cho et al., 2012; Cox et al., 2014; Ni 
et al., 2019; Schulfer et al., 2018; Zanvit et al., 2015). Now, we also know there to be a 
direct role in urological conditions (Tasian et al., 2018). Even when used appropriately, 
antibiotics can lead to subsequent infection by resistant organisms in the patient, as well 
as the dissemination of resistant organisms in the community — a separate but very 
significant global public health issue (Barancheshme and Munir, 2018; Costelloe et al., 
2010). Together, these factors lead to a multi-pronged depletion in the diverse beneficial 
microbiome, reduction of key functional pathways, and enrichment of inflammatory, 
drug-resistant pathogens (Lozupone et al., 2012).  
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Simply put, substances capable of disrupting the microbiome are likely capable of 
causing disease. The net effect of disruption has been termed “dysbiosis”, but this is 
poorly defined and relatively uninformative, as there is no single healthy microbiome nor 
an all-encompassing harmful one. The relationships between the microbiome and 
diseased states are often not defined mechanistically. This knowledge gap with regards to 
a mechanistic role of uropathogens and stone formation was investigated in Chapter 5 
using a Drosophila melanogaster (DM) model of stone formation and in vitro tissue 
culture experiments. It was discovered that the Escherichia coli strain UTI89 and a 
struvite kidney stone isolate of Proteus mirabilis (PM175) had very different outcomes. 
The DM stone burden along with calcium oxalate monohydrate (COM) crystal 
aggregation and adhesion to renal epithelial cells increased significantly with UTI89. 
Whereas, PM175 increased DM mortality but did not exacerbate stone formation, and 
trended towards increased COM crystal adhesion, though that result was not statistically 
significant. Although only two uropathogenic bacteria were tested, these results 
demonstrated that the strains had vastly different mechanisms of action in their ability to 
potentiate kidney stone formation: one by a urease-mediated increase in urine pH 
(PM175), and the other potentially by bacterial adhesive mechanisms or citrate lyase-
mediated hypocitraturia (UTI89). It is mechanistic studies such as these that will push the 
microbiome research field beyond simply exploratory characterization, and towards 
hypothesis driven investigations and the development of biologically relevant solutions. 
6.5 Mitigating microbiome damage 
Although the negative impact of our ‘Western’ lifestyle on the microbiome may seem 
overwhelming, all hope is not lost. It is through first understanding the microbial 
involvement in human diseases and defining the relevant mechanisms of action, that we 
can then work towards targeted microbial-based therapeutics. Probiotics, or “live 
microorganisms that, when administered in adequate amounts, confer a health benefit on 
the host”, are just one potential course of action (Hill et al., 2014; WHO, 2001). It is 
important when investigating potential probiotic bacteria that they are evaluated for 
strain-specific niche applications. Where past studies have failed to demonstrate the 
benefit of a potentially beneficial microbe, they have often lacked a rationale for strain 
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selection (Suez et al., 2018). Indeed, although probiotics likely would not offer a 
community-wide shift from a depleted microbiota, they could be best utilized for 
replenishment of a specific functional outcome, such as repair a loss-of-function 
phenotype of oxalate degradation in stone-formers.  
In Chapter 5 of this thesis, Bacillus subtilis strain 168 (BS168), a resilient spore-forming 
bacterium with the capability to degrade oxalate through the enzyme oxalate 
decarboxylase, was investigated (Sorokulova et al., 2008; Tanner and Bornemann, 2000). 
The rationale was that oral consumption of this microbe could decrease urinary oxalate 
concentrations by degrading dietary oxalate in the gut. O. formigenes and other oxalate-
degrading bacteria are currently sold as “probiotics” for this purpose, although trials and 
validation studies have had underwhelming results, potentially due to O. formigenes’ 
strict anaerobic nature and difficulty in retaining its viability (Ellis et al., 2015; Milliner 
et al., 2018). Unlike current products on the market, BS168 was able to grow in very high 
levels of oxalate, reduce stone burden, and improve markers of health in our DM model 
of the disease (Ellis et al., 2015). This microbe is also a component of various fermented 
foods (Kim et al., 2014). Based on these findings and the fact that Bacillus spp. are 
gaining favour as probiotics for other purposes in humans, BS168 should be further 
evaluated for its therapeutic efficacy and safety in humans with nephrolithiasis 
(Poormontaseri et al., 2017; Sorokulova et al., 2008).  
6.6 Future directions 
Beyond probiotics, there are numerous other techniques available to reshape a damaged 
microbiome. These could include prebiotics, “a substrate that is selectively utilized by 
host microorganisms conferring a health benefit”, or whole community transformation 
via fecal microbiota transplant (FMT) (Gibson and Roberfroid, 1995; Gibson et al., 
2017). With recent interest in the gut microbiota of nephrolithiasis patients has come 
curiosity surrounding the therapeutic potential of FMTs (Miller et al., 2017; Stern et al., 
2019). As of yet, this has only been investigated in animal models, which tend to poorly 
recapitulate the complex human disease phenotype (Khan, 1997). As leaders in the field 
of FMT research (having established studies involving FMT for non-alcoholic fatty liver 
disease, multiple sclerosis, schizophrenia, and cancer immunotherapy, among others), as 
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well as utilizing the technique clinically for C. difficile infection, our centre has the 
potential to be the first to investigate this therapy in humans with stone disease (studies 
ongoing; Craven et al., 2020). 
A major point of attention when undertaking an FMT study is appropriate donor 
selection. Donors are routinely screened and excluded based on relevant diseases, family 
history, and detection of transmissible agents (Craven et al., 2017; Duvallet et al., 2019; 
Woodworth et al., 2017). However, the broader recommendations of what an appropriate 
donor looks like based on the disease of focus is often unclear, when we know for 
example that such phenotypes as leanness and obesity could be transferred through the 
microbiome (Vrieze et al., 2012). Without knowing what a healthy microbiome actually 
is, how can an optimal donor be identified? The criteria should encompass much more 
than simply a lean person that does not harbour Helicobacter pylori or HIV.  
It is hoped that the research undertaken in this thesis will advance the field in several 
ways. For example, based on the findings herein, the ideal FMT donor for a middle aged, 
male, nephrolithiasis patient should likely be: middle aged, male, with no family history 
of stones or urological conditions, consuming a healthy diet, physically active, hasn’t 
used antibiotics in the last 5 years, has a robust gut microbiota oxalate degradation 
network (i.e. Oxalobacter, Lactobacillus, and Bifidobacterium spp., or Bacillus subtilis), 
has low to normal urinary oxalate concentration, absent or low numbers of uropathogenic 
bacteria in the gut, absent or low numbers of antibiotic resistant organisms in the gut, 
robust gut microbiota capacity for vitamin production (i.e. B6), with reduced ascorbate 
utilization. The search for donors who match such criteria based on the recipient may be 
exceptionally expensive and challenging, and weighing each element may require some 
mathematical modeling. But ultimately, a study could test FMT from such a disease-
based selection process to determine whether stone recurrence rates in a patient 
population are decreased after receiving the autologous vs. an allogeneic transplant. 
In addition to investigating FMT as a potential therapeutic, many of the other findings in 
this work warrant further investigation and in vitro validation. To confirm the gut 
microbiota findings and functional differences detected by shotgun metagenomic 
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sequencing, a dynamic host-free model system of the gut (a chemostat) should be enlisted 
(Allen-Vercoe, 2013). In this in vitro culture vessel system that mimics microbial 
metabolism in the distal colon, stool from both healthy controls and recurrent stone 
patients could be separately investigated and compared for their functional capacity. For 
example, the concentration of free oxalate could be quantitated after dosing the systems 
with a known quantity of ascorbate (the oxalate concentration could be measured in 
chemostat effluent using HPLC, as was done in Chapter 3). Similarly, the capacity of the 
respective microbiomes to generate relevant micronutrients could be assessed following 
the addition of a standard media “meal” (i.e. concentrations of Vitamins B6 or K2, which 
could be quantitated with ELISA). 
Future studies should help to clarify the contribution of uropathogens to stone formation. 
In chapter 5, renal epithelial cell culture and COM crystal adhesion assays were 
combined to evaluate how bacteria may be directly interacting with crystals. These were 
quite short experiments by nature as the renal cell line and bacteria could not co-exist 
long term. A stone generator apparatus, as described previously, might prove to be a 
better way to investigate longer interactions (Ananth et al., 2002; Chow et al., 2004). 
This system involves the growth of crystal nidi into stones of clinically relevant size, in 
chambers supplied with COM-supersaturated artificial urine. Different urinary 
components, macromolecules, and stone types could be investigated simultaneously and 
multiplexed into a so-called “stone farm” (Ananth et al., 2002; Chow et al., 2004). 
Bacteria could be applied to the system at different stages of stone development, with 
absolute stone size and growth rate as a functional experimental output. Additionally, 
these experiments would benefit from image analysis, whereupon bacteria could be 
fluorescently labelled, and stones sectioned and imaged microscopically (Sivaguru et al., 
2018).  
What potentially makes the bacteria isolated from stones different from bacteria present 
in the bladder of healthy people is also of great interest. In Chapter 3, the genera 
Escherichia, Gardnerella, and Staphylococcus were sequenced and cultured from both 
healthy and stone forming participants’ urine samples, as well as the kidney stones 
themselves. These isolates could undergo whole genome sequencing to determine if 
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species or strain- specific traits are differentially pathogenic between the two cohorts. 
Perhaps the E. coli from stone patients harbour more adhesive pili, invoke inflammation 
or host tissue damage through toxin production, or have enhanced antimicrobial 
resistance compared to isolates from healthy participants (Wiles et al., 2008). Genomic 
differences could be investigated mechanistically using the in vitro models described 
above to determine their biological significance. 
6.7 Concluding remarks 
As we further our understanding about the intimate role that microbes play in human 
health, nephrolithiasis is an extremely important area to apply this knowledge. This often-
idiopathic condition may be better understood in the context of microbes, with beneficial 
ones harnessed as part of nephrolithiasis treatment and prevention. This disease affects a 
tremendous amount of people and causes severe morbidity and economic strain; its 
prevalence is only increasing, and we need novel solutions. This thesis provides 
information upon which to not only base future research, but also to attract the attention 
of urologists at the front line. It is my sincere hope that the work presented in this thesis 
(as well as the other publications resulting from my graduate studies) have advanced 
understanding of the microbiota, the 80th human organ, and its intertwined relationship to 
human health (Standring et al., 2015). 
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